{"PMC7445819": [["Since the end of February 2020, Italy has witnessed a complete upheaval in the organization of the national and regional health systems due to the pandemic caused by COV-SARS2 (COVID 19).", [["SARS2", "DNA", 170, 175], ["the pandemic", "PROBLEM", 143, 155], ["COV", "TEST", 166, 169]]], ["An immediate consequence is a reconversion of clinical activities in all types of hospitals (public, private, and semi-private) leading to a significant delay of scheduled clinical and surgical procedures, including uro-oncological and andrological services [1, 2].", [["surgical procedures", "TREATMENT", 185, 204]]]], "7635ed87441c9a8aee521079f6eaed0734a37f3b": [["Worldwide, it is estimated that 3 to 5 million children die annually as a result of acute respiratory disease.", [["respiratory", "ANATOMY", 90, 101], ["acute respiratory disease", "DISEASE", 84, 109], ["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55], ["acute respiratory disease", "PROBLEM", 84, 109], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory disease", "OBSERVATION", 90, 109]]], ["In the United States, respiratory diseases account for 75% to 80% of all acute morbidity.", [["respiratory", "ANATOMY", 22, 33], ["respiratory diseases", "DISEASE", 22, 42], ["respiratory diseases", "PROBLEM", 22, 42], ["all acute morbidity", "PROBLEM", 69, 88], ["respiratory diseases", "OBSERVATION", 22, 42], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["morbidity", "OBSERVATION", 79, 88]]], ["Viral infections are the greatest contributors to this morbidity rate, causing approximately 80% of respiratory illness.", [["respiratory", "ANATOMY", 100, 111], ["Viral infections", "DISEASE", 0, 16], ["respiratory illness", "DISEASE", 100, 119], ["Viral infections", "PROBLEM", 0, 16], ["this morbidity rate", "PROBLEM", 50, 69], ["respiratory illness", "PROBLEM", 100, 119], ["infections", "OBSERVATION", 6, 16], ["respiratory illness", "OBSERVATION", 100, 119]]], ["Many of these infections produce mild, selflimited symptoms of the upper respiratory tract.", [["upper respiratory tract", "ANATOMY", 67, 90], ["infections", "DISEASE", 14, 24], ["upper respiratory", "ORGANISM_SUBDIVISION", 67, 84], ["tract", "ORGANISM_SUBDIVISION", 85, 90], ["these infections", "PROBLEM", 8, 24], ["mild, selflimited symptoms of the upper respiratory tract", "PROBLEM", 33, 90], ["infections", "OBSERVATION", 14, 24], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["upper", "ANATOMY_MODIFIER", 67, 72], ["respiratory tract", "ANATOMY", 73, 90]]], ["Lower respiratory tract illness (LRI), particularly that associated with the presence of crackles or wheezes on physical examination or as parenchymal disease on a chest radiograph, accounts for the majority of severe disease.", [["Lower respiratory tract", "ANATOMY", 0, 23], ["parenchymal", "ANATOMY", 139, 150], ["chest", "ANATOMY", 164, 169], ["Lower respiratory tract illness", "DISEASE", 0, 31], ["LRI", "DISEASE", 33, 36], ["wheezes", "DISEASE", 101, 108], ["parenchymal disease", "DISEASE", 139, 158], ["respiratory tract", "ORGANISM_SUBDIVISION", 6, 23], ["Lower respiratory tract illness", "PROBLEM", 0, 31], ["crackles", "PROBLEM", 89, 97], ["wheezes", "PROBLEM", 101, 108], ["physical examination", "TEST", 112, 132], ["parenchymal disease", "PROBLEM", 139, 158], ["a chest radiograph", "TEST", 162, 180], ["severe disease", "PROBLEM", 211, 225], ["respiratory tract", "ANATOMY", 6, 23], ["crackles", "OBSERVATION", 89, 97], ["wheezes", "OBSERVATION", 101, 108], ["parenchymal", "ANATOMY_MODIFIER", 139, 150], ["disease", "OBSERVATION", 151, 158], ["chest", "ANATOMY", 164, 169], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["disease", "OBSERVATION", 218, 225]]], ["One third of children develop LRI in the fi rst year of life.", [["LRI", "DISEASE", 30, 33], ["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21], ["LRI", "PROBLEM", 30, 33], ["LRI", "OBSERVATION", 30, 33]]], ["1 Childhood asthma may be initially diffi cult to discriminate from LRI in some patients; indeed, both conditions can be present simultaneously.", [["asthma", "DISEASE", 12, 18], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["Childhood asthma", "PROBLEM", 2, 18], ["LRI", "PROBLEM", 68, 71], ["asthma", "OBSERVATION", 12, 18]]]], "cbcd581635b482b4013c420a4d02c882d6489a1d": [["IntroductionCoronavirus disease 2019 (COVID-19) outbreak was declared a Public Health Emergency of International Concern on 30 January 2020 by the World Health Organization (OMS) [1] .", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31]]], ["To date, more than 5 million people (5, 593, 631 as of May 28th, 2020) have been diagnosed, and more than 350,000 deaths have been reported [1] .", [["deaths", "DISEASE", 114, 120], ["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35]]], ["Although many people develop respiratory symptoms [2] , a considerable number of cases are asymptomatic or pre-symptomatic with a larger incubation period (potentially lasting longer than 14 days), resulting in a large number of carriers [3] .", [["respiratory", "ANATOMY", 29, 40], ["respiratory symptoms", "DISEASE", 29, 49], ["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20], ["respiratory symptoms", "PROBLEM", 29, 49], ["asymptomatic", "PROBLEM", 91, 103], ["pre-symptomatic", "PROBLEM", 107, 122], ["large", "OBSERVATION_MODIFIER", 213, 218]]], ["This fact, associated with being highly transmissible by large drops, aerosolize and, possibly, by direct contact, contribute to its rapid spread [4, 5] .IntroductionThis pandemic situation has pushed the capacity of health systems to the limit and makes it necessary to consider early diagnosis suspicion for those who have mild symptoms and it is not possible to confirm the presence of the virus [6] .", [["its rapid spread", "PROBLEM", 129, 145], ["mild symptoms", "PROBLEM", 325, 338], ["the virus", "PROBLEM", 389, 398], ["large", "OBSERVATION_MODIFIER", 57, 62], ["drops", "OBSERVATION", 63, 68]]], ["Since China's initial anecdotal reports [7] , there have been a growing number of studies describing a wide frequency range of olfactory and gustatory dysfunction (OGD) in Extended author information available on the last page of the article COVID-19 patients, and guide recommendation for selfisolation in patients with OGD [8, 9] .", [["olfactory", "ANATOMY", 127, 136], ["gustatory", "ANATOMY", 141, 150], ["olfactory and gustatory dysfunction", "DISEASE", 127, 162], ["selfisolation", "DISEASE", 290, 303], ["OGD", "DISEASE", 321, 324], ["olfactory", "TISSUE", 127, 136], ["gustatory", "ANATOMICAL_SYSTEM", 141, 150], ["patients", "ORGANISM", 251, 259], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 251, 259], ["patients", "SPECIES", 307, 315], ["gustatory dysfunction", "PROBLEM", 141, 162], ["selfisolation", "TREATMENT", 290, 303]]], ["Recent studies seem to show a trend that OGD is more frequent in a young [10] and non-hospitalized population [11, 12] .", [["OGD", "DISEASE", 41, 44], ["Recent studies", "TEST", 0, 14], ["OGD", "PROBLEM", 41, 44], ["more frequent", "OBSERVATION_MODIFIER", 48, 61]]], ["The aim of the present study was to investigate whether OGD is present in COVID-19 patients with mild disease evaluated in an ambulatory setting as compared to controls.Ethical issuesThis observational study was approved by the Ethics Committee of Hospital Clinic Barcelona (HCB/2020/0402) and Consorci Sanitari de Terrassa (02-20-188-023).", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["the present study", "TEST", 11, 28], ["OGD", "PROBLEM", 56, 59], ["mild disease", "PROBLEM", 97, 109], ["Ethical issues", "PROBLEM", 169, 183], ["This observational study", "TEST", 183, 207], ["mild", "OBSERVATION_MODIFIER", 97, 101], ["disease", "OBSERVATION", 102, 109]]], ["Verbal informed consent was obtained from all subjects.Study designA multicenter prospective cross-sectional study on SARS-CoV-2 (+) from five Spanish University Hospitals from March 21st to April 18th, 2020.Study populationThe following inclusion criteria were considered: (a) for both groups, adults (\u2265 18 years old) of any gender in an ambulatory setting, (b) COVID-19: subjects with positive RT-PCR for SARS-CoV-2; (c) controls: subjects with common cold/ flu-like symptoms and two negative RT-PCR SARS-CoV-2.", [["SARS-CoV", "SPECIES", 118, 126], ["SARS-CoV", "SPECIES", 407, 415], ["Study", "TEST", 55, 60], ["SARS", "TEST", 118, 122], ["Study population", "TEST", 208, 224], ["PCR", "TEST", 399, 402], ["SARS", "PROBLEM", 407, 411], ["CoV", "TEST", 412, 415], ["common cold/ flu-like symptoms", "PROBLEM", 447, 477], ["PCR SARS", "TEST", 498, 506], ["CoV", "TEST", 507, 510]]], ["All participants were able to be interviewed and to answer the questionnaire.", [["participants", "SPECIES", 4, 16]]], ["The exclusion criteria were: pregnancy, language barrier, psychiatric or neurocognitive impairment, and previous history of OGD (allergic rhinitis, rhinosinusitis, among others).", [["psychiatric", "DISEASE", 58, 69], ["neurocognitive impairment", "DISEASE", 73, 98], ["OGD", "DISEASE", 124, 127], ["allergic rhinitis", "DISEASE", 129, 146], ["rhinosinusitis", "DISEASE", 148, 162], ["pregnancy", "PROBLEM", 29, 38], ["language barrier", "PROBLEM", 40, 56], ["psychiatric or neurocognitive impairment", "PROBLEM", 58, 98], ["OGD (allergic rhinitis", "PROBLEM", 124, 146], ["rhinosinusitis", "PROBLEM", 148, 162], ["allergic rhinitis", "OBSERVATION", 129, 146], ["rhinosinusitis", "OBSERVATION", 148, 162]]], ["All testing was performed with the highest regard for participant's and examiner's safety with appropriate personal protective equipment (PPE).DiagnosisSARS-CoV-2 infection was assessed by RT-PCR.", [["infection", "DISEASE", 163, 172], ["CoV-2", "ORGANISM", 157, 162], ["participant", "SPECIES", 54, 65], ["All testing", "TEST", 0, 11], ["DiagnosisSARS", "TEST", 143, 156], ["CoV", "PROBLEM", 157, 160], ["2 infection", "PROBLEM", 161, 172], ["PCR", "TEST", 192, 195], ["infection", "OBSERVATION", 163, 172]]], ["Different molecular techniques were performed, including Cobas TM 6800 (E and ORF1b genes), Seegene\u2122 (N, E and RdRp genes), and LightCycler TM 480 (E and RdRp genes).", [["Cobas TM 6800", "GENE_OR_GENE_PRODUCT", 57, 70], ["E", "GENE_OR_GENE_PRODUCT", 72, 73], ["ORF1b", "GENE_OR_GENE_PRODUCT", 78, 83], ["Seegene\u2122 (N, E", "GENE_OR_GENE_PRODUCT", 92, 106], ["LightCycler TM 480", "GENE_OR_GENE_PRODUCT", 128, 146], ["E", "GENE_OR_GENE_PRODUCT", 148, 149], ["E and ORF1b genes", "DNA", 72, 89], ["Seegene\u2122", "DNA", 92, 100], ["N, E and RdRp genes", "DNA", 102, 121], ["LightCycler TM 480", "DNA", 128, 146], ["E and RdRp genes", "DNA", 148, 164], ["Different molecular techniques", "TEST", 0, 30], ["Cobas TM", "TEST", 57, 65], ["Seegene\u2122", "TEST", 92, 100], ["LightCycler TM", "TEST", 128, 142]]], ["In a real-time PCR assay, a cycle threshold (CT) is defined as the number of cycles required for the fluorescent signal to cross the threshold.", [["a cycle threshold", "TEST", 26, 43], ["CT", "TEST", 45, 47], ["the fluorescent signal", "TEST", 97, 119]]], ["In our study, a positive result was considered when both analyzed genes were positive.", [["our study", "TEST", 3, 12]]], ["If only one gene was positive with CT < 37, it was also considered positive.", [["CT", "TEST", 35, 37], ["positive", "PROBLEM", 67, 75], ["positive", "OBSERVATION", 67, 75]]], ["If CT was > 37, the exam was repeated in another platform.", [["CT", "TEST", 3, 5], ["the exam", "TEST", 16, 24]]], ["In this new analysis, if both genes were positive, it was considered a positive result, but if it was only one gene with CT > 37, it was considered inconclusive.OutcomesDemographics on gender and age were registered.", [["this new analysis", "TEST", 3, 20], ["CT", "TEST", 121, 123]]], ["A complete questionnaire exploring OGD was created and performed in-person.", [["person", "SPECIES", 68, 74]]], ["The questionnaire included four items: (a) a smell loss visual analogue scale (VAS, 0-10 cm, being 0 no smell loss and 10 maximum smell loss focusing on smell and food/drink flavor; (b) a taste loss VAS with the same score range and grouping where, to avoid confusion between taste and smell/flavor, real taste perceptions (salty, sweet, bitter, and sour/acidic) were emphasized; (c) a question about OGD symptoms onset (days before or after the other COVID-19 symptoms); and (d) a question about recovering from OGD (durations in days).", [["smell loss", "DISEASE", 104, 114], ["smell loss", "DISEASE", 130, 140], ["confusion", "DISEASE", 258, 267], ["sweet", "ORGANISM_SUBDIVISION", 331, 336], ["a smell loss visual analogue scale", "PROBLEM", 43, 77], ["VAS", "TEST", 79, 82], ["smell loss", "PROBLEM", 104, 114], ["maximum smell loss", "PROBLEM", 122, 140], ["a taste loss VAS", "PROBLEM", 186, 202], ["confusion", "PROBLEM", 258, 267], ["OGD symptoms", "PROBLEM", 401, 413], ["symptoms", "PROBLEM", 461, 469]]], ["Participants were asked about the timeline of the onset, duration, and the eventual recovery of the chemosensory symptoms.", [["Participants", "SPECIES", 0, 12], ["the chemosensory symptoms", "PROBLEM", 96, 121]]], ["The VAS for sinonasal symptoms based on the EPOS guidelines classifies related symptoms in mild (VAS > 0-3), moderate (VAS > 3-7) and severe (VAS > 7-10) disease [13] .", [["sinonasal", "ANATOMY", 12, 21], ["sinonasal", "ORGAN", 12, 21], ["sinonasal symptoms", "PROBLEM", 12, 30], ["the EPOS guidelines", "TREATMENT", 40, 59], ["symptoms in mild (VAS", "PROBLEM", 79, 100], ["VAS", "TEST", 119, 122], ["severe (VAS", "PROBLEM", 134, 145], ["disease", "PROBLEM", 154, 161], ["mild", "OBSERVATION_MODIFIER", 91, 95], ["moderate", "OBSERVATION_MODIFIER", 109, 117], ["severe", "OBSERVATION_MODIFIER", 134, 140]]], ["Due to limitations related to the severity of the COVID-19 pandemic, instrumental smell assessment, or chemical gustometry were not performed.Statistical analysisMean and standard deviation for the age, median and the interquartile range for continuous variables were calculated.", [["the COVID", "TEST", 46, 55], ["pandemic", "PROBLEM", 59, 67], ["instrumental smell assessment", "TEST", 69, 98], ["chemical gustometry", "TEST", 103, 122], ["Statistical analysisMean", "TEST", 142, 166]]], ["The normality of the continuous variables was evaluated through the Shapiro-Wilk test with a significance level of p = 0.01.", [["the Shapiro-Wilk test", "TEST", 64, 85]]], ["Chi-square test and Fisher's exact test were used to compare categorical variables between COVID-19 patient's vs controls.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["Chi-square test", "TEST", 0, 15], ["Fisher's exact test", "TEST", 20, 39], ["COVID", "TEST", 91, 96]]], ["T Student test or Mann-Whitney U test helped to compare continuous variables.", [["Whitney U test", "TEST", 23, 37]]], ["Chi-square test and Fisher's exact test were used to compare loss of smell and taste severity in the categorical variables and Kruskal-Wallis test in the continuous variables.", [["loss of smell", "DISEASE", 61, 74], ["taste", "ORGANISM_SUBDIVISION", 79, 84], ["Chi-square test", "TEST", 0, 15], ["Fisher's exact test", "TEST", 20, 39], ["loss of smell", "PROBLEM", 61, 74], ["taste severity in the categorical variables", "PROBLEM", 79, 122], ["Kruskal-Wallis test", "TEST", 127, 146]]], ["Data management and statistical analysis were performed by means of SPSS vs. 21 (SPSS Inc., Chicago, IL, USA) with the alpha level set at 0.05.COVID-19 subjects and controlsA t o t a l o f 1 9 7 C OV I D -1 9 s u b j e c t s ( m e a n age = 46.5 \u00b1 14.5, range 21-89 years, 63.5% female) and 107 controls (mean age = 50.6 \u00b1 16.6, range 20-88 years, 53.3% female) completed the survey.", [["COVID", "PROTEIN", 143, 148], ["statistical analysis", "TEST", 20, 40], ["the alpha level", "TEST", 115, 130], ["COVID", "TEST", 143, 148], ["D", "TEST", 202, 203], ["j e", "TEST", 215, 218], ["t s", "TEST", 221, 224], ["a n age", "TEST", 231, 238], ["\u00b1", "TEST", 246, 247], ["range", "TEST", 254, 259], ["mean age", "TEST", 305, 313]]], ["Demographics and clinical characteristics of both groups are summarized in Table 1 .COVID-19 subjects and controlsThe frequencies of smell and taste loss were significantly higher among COVID-19 subjects (70.1% and 65%, p < 0.001) than in the control group (20.6% and 19.6%), respectively (Fig. 1a) .", [["taste loss", "DISEASE", 143, 153], ["COVID", "PROTEIN", 84, 89], ["COVID", "TEST", 84, 89], ["taste loss", "PROBLEM", 143, 153], ["COVID", "TEST", 186, 191]]], ["Simultaneous OGD was more frequent in COVID-19 group (61.9%) compared to controls (10.3%) (p < 0.001).COVID-19 subjects and controlsBoth, the severity of loss of smell (median = 9, IQR = 3.2 vs median = 5, IQR = 5.8) and loss of taste (median = 9, IQR = 3.8 vs median = 3, IQR = 5) (p < 0.001) as measured by VAS were scored higher in COVID-19 subjects vs controls (Fig. 1b) .Characteristics of COVID-19 subjects by genderFrom a total of 197 COVID-19 subjects 125 (63.5%) were females (mean age = 45.7 \u00b1 14.2 years) and 72 (36.5%) were males (mean age = 47.8 \u00b1 15 years) ( Table 2 ).Characteristics of COVID-19 subjects by genderThe frequencies of simultaneous OGD were significantly higher among females (68%) than in the males group (51.4%, p = 0.021), along with loss of taste (71.2% vs 54.2%, p = 0.016).", [["loss of smell", "DISEASE", 154, 167], ["loss of taste", "DISEASE", 221, 234], ["loss of taste", "DISEASE", 766, 779], ["Simultaneous OGD", "PROBLEM", 0, 16], ["COVID", "TEST", 38, 43], ["COVID", "TEST", 102, 107], ["loss of smell", "PROBLEM", 154, 167], ["IQR", "TEST", 181, 184], ["median", "TEST", 194, 200], ["IQR", "TEST", 206, 209], ["loss of taste", "PROBLEM", 221, 234], ["IQR", "TEST", 248, 251], ["median", "TEST", 261, 267], ["IQR", "TEST", 273, 276], ["VAS", "TEST", 309, 312], ["COVID", "TEST", 335, 340], ["COVID", "TEST", 395, 400], ["COVID", "TEST", 442, 447], ["COVID", "TEST", 602, 607], ["simultaneous OGD", "TEST", 648, 664], ["loss of taste", "PROBLEM", 766, 779], ["p", "TEST", 797, 798]]], ["However, no differences were found in loss of smell (72% vs 66.7%, p = 0.431).", [["loss of smell", "DISEASE", 38, 51], ["loss of smell", "PROBLEM", 38, 51], ["p", "TEST", 67, 68], ["no", "UNCERTAINTY", 9, 11]]], ["As for the severity, females VAS scored higher in loss of taste than males (median = 7, IQR = 10 vs median = 3.8, IQR = 8, p = 0.014), with no differences in loss of smell.Stratification by loss of smell severityA total of 138 COVID-19 subjects reported olfactory dysfunction of which 8 (5.8%) had mild, 32 (23.2%) moderate, and 98 (71%) severe smell loss.", [["olfactory", "ANATOMY", 254, 263], ["loss of taste", "DISEASE", 50, 63], ["loss of smell", "DISEASE", 158, 171], ["loss of smell severityA", "DISEASE", 190, 213], ["olfactory dysfunction", "DISEASE", 254, 275], ["smell loss", "DISEASE", 345, 355], ["olfactory", "ORGAN", 254, 263], ["the severity", "PROBLEM", 7, 19], ["females VAS", "PROBLEM", 21, 32], ["loss of taste", "PROBLEM", 50, 63], ["IQR", "TEST", 88, 91], ["median", "TEST", 100, 106], ["IQR", "TEST", 114, 117], ["p", "TEST", 123, 124], ["differences in loss of smell", "PROBLEM", 143, 171], ["smell severityA", "TEST", 198, 213], ["COVID", "TEST", 227, 232], ["olfactory dysfunction", "PROBLEM", 254, 275], ["severe smell loss", "PROBLEM", 338, 355], ["no", "UNCERTAINTY", 140, 142], ["loss", "OBSERVATION", 158, 162], ["smell", "OBSERVATION", 166, 171], ["mild", "OBSERVATION_MODIFIER", 298, 302], ["moderate", "OBSERVATION_MODIFIER", 315, 323], ["severe", "OBSERVATION_MODIFIER", 338, 344], ["smell loss", "OBSERVATION", 345, 355]]], ["The profile of subjects with severe loss of smell was younger (42.7 years old vs 45.5 years old, p = 0.045), and recovered later (median = 7, IQR = 5.5 vs median = 4, IQR = 3, p = 0.009) than those with mild loss of smell.", [["loss of smell", "DISEASE", 36, 49], ["loss of smell", "DISEASE", 208, 221], ["severe loss of smell", "PROBLEM", 29, 49], ["IQR", "TEST", 142, 145], ["median", "TEST", 155, 161], ["IQR", "TEST", 167, 170], ["mild loss of smell", "PROBLEM", 203, 221], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["mild", "OBSERVATION_MODIFIER", 203, 207], ["loss", "OBSERVATION", 208, 212], ["smell", "OBSERVATION", 216, 221]]], ["However, no differences by severity were found in loss of smell manifested as a first symptom, recovery-rate, and gender (Table 3) .Stratification by loss of taste severityA total of 128 COVID-19 subjects reported taste dysfunction of which 8 (6.3%) had mild, 36 (28.1%) moderate, and 84 (65.6%) severe loss of taste.", [["loss of smell", "DISEASE", 50, 63], ["loss of taste severityA", "DISEASE", 150, 173], ["taste dysfunction", "DISEASE", 214, 231], ["loss of taste", "DISEASE", 303, 316], ["loss of smell", "PROBLEM", 50, 63], ["a first symptom", "PROBLEM", 78, 93], ["taste severityA", "TEST", 158, 173], ["COVID", "TEST", 187, 192], ["taste dysfunction", "PROBLEM", 214, 231], ["severe loss of taste", "PROBLEM", 296, 316], ["no", "UNCERTAINTY", 9, 11], ["mild", "OBSERVATION_MODIFIER", 254, 258]]], ["Some differences were observed compared to findings by stratifying for loss of smell severity.", [["loss of smell", "DISEASE", 71, 84], ["loss of smell severity", "PROBLEM", 71, 93]]], ["No differences by severity were found by age or gender, in taste loss manifested as a first symptom, and recoveryrate.", [["taste loss", "DISEASE", 59, 69], ["taste loss", "PROBLEM", 59, 69], ["a first symptom", "PROBLEM", 84, 99]]], ["However, patients with severe loss of taste recovered later in days (median = 7, IQR = 6 vs median = 2, IQR = 2, p = 0.021), compared to those with mild loss (Table 4 ).DiscussionThe main findings of our study were: (1) subjects with diagnosed COVID-19 were younger, with similar gender, and their olfactory and taste dysfunction was sixfold more common than in control subjects when the impairment was of (3) females had more frequent and more severe loss of taste than males, and more frequently simultaneous OGD; and (4) among COVID-19 subjects with OGD, one out of two had a severe loss of smell and/or taste and late recovery than patients with a milder dysfunction.", [["olfactory", "ANATOMY", 298, 307], ["loss of taste", "DISEASE", 30, 43], ["taste dysfunction", "DISEASE", 312, 329], ["OGD", "DISEASE", 511, 514], ["OGD", "DISEASE", 553, 556], ["loss of smell", "DISEASE", 586, 599], ["patients", "ORGANISM", 9, 17], ["olfactory", "ORGAN", 298, 307], ["taste", "ORGANISM_SUBDIVISION", 312, 317], ["patients", "ORGANISM", 636, 644], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 636, 644], ["severe loss of taste", "PROBLEM", 23, 43], ["IQR", "TEST", 81, 84], ["median", "TEST", 92, 98], ["IQR", "TEST", 104, 107], ["mild loss", "PROBLEM", 148, 157], ["our study", "TEST", 200, 209], ["taste dysfunction", "PROBLEM", 312, 329], ["the impairment", "PROBLEM", 384, 398], ["more severe loss of taste", "PROBLEM", 440, 465], ["OGD", "PROBLEM", 553, 556], ["a severe loss of smell", "PROBLEM", 577, 599], ["a milder dysfunction", "PROBLEM", 650, 670], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["mild", "OBSERVATION_MODIFIER", 148, 152], ["loss", "OBSERVATION", 153, 157], ["severe", "OBSERVATION_MODIFIER", 445, 451], ["severe", "OBSERVATION_MODIFIER", 579, 585], ["loss", "OBSERVATION", 586, 590]]], ["Moreover, subjects with severe loss of smell were younger than those with mild loss.", [["loss of smell", "DISEASE", 31, 44], ["severe loss of smell", "PROBLEM", 24, 44], ["mild loss", "PROBLEM", 74, 83], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["loss", "OBSERVATION_MODIFIER", 31, 35], ["mild", "OBSERVATION_MODIFIER", 74, 78], ["loss", "OBSERVATION", 79, 83]]], ["In our study, a self-reported ordinal quantitative assessment of the chemosensory dysfunction was performed by a validated VAS scale for smell and taste loss separately.DiscussionTong et al. [8] described in a recent meta-analysis of OGD a 52.7% prevalence of smell loss and 43.9% of taste loss in COVID-19 subjects.", [["chemosensory dysfunction", "DISEASE", 69, 93], ["taste loss", "DISEASE", 147, 157], ["smell loss", "DISEASE", 260, 270], ["taste loss", "DISEASE", 284, 294], ["smell", "ORGANISM_SUBDIVISION", 260, 265], ["taste", "ORGANISM_SUBDIVISION", 284, 289], ["our study", "TEST", 3, 12], ["the chemosensory dysfunction", "PROBLEM", 65, 93], ["a validated VAS scale", "TEST", 111, 132], ["smell and taste loss", "PROBLEM", 137, 157], ["smell loss", "PROBLEM", 260, 270], ["taste loss", "PROBLEM", 284, 294], ["COVID", "TEST", 298, 303]]], ["In subgroup analyses of olfactory dysfunction, they demonstrated that studies using validated instruments (such as the University of Pennsylvania Smell Identification Test (UPSIT) [14] , smell component of the National Health and Nutrition Examination Survey (NHANES), short version of the Questionnaire of Olfactory Disorders-Negative Statements [15] , and the COVID-19 Anosmia Reporting Tool [16] ) showed an 86.60% smell loss prevalence compared to 36.64% in studies which used non-validated instruments [8] .", [["olfactory", "ANATOMY", 24, 33], ["olfactory dysfunction", "DISEASE", 24, 45], ["smell loss", "DISEASE", 418, 428], ["olfactory", "ORGAN", 24, 33], ["olfactory dysfunction", "PROBLEM", 24, 45], ["Nutrition Examination", "TEST", 230, 251], ["Olfactory Disorders", "PROBLEM", 307, 326], ["the COVID", "TEST", 358, 367], ["Anosmia", "PROBLEM", 371, 378], ["an 86.60% smell loss prevalence", "PROBLEM", 408, 439], ["olfactory dysfunction", "OBSERVATION", 24, 45]]], ["However, only the study of Lechien et al. [15] used a validated measure to assess In our results, the frequencies of loss of smell (70.1%), loss of taste (65%) or both (61.9%) in the COVID-19 group are similar to those found by Menni et al. [6] , where they reported a 64.76% frequency of OGD, compared with 22.68% on those who tested negative for SARS-CoV-2.DiscussionOur findings on OGD, being predominant in younger subjects and females, were similar to those reported by Lee et al. [10] .", [["loss of smell", "DISEASE", 117, 130], ["loss of taste", "DISEASE", 140, 153], ["OGD", "DISEASE", 289, 292], ["SARS", "DISEASE", 348, 352], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 348, 358], ["SARS-CoV", "SPECIES", 348, 356], ["the study", "TEST", 14, 23], ["loss of smell", "PROBLEM", 117, 130], ["loss of taste", "PROBLEM", 140, 153], ["OGD", "TEST", 289, 292], ["SARS", "TEST", 348, 352], ["CoV", "TEST", 353, 356], ["OGD", "PROBLEM", 385, 388], ["predominant", "OBSERVATION_MODIFIER", 396, 407]]], ["In the normal population, the olfactory dysfunction (OD) and gustatory dysfunction (GD) are commonly described more frequently with older age [17, 18] , while females outperformed males for taste [18] and smell [19] .", [["olfactory", "ANATOMY", 30, 39], ["olfactory dysfunction", "DISEASE", 30, 51], ["gustatory dysfunction", "DISEASE", 61, 82], ["GD", "DISEASE", 84, 86], ["olfactory", "ORGAN", 30, 39], ["the olfactory dysfunction", "PROBLEM", 26, 51], ["gustatory dysfunction", "PROBLEM", 61, 82], ["normal", "OBSERVATION_MODIFIER", 7, 13], ["population", "OBSERVATION_MODIFIER", 14, 24], ["olfactory dysfunction", "OBSERVATION", 30, 51]]], ["In post-viral OD, a higher prevalence in middle-aged women (age 40-69 years) has been described [20] .", [["women", "ORGANISM", 53, 58], ["women", "SPECIES", 53, 58]]], ["Concerning gustatory dysfunction (GD), taste seems to decrease proportionally to the degree of OD regardless of the underlying cause (post-traumatic, idiopathic, post-infectious or chronic rhinosinusitis) [21] and persisted after age-correction [22] .", [["gustatory", "ANATOMY", 11, 20], ["gustatory dysfunction", "DISEASE", 11, 32], ["GD", "DISEASE", 34, 36], ["traumatic", "DISEASE", 139, 148], ["idiopathic", "DISEASE", 150, 160], ["rhinosinusitis", "DISEASE", 189, 203], ["gustatory", "ANATOMICAL_SYSTEM", 11, 20], ["gustatory dysfunction", "PROBLEM", 11, 32], ["traumatic", "PROBLEM", 139, 148], ["idiopathic", "PROBLEM", 150, 160], ["chronic rhinosinusitis", "PROBLEM", 181, 203], ["gustatory dysfunction", "OBSERVATION", 11, 32], ["idiopathic", "OBSERVATION_MODIFIER", 150, 160], ["infectious", "OBSERVATION_MODIFIER", 167, 177], ["chronic", "OBSERVATION_MODIFIER", 181, 188], ["rhinosinusitis", "OBSERVATION", 189, 203]]], ["There have been hypotheses that chemical senses intimately interact, associating impaired olfactory function with decreased gustatory function.", [["olfactory", "ANATOMY", 90, 99], ["gustatory", "ANATOMY", 124, 133], ["olfactory", "ORGAN", 90, 99], ["gustatory", "ORGANISM_SUBDIVISION", 124, 133], ["decreased gustatory function", "PROBLEM", 114, 142], ["impaired", "OBSERVATION_MODIFIER", 81, 89], ["olfactory function", "OBSERVATION", 90, 108], ["decreased", "OBSERVATION_MODIFIER", 114, 123], ["gustatory function", "OBSERVATION", 124, 142]]], ["In contrast to other sensory modalities, they do not tend to show compensatory mechanisms, but rather mutual weakening [22] .", [["compensatory mechanisms", "PROBLEM", 66, 89]]], ["A greater analysis regarding the aetiopathogenesis of the OGD in COVID-19 infection will need further research.DiscussionIn our study, COVID-19 subjects reported most commonly their loss of smell and loss of taste as severe (71% and 65.6%) rather than mild (5.8% and 6.3%).", [["OGD", "DISEASE", 58, 61], ["COVID-19", "CHEMICAL", 65, 73], ["infection", "DISEASE", 74, 83], ["loss of smell", "DISEASE", 182, 195], ["loss of taste", "DISEASE", 200, 213], ["COVID-19", "ORGANISM", 65, 73], ["COVID-19", "SPECIES", 65, 73], ["A greater analysis", "TEST", 0, 18], ["the OGD", "PROBLEM", 54, 61], ["COVID", "TEST", 65, 70], ["19 infection", "PROBLEM", 71, 83], ["further research", "TREATMENT", 94, 110], ["our study", "TEST", 124, 133], ["COVID", "TEST", 135, 140], ["their loss of smell", "PROBLEM", 176, 195], ["loss of taste", "PROBLEM", 200, 213], ["infection", "OBSERVATION", 74, 83], ["severe", "OBSERVATION_MODIFIER", 217, 223]]], ["Moreover, a shorter recovery time was observed in those patients with mild OGD (VAS > 0-3 cm).", [["OGD", "DISEASE", 75, 78], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["mild OGD", "PROBLEM", 70, 78], ["VAS", "TEST", 80, 83], ["mild", "OBSERVATION_MODIFIER", 70, 74], ["OGD", "OBSERVATION", 75, 78]]], ["These results are in agreement with those reported by London et al. [24] in post-infectious OD, where microsmic patients were more than twice as likely to improve into the normal range of smell than anosmic patients.", [["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 207, 215], ["post-infectious", "OBSERVATION_MODIFIER", 76, 91], ["normal range", "OBSERVATION_MODIFIER", 172, 184]]], ["This was also found by Cavazzana et al. [25] , showing that higher/better initial smell scores using Sniffin' Sticks were associated with higher probability of later normosmia.DiscussionOur study had the following strengths: (1) RT-PCR confirmed positive COVID-19 and control group matched by age with common cold/flu-like symptoms and two negative RT-PCR; (2) in-place personal interview using PPE allowing a better comprehension of the questionnaire, emphasizing the difference between flavor and taste to avoid confusion; (3) VAS scores for both smell and taste loss was obtained, allowing a self-reported ordinal quantitative assessment of the sensory dysfunction.", [["normosmia", "DISEASE", 166, 175], ["confusion", "DISEASE", 514, 523], ["taste loss", "DISEASE", 559, 569], ["sensory dysfunction", "DISEASE", 648, 667], ["COVID-19", "DNA", 255, 263], ["Sniffin' Sticks", "TREATMENT", 101, 116], ["later normosmia", "PROBLEM", 160, 175], ["DiscussionOur study", "TEST", 176, 195], ["RT-PCR", "TEST", 229, 235], ["COVID", "TEST", 255, 260], ["common cold/flu-like symptoms", "PROBLEM", 302, 331], ["PPE", "TREATMENT", 395, 398], ["confusion", "PROBLEM", 514, 523], ["VAS scores", "TEST", 529, 539], ["both smell and taste loss", "PROBLEM", 544, 569], ["the sensory dysfunction", "PROBLEM", 644, 667], ["sensory dysfunction", "OBSERVATION", 648, 667]]], ["On the other hand, our study also had limitations: (1) suboptimal sensitivity of SARS-CoV-2 RT-PCR on nasopharyngeal swab might have led to misclassification and diagnostic bias (false positives and/ or false negatives); (2) lack of respiratory viruses RT-PCR test detection for the control group (rhinovirus, influenza, parainfluenza, among others); (3) due to unnecessary safety risk for physicians and discomfort for patients due to their medical condition, no validated questionnaire, instrumental olfaction or gustatory assessment were considered; and (4) COVID-19 survey was measured at only one point related to its onset date, although further follow-up will be performed.ConclusionsOGD is a prevalent symptom in COVID-19 ambulatory subjects, with higher frequencies and severity of the chemosensory impairment compared to controls (other respiratory viruses), this difference being more outstanding in the loss of both senses together.", [["nasopharyngeal swab", "ANATOMY", 102, 121], ["influenza", "DISEASE", 310, 319], ["parainfluenza", "DISEASE", 321, 334], ["chemosensory impairment", "DISEASE", 795, 818], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 102, 121], ["rhinovirus", "ORGANISM", 298, 308], ["parainfluenza", "ORGANISM", 321, 334], ["patients", "ORGANISM", 420, 428], ["parainfluenza", "SPECIES", 321, 334], ["patients", "SPECIES", 420, 428], ["SARS-CoV", "SPECIES", 81, 89], ["our study", "TEST", 19, 28], ["SARS", "TEST", 81, 85], ["CoV", "TEST", 86, 89], ["PCR", "TEST", 95, 98], ["nasopharyngeal swab", "TEST", 102, 121], ["diagnostic bias", "TEST", 162, 177], ["false positives", "TEST", 179, 194], ["false negatives)", "PROBLEM", 203, 219], ["respiratory viruses", "PROBLEM", 233, 252], ["PCR test detection", "TEST", 256, 274], ["rhinovirus", "PROBLEM", 298, 308], ["influenza", "PROBLEM", 310, 319], ["parainfluenza", "PROBLEM", 321, 334], ["discomfort", "PROBLEM", 405, 415], ["their medical condition", "PROBLEM", 436, 459], ["gustatory assessment", "TEST", 515, 535], ["COVID", "TEST", 561, 566], ["a prevalent symptom", "PROBLEM", 698, 717], ["COVID", "TEST", 721, 726], ["higher frequencies", "PROBLEM", 756, 774], ["the chemosensory impairment", "PROBLEM", 791, 818], ["other respiratory viruses", "PROBLEM", 841, 866], ["nasopharyngeal", "ANATOMY", 102, 116], ["respiratory", "ANATOMY", 233, 244], ["viruses", "OBSERVATION", 245, 252]]], ["In the COVID-19 group, OGD was predominant in younger subjects and females.", [["OGD", "PROBLEM", 23, 26], ["predominant", "OBSERVATION_MODIFIER", 31, 42]]], ["Stratified analysis by the severity of OGD showed that more than 60% of COVID-19 subjects presented a severe OGD that took a longer time to recover as compared to those with mild symptoms.", [["OGD", "DISEASE", 109, 112], ["Stratified analysis", "TEST", 0, 19], ["OGD", "TEST", 39, 42], ["COVID", "TEST", 72, 77], ["a severe OGD", "PROBLEM", 100, 112], ["mild symptoms", "PROBLEM", 174, 187], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["OGD", "OBSERVATION", 109, 112]]], ["Concerning loss of smell severity, the subjects with higher VAS scores were younger.", [["loss of smell", "DISEASE", 11, 24], ["loss of smell severity", "PROBLEM", 11, 33], ["higher VAS scores", "PROBLEM", 53, 70], ["loss", "OBSERVATION_MODIFIER", 11, 15], ["smell severity", "OBSERVATION_MODIFIER", 19, 33]]], ["Further studies will be needed to provide explanations for these chemosensory impairments.ConclusionsAuthor contributions AID and MJRL: designed, collect data and analyze results and final approval of the manuscript.", [["chemosensory impairments", "DISEASE", 65, 89], ["Further studies", "TEST", 0, 15], ["these chemosensory impairments", "PROBLEM", 59, 89], ["collect data", "TEST", 146, 158]]], ["GCC: collaborate with the revisions of the final manuscript.ConclusionsFunding The authors declare that no funding was received for the present study.", [["the present study", "TEST", 132, 149]]]], "6c6105efac1b65a91a4559fa9f0c8c79ec56cd08": [["As early as 2007, a paper published in the Clinical Microbiology Reviews on SARS coronavirus infection already warned us that \"the presence of a large reservoir of SARS-CoV-like viruses in horseshoe bats, together with the culture of eating exotic mammals in southern China, is a time bomb\".", [["SARS coronavirus infection", "DISEASE", 76, 102], ["SARS", "DISEASE", 164, 168], ["SARS coronavirus", "ORGANISM", 76, 92], ["SARS-CoV-like viruses", "ORGANISM", 164, 185], ["horseshoe bats", "ORGANISM", 189, 203], ["SARS coronavirus", "SPECIES", 76, 92], ["SARS-CoV", "SPECIES", 164, 172], ["SARS coronavirus infection", "PROBLEM", 76, 102], ["SARS", "PROBLEM", 164, 168], ["CoV", "PROBLEM", 169, 172], ["the culture", "TEST", 219, 230], ["large", "OBSERVATION_MODIFIER", 145, 150], ["reservoir", "OBSERVATION", 151, 160]]], ["1 In spite of this grave alert, we are currently experiencing one of the most serious pandemias in human history.", [["pandemias", "DISEASE", 86, 95], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104]]], ["I believe most of us are still in absolute dismay with this disease, which was first detected in hospitals in Wuhan and probably originated in the Huanan seafood market in China.", [["this disease", "PROBLEM", 55, 67]]], ["2 Due to the high degree of contamination of this virus, the world came to a halt or at least 1/3 of it.", [["this virus", "PROBLEM", 45, 55], ["high degree", "OBSERVATION_MODIFIER", 13, 24], ["contamination", "OBSERVATION", 28, 41]]], ["So much so that leaders in the world seem to be lost, divided in their roles of great responsibility, between saving lives due to the corona virus or focusing on the consequences of the economic lag that will follow due to social isolation.", [["corona virus", "ORGANISM", 134, 146], ["the corona virus", "PROBLEM", 130, 146], ["social isolation", "TREATMENT", 223, 239]]]], "162d4fb4e8ab8fb119ef898b1173b61e4049c239": [["Virus BuddingLara Rheinemann and Wesley I Sundquist, University of Utah, Salt Lake City, UT, United States r 2020 Elsevier Inc. All rights reserved.OverviewTo spread infection, viruses must exit producer cells and transmit their genetic material into target cells.", [["cells", "ANATOMY", 204, 209], ["cells", "ANATOMY", 258, 263], ["infection", "DISEASE", 166, 175], ["Virus", "ORGANISM", 0, 5], ["producer cells", "CELL", 195, 209], ["cells", "CELL", 258, 263], ["producer cells", "CELL_TYPE", 195, 209], ["target cells", "CELL_TYPE", 251, 263], ["OverviewTo spread infection", "PROBLEM", 148, 175], ["viruses", "PROBLEM", 177, 184], ["spread", "OBSERVATION_MODIFIER", 159, 165], ["infection", "OBSERVATION", 166, 175], ["target cells", "OBSERVATION", 251, 263]]], ["Viruses have evolved two general strategies for cellular egress: (1) Enveloped viruses acquire a host-derived lipid membrane as they breach the limiting membranes of the cell.", [["cellular", "ANATOMY", 48, 56], ["lipid membrane", "ANATOMY", 110, 124], ["membranes", "ANATOMY", 153, 162], ["cell", "ANATOMY", 170, 174], ["cellular", "CELL", 48, 56], ["Enveloped viruses", "ORGANISM", 69, 86], ["lipid membrane", "MULTI-TISSUE_STRUCTURE", 110, 124], ["membranes", "CELLULAR_COMPONENT", 153, 162], ["cell", "CELL", 170, 174], ["Viruses", "PROBLEM", 0, 7], ["Enveloped viruses", "PROBLEM", 69, 86], ["a host-derived lipid membrane", "TREATMENT", 95, 124], ["viruses", "OBSERVATION", 79, 86]]], ["During this process, the viral membrane typically also acquires one or more viral glycoproteins that bind target cell receptors and facilitate the membrane fusion step required for viral entry.Overview(2) Non-enveloped viruses, by contrast, exit cells when the plasma membrane is disrupted, typically by cell lysis.", [["membrane", "ANATOMY", 31, 39], ["cell", "ANATOMY", 113, 117], ["membrane", "ANATOMY", 147, 155], ["cells", "ANATOMY", 246, 251], ["plasma membrane", "ANATOMY", 261, 276], ["cell", "ANATOMY", 304, 308], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["cell", "CELL", 113, 117], ["membrane", "CELLULAR_COMPONENT", 147, 155], ["cells", "CELL", 246, 251], ["plasma membrane", "CELLULAR_COMPONENT", 261, 276], ["cell", "CELL", 304, 308], ["viral glycoproteins", "PROTEIN", 76, 95], ["target cell receptors", "PROTEIN", 106, 127], ["exit cells", "CELL_TYPE", 241, 251], ["the viral membrane", "PROBLEM", 21, 39], ["viral glycoproteins", "TREATMENT", 76, 95], ["target cell receptors", "TREATMENT", 106, 127], ["the membrane fusion step", "TREATMENT", 143, 167], ["viral entry", "PROBLEM", 181, 192], ["Non-enveloped viruses", "PROBLEM", 205, 226], ["the plasma membrane", "TEST", 257, 276], ["viral membrane", "OBSERVATION", 25, 39], ["cell lysis", "OBSERVATION", 304, 314]]], ["Non-enveloped viruses then infect target cells either by disrupting limiting membranes to gain access to the cytoplasm or by pumping their nucleic acids directly into the cell.", [["cells", "ANATOMY", 41, 46], ["membranes", "ANATOMY", 77, 86], ["cytoplasm", "ANATOMY", 109, 118], ["cell", "ANATOMY", 171, 175], ["nucleic acids", "CHEMICAL", 139, 152], ["cells", "CELL", 41, 46], ["membranes", "CELLULAR_COMPONENT", 77, 86], ["cytoplasm", "ORGANISM_SUBSTANCE", 109, 118], ["cell", "CELL", 171, 175], ["target cells", "CELL_TYPE", 34, 46], ["Non-enveloped viruses", "PROBLEM", 0, 21], ["infect target cells", "PROBLEM", 27, 46], ["pumping their nucleic acids", "TREATMENT", 125, 152], ["viruses", "OBSERVATION", 14, 21], ["cell", "ANATOMY", 171, 175]]], ["In recent years, the distinction between enveloped and non-enveloped viruses has been blurred by the discovery that some viruses, traditionally thought of as non-enveloped, can exit cells within vesicles.", [["cells", "ANATOMY", 182, 187], ["vesicles", "ANATOMY", 195, 203], ["cells", "CELL", 182, 187], ["vesicles", "CELLULAR_COMPONENT", 195, 203], ["the distinction between enveloped and non-enveloped viruses", "PROBLEM", 17, 76], ["some viruses", "PROBLEM", 116, 128], ["non-enveloped", "OBSERVATION_MODIFIER", 55, 68], ["viruses", "OBSERVATION", 69, 76], ["viruses", "OBSERVATION", 121, 128], ["exit cells", "OBSERVATION", 177, 187]]], ["These are termed \"quasi-enveloped\" viruses.OverviewThe process of enveloped virus release comprises a series of coordinated steps, which are illustrated for human immunodeficiency virus type 1 (HIV-1) in Fig. 1 :Overview(1) Assembly: Viral proteins and other essential components co-assemble to form virions.", [["virions", "ANATOMY", 300, 307], ["human immunodeficiency virus", "DISEASE", 157, 185], ["human immunodeficiency virus type 1", "ORGANISM", 157, 192], ["HIV-1", "ORGANISM", 194, 199], ["Viral", "ORGANISM", 234, 239], ["virions", "CELLULAR_COMPONENT", 300, 307], ["Viral proteins", "PROTEIN", 234, 248], ["human immunodeficiency virus type 1", "SPECIES", 157, 192], ["HIV-1", "SPECIES", 194, 199], ["human immunodeficiency virus type 1", "SPECIES", 157, 192], ["HIV-1", "SPECIES", 194, 199], ["enveloped virus release", "TREATMENT", 66, 89], ["human immunodeficiency virus type", "PROBLEM", 157, 190], ["Viral proteins", "PROBLEM", 234, 248]]], ["Many viruses assemble at the plasma membrane, but others assemble at internal membranes or in the cytoplasm before trafficking to the plasma membrane or exiting via the secretory system.", [["plasma membrane", "ANATOMY", 29, 44], ["membranes", "ANATOMY", 78, 87], ["cytoplasm", "ANATOMY", 98, 107], ["plasma membrane", "ANATOMY", 134, 149], ["secretory system", "ANATOMY", 169, 185], ["plasma membrane", "CELLULAR_COMPONENT", 29, 44], ["internal membranes", "CELLULAR_COMPONENT", 69, 87], ["cytoplasm", "ORGANISM_SUBSTANCE", 98, 107], ["plasma membrane", "CELLULAR_COMPONENT", 134, 149], ["Many viruses", "PROBLEM", 0, 12], ["viruses", "OBSERVATION", 5, 12], ["internal membranes", "ANATOMY", 69, 87], ["secretory system", "ANATOMY", 169, 185]]], ["(2) Envelopment: The host membrane is bent and wrapped around the nascent virion.Overview(3) Budding: The membrane stalk connecting the virion to the host membrane is constricted and severed to release the enveloped particle.", [["membrane", "ANATOMY", 26, 34], ["virion", "ANATOMY", 74, 80], ["membrane stalk", "ANATOMY", 106, 120], ["virion", "ANATOMY", 136, 142], ["membrane", "ANATOMY", 155, 163], ["membrane", "CELLULAR_COMPONENT", 26, 34], ["virion", "CELLULAR_COMPONENT", 74, 80], ["membrane stalk", "CELLULAR_COMPONENT", 106, 120], ["virion", "CELLULAR_COMPONENT", 136, 142], ["membrane", "CELLULAR_COMPONENT", 155, 163], ["The membrane stalk", "TREATMENT", 102, 120], ["nascent virion", "OBSERVATION", 66, 80], ["host membrane", "ANATOMY", 150, 163], ["constricted", "OBSERVATION", 167, 178], ["enveloped", "OBSERVATION_MODIFIER", 206, 215], ["particle", "OBSERVATION_MODIFIER", 216, 224]]], ["(4) Maturation: Most enveloped viruses undergo further proteolytic and conformational maturation steps during or after budding.", [["further proteolytic", "TREATMENT", 47, 66], ["conformational maturation steps", "TREATMENT", 71, 102]]], ["Maturation converts the assembly-competent virion into an infectious virus that can enter, uncoat, and replicate in the new target cell.OverviewThe complex series of events that accompany enveloped viral egress must be coordinated spatially and temporally, and these events are typically orchestrated by virally-encoded, multifunctional structural proteins.", [["cell", "ANATOMY", 131, 135], ["cell", "CELL", 131, 135], ["target cell", "CELL_TYPE", 124, 135], ["multifunctional structural proteins", "PROTEIN", 321, 356], ["an infectious virus", "PROBLEM", 55, 74], ["enveloped viral egress", "PROBLEM", 188, 210], ["infectious", "OBSERVATION", 58, 68], ["new", "OBSERVATION_MODIFIER", 120, 123], ["target cell", "OBSERVATION", 124, 135], ["viral egress", "OBSERVATION", 198, 210]]], ["These proteins bind and remodel the membrane, self-assemble into virions, package other essential components such as nucleic acids into the nascent virion, and contain or recruit all of the activities necessary for budding and maturation.", [["membrane", "ANATOMY", 36, 44], ["virions", "ANATOMY", 65, 72], ["virion", "ANATOMY", 148, 154], ["nucleic acids", "CHEMICAL", 117, 130], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["virion", "CELLULAR_COMPONENT", 148, 154], ["These proteins bind", "PROBLEM", 0, 19], ["nucleic acids", "TREATMENT", 117, 130], ["the nascent virion", "TREATMENT", 136, 154], ["budding", "PROBLEM", 215, 222], ["nascent virion", "OBSERVATION", 140, 154]]], ["This article will describe general principles of enveloped virus assembly and release using the well-characterized HIV-1 Gag protein as a paradigm for a viral structural protein.", [["HIV-1", "ORGANISM", 115, 120], ["Gag", "ORGANISM", 121, 124], ["HIV-1 Gag protein", "PROTEIN", 115, 132], ["viral structural protein", "PROTEIN", 153, 177], ["HIV-1", "SPECIES", 115, 120], ["HIV-1", "SPECIES", 115, 120], ["enveloped virus", "PROBLEM", 49, 64], ["a viral structural protein", "PROBLEM", 151, 177]]], ["Important principles employed by other viral families will also be discussed.AssemblyAll retroviruses, including HIV-1, express a Gag polyprotein that coordinates assembly of the immature virion (Sundquist and Krausslich, 2012; Meng and Lever, 2013; Lingappa et al., 2014) .", [["retroviruses", "ORGANISM", 89, 101], ["HIV-1", "ORGANISM", 113, 118], ["Gag", "GENE_OR_GENE_PRODUCT", 130, 133], ["Gag polyprotein", "PROTEIN", 130, 145], ["HIV-1", "SPECIES", 113, 118], ["HIV-1", "SPECIES", 113, 118], ["HIV", "TEST", 113, 116], ["a Gag polyprotein", "PROBLEM", 128, 145], ["retroviruses", "OBSERVATION", 89, 101]]], ["When expressed alone, Gag is released within virus-like particles (VLPs), indicating that it contains or recruits all activities necessary for assembly, envelopment, and budding.", [["Gag", "GENE_OR_GENE_PRODUCT", 22, 25], ["virus-like particles", "ORGANISM", 45, 65], ["VLPs", "ORGANISM", 67, 71], ["Gag", "PROTEIN", 22, 25]]], ["An exciting new Fig. 1 Stages of HIV-1 virion formation.", [["HIV-1 virion", "ORGANISM", 33, 45], ["HIV-1", "SPECIES", 33, 38], ["HIV-1", "SPECIES", 33, 38], ["HIV", "PROBLEM", 33, 36], ["new", "OBSERVATION_MODIFIER", 12, 15], ["Fig", "OBSERVATION_MODIFIER", 16, 19], ["HIV", "OBSERVATION", 33, 36]]], ["HIV-1 virion formation is coordinated by the multifunctional structural polyprotein Gag.", [["HIV-1", "ORGANISM", 0, 5], ["virion", "ORGANISM", 6, 12], ["Gag", "GENE_OR_GENE_PRODUCT", 84, 87], ["multifunctional structural polyprotein Gag", "PROTEIN", 45, 87], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["polyprotein Gag", "OBSERVATION", 72, 87]]], ["Complexes of Gag with the viral RNA genome (blue) traffic to the plasma membrane where Gag assembles and binds other virion components, including the longer Gag-Pol polyprotein, which contains the viral protease, reverse transcriptase and RNase H enzymes.", [["plasma membrane", "ANATOMY", 65, 80], ["Gag", "GENE_OR_GENE_PRODUCT", 13, 16], ["plasma membrane", "CELLULAR_COMPONENT", 65, 80], ["Gag", "GENE_OR_GENE_PRODUCT", 87, 90], ["Pol", "GENE_OR_GENE_PRODUCT", 161, 164], ["RNase H enzymes", "GENE_OR_GENE_PRODUCT", 239, 254], ["Gag", "PROTEIN", 13, 16], ["viral RNA genome", "DNA", 26, 42], ["Gag", "PROTEIN", 87, 90], ["virion components", "PROTEIN", 117, 134], ["Gag", "PROTEIN", 157, 160], ["Pol polyprotein", "PROTEIN", 161, 176], ["viral protease", "PROTEIN", 197, 211], ["reverse transcriptase", "PROTEIN", 213, 234], ["RNase H enzymes", "PROTEIN", 239, 254], ["Complexes of Gag", "PROBLEM", 0, 16], ["the viral RNA genome (blue)", "PROBLEM", 22, 49], ["the longer Gag", "TEST", 146, 160], ["Pol polyprotein", "TREATMENT", 161, 176], ["the viral protease", "TREATMENT", 193, 211], ["RNase H enzymes", "TEST", 239, 254], ["Gag", "OBSERVATION", 13, 16], ["viral RNA genome", "OBSERVATION", 26, 42], ["Gag", "OBSERVATION", 87, 90], ["viral protease", "OBSERVATION", 197, 211]]], ["Gag also recruits three different host factors to facilitate membrane constriction and fission: AMOT-NEDD4L (orange and light purple, respectively), and the early-acting ESCRTassociated factors, ESCRT-I/II (pink) and ALIX (blue), which in turn recruit ESCRT-III proteins (green).", [["membrane", "ANATOMY", 61, 69], ["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["membrane", "CELLULAR_COMPONENT", 61, 69], ["AMOT-NEDD4L", "GENE_OR_GENE_PRODUCT", 96, 107], ["ESCRT-I/II (pink)", "GENE_OR_GENE_PRODUCT", 195, 212], ["ALIX (blue)", "GENE_OR_GENE_PRODUCT", 217, 228], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 252, 261], ["Gag", "PROTEIN", 0, 3], ["AMOT", "PROTEIN", 96, 100], ["NEDD4L", "PROTEIN", 101, 107], ["early-acting ESCRTassociated factors", "PROTEIN", 157, 193], ["ESCRT", "PROTEIN", 195, 200], ["I/II", "PROTEIN", 201, 205], ["pink", "PROTEIN", 207, 211], ["ALIX", "PROTEIN", 217, 221], ["ESCRT-III proteins", "PROTEIN", 252, 270], ["facilitate membrane constriction", "PROBLEM", 50, 82], ["AMOT", "TEST", 96, 100]]], ["ESCRT-III proteins form polymeric filaments that constrict the bud neck with the help of the VPS4 AAA \u00fe ATPase and its cofactor LIP5.", [["filaments", "ANATOMY", 34, 43], ["bud neck", "ANATOMY", 63, 71], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 0, 9], ["bud neck", "ORGAN", 63, 71], ["VPS4 AAA \u00fe ATPase", "GENE_OR_GENE_PRODUCT", 93, 110], ["LIP5", "GENE_OR_GENE_PRODUCT", 128, 132], ["ESCRT-III proteins", "PROTEIN", 0, 18], ["VPS4", "PROTEIN", 93, 97], ["AAA", "PROTEIN", 98, 101], ["ATPase", "PROTEIN", 104, 110], ["LIP5", "PROTEIN", 128, 132], ["polymeric filaments", "PROBLEM", 24, 43], ["III proteins", "OBSERVATION_MODIFIER", 6, 18], ["polymeric filaments", "OBSERVATION", 24, 43], ["bud", "ANATOMY_MODIFIER", 63, 66], ["neck", "ANATOMY", 67, 71], ["AAA", "OBSERVATION", 98, 101]]], ["Protease activation during budding leads to Gag and Gag-Pol processing and formation of the mature, infectious virion. variation on this same theme is the discovery of Gag-related cellular proteins that can self-assemble, exit producer cells, and transfer RNA molecules between cells (Pastuzyn et al., 2018; Ashley et al., 2018) .AssemblyAs illustrated in Fig. 2 , HIV-1 Gag comprises four functional elements: MA, CA, NC and p6, connected by two spacer peptides: SP1 and SP2.", [["cellular", "ANATOMY", 180, 188], ["cells", "ANATOMY", 236, 241], ["cells", "ANATOMY", 278, 283], ["Protease", "GENE_OR_GENE_PRODUCT", 0, 8], ["budding", "CELLULAR_COMPONENT", 27, 34], ["Gag", "GENE_OR_GENE_PRODUCT", 44, 47], ["Gag-Pol", "GENE_OR_GENE_PRODUCT", 52, 59], ["Gag-", "GENE_OR_GENE_PRODUCT", 168, 172], ["cellular", "CELL", 180, 188], ["cells", "CELL", 236, 241], ["cells", "CELL", 278, 283], ["HIV-1 Gag", "ORGANISM", 365, 374], ["MA", "GENE_OR_GENE_PRODUCT", 411, 413], ["CA", "GENE_OR_GENE_PRODUCT", 415, 417], ["NC", "GENE_OR_GENE_PRODUCT", 419, 421], ["p6", "GENE_OR_GENE_PRODUCT", 426, 428], ["SP1", "GENE_OR_GENE_PRODUCT", 464, 467], ["SP2", "GENE_OR_GENE_PRODUCT", 472, 475], ["Gag", "PROTEIN", 44, 47], ["Gag", "PROTEIN", 52, 55], ["Pol", "PROTEIN", 56, 59], ["Gag-related cellular proteins", "PROTEIN", 168, 197], ["producer cells", "CELL_TYPE", 227, 241], ["RNA molecules", "PROTEIN", 256, 269], ["HIV-1 Gag", "PROTEIN", 365, 374], ["MA", "PROTEIN", 411, 413], ["CA", "PROTEIN", 415, 417], ["p6", "DNA", 426, 428], ["SP1", "PROTEIN", 464, 467], ["SP2", "PROTEIN", 472, 475], ["HIV-1", "SPECIES", 365, 370], ["HIV-1", "SPECIES", 365, 370], ["Protease activation", "TREATMENT", 0, 19], ["Gag-related cellular proteins", "PROBLEM", 168, 197], ["exit producer cells", "PROBLEM", 222, 241], ["HIV", "PROBLEM", 365, 368], ["CA, NC and p6", "TREATMENT", 415, 428], ["infectious virion", "OBSERVATION", 100, 117], ["cellular proteins", "OBSERVATION", 180, 197]]], ["The MA domain in Gag (MA Gag ) targets assembly to the plasma membrane, NC Gag binds the dimeric viral RNA genome, the CA Gag and SP1 Gag elements mediate spherical particle assembly, and p6 Gag recruits cellular ESCRT (Endosomal Sorting Complexes Required for Transport) pathway factors required for virus budding.", [["plasma membrane", "ANATOMY", 55, 70], ["cellular", "ANATOMY", 204, 212], ["Gag (MA Gag", "GENE_OR_GENE_PRODUCT", 17, 28], ["plasma membrane", "CELLULAR_COMPONENT", 55, 70], ["NC Gag", "GENE_OR_GENE_PRODUCT", 72, 78], ["CA Gag", "GENE_OR_GENE_PRODUCT", 119, 125], ["SP1", "GENE_OR_GENE_PRODUCT", 130, 133], ["p6 Gag", "GENE_OR_GENE_PRODUCT", 188, 194], ["cellular", "CELL", 204, 212], ["Endosomal Sorting Complexes", "GENE_OR_GENE_PRODUCT", 220, 247], ["MA domain", "PROTEIN", 4, 13], ["Gag", "PROTEIN", 17, 20], ["MA Gag", "PROTEIN", 22, 28], ["NC Gag", "PROTEIN", 72, 78], ["dimeric viral RNA genome", "DNA", 89, 113], ["CA Gag and SP1 Gag elements", "DNA", 119, 146], ["p6 Gag", "PROTEIN", 188, 194], ["cellular ESCRT", "PROTEIN", 204, 218], ["Endosomal Sorting Complexes Required for Transport) pathway factors", "PROTEIN", 220, 287], ["the plasma membrane", "TEST", 51, 70], ["the dimeric viral RNA genome", "PROBLEM", 85, 113], ["the CA Gag", "TEST", 115, 125], ["Transport) pathway factors", "TREATMENT", 261, 287], ["virus budding", "PROBLEM", 301, 314], ["Gag", "OBSERVATION", 17, 20], ["viral RNA genome", "OBSERVATION", 97, 113], ["spherical particle", "OBSERVATION", 155, 173], ["cellular ESCRT", "OBSERVATION", 204, 218]]], ["Gag also packages several other components required for full infectivity, including the viral enzymes, which are packaged as co-assembling Gag-Pol fusion proteins, the viral Env protein, whose intracellular domain interacts with MA Gag , and Viral Protein R (Vpr), which binds p6 Gag .Assembly(1) RNA packaging: Following synthesis in the cytoplasm, Gag monomers or low-order multimers bind two associated copies of the full-length viral genomic RNA through a highly structured packaging site located near the 5 0 end of the genome (Jouvenet et al., 2009; Kutluay and Bieniasz, 2010; Keane et al., 2015) .", [["intracellular", "ANATOMY", 193, 206], ["cytoplasm", "ANATOMY", 339, 348], ["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["Gag", "GENE_OR_GENE_PRODUCT", 139, 142], ["Pol", "GENE_OR_GENE_PRODUCT", 143, 146], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 193, 206], ["MA Gag", "GENE_OR_GENE_PRODUCT", 229, 235], ["Viral Protein R", "GENE_OR_GENE_PRODUCT", 242, 257], ["Vpr", "GENE_OR_GENE_PRODUCT", 259, 262], ["p6 Gag", "GENE_OR_GENE_PRODUCT", 277, 283], ["cytoplasm", "ORGANISM_SUBSTANCE", 339, 348], ["Gag", "GENE_OR_GENE_PRODUCT", 350, 353], ["Gag", "PROTEIN", 0, 3], ["viral enzymes", "PROTEIN", 88, 101], ["Gag", "PROTEIN", 139, 142], ["Pol fusion proteins", "PROTEIN", 143, 162], ["viral Env protein", "PROTEIN", 168, 185], ["intracellular domain", "PROTEIN", 193, 213], ["MA Gag", "PROTEIN", 229, 235], ["Viral Protein R", "PROTEIN", 242, 257], ["Vpr", "PROTEIN", 259, 262], ["p6 Gag", "PROTEIN", 277, 283], ["Gag monomers", "PROTEIN", 350, 362], ["low-order multimers", "PROTEIN", 366, 385], ["viral genomic RNA", "RNA", 432, 449], ["packaging site", "DNA", 478, 492], ["5 0 end", "DNA", 510, 517], ["full infectivity", "PROBLEM", 56, 72], ["the viral enzymes", "TEST", 84, 101], ["Gag", "TEST", 139, 142], ["Pol fusion proteins", "TEST", 143, 162], ["the viral Env protein", "TEST", 164, 185], ["MA Gag", "TEST", 229, 235], ["Viral Protein", "TEST", 242, 255], ["Vpr", "TEST", 259, 262], ["RNA packaging", "TREATMENT", 297, 310], ["synthesis in the cytoplasm", "TREATMENT", 322, 348], ["Gag monomers", "PROBLEM", 350, 362], ["the full-length viral genomic RNA", "PROBLEM", 416, 449], ["a highly structured packaging site", "PROBLEM", 458, 492], ["viral Env", "OBSERVATION", 168, 177], ["genomic RNA", "OBSERVATION", 438, 449]]], ["This interaction is mediated by NC Gag and enables specific selection of the HIV-1 genome over cellular RNAs and viral RNAs undergoing translation (Kaddis Maldonado and Parent, 2016; Dubois et al., 2018; Kuzembayeva et al., 2014 , Brown et al., 2020 .", [["cellular", "ANATOMY", 95, 103], ["NC Gag", "GENE_OR_GENE_PRODUCT", 32, 38], ["HIV-1", "ORGANISM", 77, 82], ["cellular", "CELL", 95, 103], ["NC Gag", "PROTEIN", 32, 38], ["HIV-1 genome", "DNA", 77, 89], ["cellular RNAs", "RNA", 95, 108], ["viral RNAs", "RNA", 113, 123], ["HIV-1", "SPECIES", 77, 82], ["HIV-1", "SPECIES", 77, 82], ["the HIV", "PROBLEM", 73, 80], ["viral RNAs", "OBSERVATION", 113, 123]]], ["Several host proteins, including ABCE1, Staufen1, and DDX6, can associate with Gag-RNA complexes and have been proposed to promote Gag trafficking, multimerization, and/or genome encapsidation, although these activities are not yet fully defined (Reed et al., 2012; Zimmerman et al., 2002; Chatel-Chaix et al., 2007) .", [["ABCE1", "GENE_OR_GENE_PRODUCT", 33, 38], ["Staufen1", "GENE_OR_GENE_PRODUCT", 40, 48], ["DDX6", "GENE_OR_GENE_PRODUCT", 54, 58], ["Gag", "GENE_OR_GENE_PRODUCT", 79, 82], ["Gag", "GENE_OR_GENE_PRODUCT", 131, 134], ["genome", "CELLULAR_COMPONENT", 172, 178], ["ABCE1", "PROTEIN", 33, 38], ["Staufen1", "PROTEIN", 40, 48], ["DDX6", "PROTEIN", 54, 58], ["Gag-RNA complexes", "PROTEIN", 79, 96], ["Gag", "PROTEIN", 131, 134], ["Several host proteins", "TEST", 0, 21], ["ABCE1", "TEST", 33, 38], ["Staufen1", "TEST", 40, 48], ["genome encapsidation", "PROBLEM", 172, 192], ["host proteins", "OBSERVATION", 8, 21], ["Gag trafficking", "OBSERVATION", 131, 146], ["encapsidation", "OBSERVATION", 179, 192]]], ["(2) Membrane trafficking: Gag and Gag-RNA complexes move to the plasma membrane and associate with cholesterol-rich microdomains, commonly termed \"lipid rafts\" (Ono and Freed, 2001) .", [["Membrane", "ANATOMY", 4, 12], ["plasma membrane", "ANATOMY", 64, 79], ["cholesterol-rich microdomains", "ANATOMY", 99, 128], ["lipid rafts", "ANATOMY", 147, 158], ["cholesterol", "CHEMICAL", 99, 110], ["cholesterol", "CHEMICAL", 99, 110], ["Membrane", "CELLULAR_COMPONENT", 4, 12], ["Gag", "GENE_OR_GENE_PRODUCT", 26, 29], ["Gag", "GENE_OR_GENE_PRODUCT", 34, 37], ["plasma membrane", "CELLULAR_COMPONENT", 64, 79], ["cholesterol", "SIMPLE_CHEMICAL", 99, 110], ["rich microdomains", "CELLULAR_COMPONENT", 111, 128], ["lipid rafts", "CELLULAR_COMPONENT", 147, 158], ["Gag", "PROTEIN", 26, 29], ["Gag", "PROTEIN", 34, 37], ["RNA complexes", "PROTEIN", 38, 51], ["RNA complexes", "PROBLEM", 38, 51], ["the plasma membrane", "TEST", 60, 79], ["cholesterol-rich microdomains", "PROBLEM", 99, 128]]], ["Binding of Gag to the plasma membrane is mediated by a bipartite signal in the MA Gag domain that comprises a post-translational myristic acid modification at the amino-terminus and a cluster of basic residues, the highly basic region (HBR).", [["plasma membrane", "ANATOMY", 22, 37], ["myristic acid", "CHEMICAL", 129, 142], ["myristic acid", "CHEMICAL", 129, 142], ["amino", "CHEMICAL", 163, 168], ["Gag", "GENE_OR_GENE_PRODUCT", 11, 14], ["plasma membrane", "CELLULAR_COMPONENT", 22, 37], ["myristic acid", "SIMPLE_CHEMICAL", 129, 142], ["Gag", "PROTEIN", 11, 14], ["MA Gag domain", "PROTEIN", 79, 92], ["amino-terminus", "PROTEIN", 163, 177], ["basic residues", "PROTEIN", 195, 209], ["highly basic region", "PROTEIN", 215, 234], ["HBR", "PROTEIN", 236, 239], ["a bipartite signal in the MA Gag domain", "PROBLEM", 53, 92], ["a post-translational myristic acid modification", "PROBLEM", 108, 155], ["basic residues", "PROBLEM", 195, 209], ["Gag", "OBSERVATION", 11, 14], ["post-translational", "OBSERVATION", 110, 128], ["myristic acid modification", "OBSERVATION", 129, 155], ["terminus", "ANATOMY_MODIFIER", 169, 177], ["cluster", "OBSERVATION_MODIFIER", 184, 191], ["basic residues", "OBSERVATION", 195, 209], ["highly", "OBSERVATION_MODIFIER", 215, 221], ["basic", "OBSERVATION_MODIFIER", 222, 227], ["region", "OBSERVATION_MODIFIER", 228, 234]]], ["Prior to membrane binding, the myristate is sequestered in a hydrophobic cavity within the globular MA Gag domain.", [["membrane", "ANATOMY", 9, 17], ["myristate", "CHEMICAL", 31, 40], ["myristate", "CHEMICAL", 31, 40], ["membrane", "CELLULAR_COMPONENT", 9, 17], ["myristate", "SIMPLE_CHEMICAL", 31, 40], ["globular MA Gag domain", "PROTEIN", 91, 113], ["membrane binding", "PROBLEM", 9, 25], ["the myristate", "TREATMENT", 27, 40], ["Gag domain", "OBSERVATION", 103, 113]]], ["The HBR interacts with acidic head groups of the plasma membranespecific phospholipid phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P 2 ) and this interaction, perhaps in concert with Gag multimerization, exposes the myristate moiety.", [["plasma", "ANATOMY", 49, 55], ["HBR", "CHEMICAL", 4, 7], ["phosphatidylinositol-(4,5)-bisphosphate", "CHEMICAL", 86, 125], ["phosphatidylinositol-(4,5)-bisphosphate", "CHEMICAL", 86, 125], ["PI(4,5)P", "CHEMICAL", 127, 135], ["myristate", "CHEMICAL", 219, 228], ["HBR", "SIMPLE_CHEMICAL", 4, 7], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["phospholipid phosphatidylinositol-(4,5)-bisphosphate", "SIMPLE_CHEMICAL", 73, 125], ["PI(4,5)P 2", "SIMPLE_CHEMICAL", 127, 137], ["Gag", "GENE_OR_GENE_PRODUCT", 186, 189], ["myristate moiety", "SIMPLE_CHEMICAL", 219, 235], ["HBR", "PROTEIN", 4, 7], ["Gag", "PROTEIN", 186, 189], ["the plasma membranespecific phospholipid phosphatidylinositol", "TEST", 45, 106], ["bisphosphate (PI", "TREATMENT", 113, 129], ["Gag multimerization", "TREATMENT", 186, 205], ["the myristate moiety", "TREATMENT", 215, 235], ["Gag multimerization", "OBSERVATION", 186, 205], ["myristate moiety", "OBSERVATION", 219, 235]]], ["PI(4,5)P 2 and the conformational \"myristoyl switch\" enable targeting and stable Gag association with the plasma membrane (Chukkapalli and Ono, 2011; Tang et al., 2004) .", [["plasma membrane", "ANATOMY", 106, 121], ["PI(4,5)P", "CHEMICAL", 0, 8], ["myristoyl", "CHEMICAL", 35, 44], ["PI(4,5)P 2", "GENE_OR_GENE_PRODUCT", 0, 10], ["myristoyl", "SIMPLE_CHEMICAL", 35, 44], ["Gag", "GENE_OR_GENE_PRODUCT", 81, 84], ["plasma membrane", "CELLULAR_COMPONENT", 106, 121], ["PI(4,5)P 2", "DNA", 0, 10], ["Gag", "PROTEIN", 81, 84], ["PI", "TEST", 0, 2], ["the conformational \"myristoyl switch", "TREATMENT", 15, 51], ["stable", "OBSERVATION_MODIFIER", 74, 80], ["Gag", "OBSERVATION", 81, 84]]], ["In addition to PI(4,5)P 2 , MA Gag can also bind cellular RNA, especially tRNAs.", [["cellular", "ANATOMY", 49, 57], ["PI(4,5)P", "CHEMICAL", 15, 23], ["PI(4,5)P 2", "SIMPLE_CHEMICAL", 15, 25], ["MA Gag", "GENE_OR_GENE_PRODUCT", 28, 34], ["cellular", "CELL", 49, 57], ["PI(4,5)P 2", "DNA", 15, 25], ["Gag", "PROTEIN", 31, 34], ["cellular RNA", "RNA", 49, 61], ["tRNAs", "RNA", 74, 79], ["PI", "TEST", 15, 17], ["bind cellular RNA", "PROBLEM", 44, 61], ["cellular RNA", "OBSERVATION", 49, 61]]], ["The MA-tRNA interactions likely prevent nonspecific binding of Gag to cellular membranes other than the plasma membrane (Chukkapalli et al., 2010; Alfadhli et al., 2011; Kutluay et al., 2014; Gaines et al., 2018) .", [["cellular membranes", "ANATOMY", 70, 88], ["plasma membrane", "ANATOMY", 104, 119], ["MA", "GENE_OR_GENE_PRODUCT", 4, 6], ["Gag", "GENE_OR_GENE_PRODUCT", 63, 66], ["cellular membranes", "CELLULAR_COMPONENT", 70, 88], ["plasma membrane", "CELLULAR_COMPONENT", 104, 119], ["MA", "PROTEIN", 4, 6], ["Gag", "PROTEIN", 63, 66], ["nonspecific binding of Gag to cellular membranes", "PROBLEM", 40, 88], ["Gag", "OBSERVATION", 63, 66], ["cellular membranes", "OBSERVATION", 70, 88], ["plasma membrane", "ANATOMY", 104, 119]]], ["(3) Virion assembly: At the plasma membrane, Gag molecules multimerize and assemble into a hexagonal lattice through lateral protein-protein interactions that are mediated by the CA-SP1 region Wagner et al., 2016) .", [["plasma membrane", "ANATOMY", 28, 43], ["plasma membrane", "CELLULAR_COMPONENT", 28, 43], ["Gag", "GENE_OR_GENE_PRODUCT", 45, 48], ["CA-SP1", "GENE_OR_GENE_PRODUCT", 179, 185], ["Gag molecules", "PROTEIN", 45, 58], ["CA", "PROTEIN", 179, 181], ["SP1", "PROTEIN", 182, 185], ["a hexagonal lattice through lateral protein-protein interactions", "TREATMENT", 89, 153]]], ["Host-derived inositol hexakisphosphate (IP 6 ) binds within the CA-SP1 hexamers and facilitates formation of the immature Gag lattice (Dick et al., 2018; Mallery et al., 2018) .", [["inositol hexakisphosphate", "CHEMICAL", 13, 38], ["IP 6", "CHEMICAL", 40, 44], ["inositol hexakisphosphate", "CHEMICAL", 13, 38], ["IP 6", "CHEMICAL", 40, 44], ["Host-derived inositol hexakisphosphate", "GENE_OR_GENE_PRODUCT", 0, 38], ["IP 6", "GENE_OR_GENE_PRODUCT", 40, 44], ["CA", "GENE_OR_GENE_PRODUCT", 64, 66], ["SP1", "GENE_OR_GENE_PRODUCT", 67, 70], ["CA", "PROTEIN", 64, 66], ["SP1", "PROTEIN", 67, 70], ["inositol hexakisphosphate (IP", "TREATMENT", 13, 42], ["the CA-SP1 hexamers", "TREATMENT", 60, 79], ["immature", "OBSERVATION_MODIFIER", 113, 121], ["Gag lattice", "OBSERVATION", 122, 133]]], ["In addition to the genomic RNA, Gag interacts directly with other viral proteins that are incorporated into the nascent virion, including the multifunctional accessory protein Vpr, which binds a leucine-rich element located within p6 Gag (Kondo et al., 1995) , and the cytoplasmic tail of the gp41 subunit of the heterotrimeric transmembrane Env protein, which is incorporated within holes in the associating Gag lattice created by MA trimerization (Tedbury and Freed, 2014; Tedbury et al., 2016; Hill et al., 1996; Pezeshkian et al., 2019) .", [["cytoplasmic tail", "ANATOMY", 269, 285], ["leucine", "CHEMICAL", 195, 202], ["leucine", "CHEMICAL", 195, 202], ["Gag", "GENE_OR_GENE_PRODUCT", 32, 35], ["virion", "CELLULAR_COMPONENT", 120, 126], ["Vpr", "GENE_OR_GENE_PRODUCT", 176, 179], ["cytoplasmic", "ORGANISM_SUBSTANCE", 269, 280], ["MA", "GENE_OR_GENE_PRODUCT", 432, 434], ["genomic RNA", "RNA", 19, 30], ["Gag", "PROTEIN", 32, 35], ["viral proteins", "PROTEIN", 66, 80], ["multifunctional accessory protein", "PROTEIN", 142, 175], ["Vpr", "PROTEIN", 176, 179], ["leucine-rich element", "PROTEIN", 195, 215], ["p6 Gag", "PROTEIN", 231, 237], ["cytoplasmic tail", "PROTEIN", 269, 285], ["gp41 subunit", "PROTEIN", 293, 305], ["heterotrimeric transmembrane Env protein", "PROTEIN", 313, 353], ["Gag lattice", "PROTEIN", 409, 420], ["the genomic RNA", "PROBLEM", 15, 30], ["other viral proteins", "PROBLEM", 60, 80], ["the multifunctional accessory protein Vpr", "PROBLEM", 138, 179], ["a leucine-rich element", "TREATMENT", 193, 215], ["the heterotrimeric transmembrane Env protein", "TEST", 309, 353], ["genomic RNA", "ANATOMY", 19, 30], ["Gag", "OBSERVATION", 32, 35], ["nascent virion", "OBSERVATION", 112, 126], ["protein Vpr", "OBSERVATION", 168, 179], ["Env protein", "OBSERVATION", 342, 353], ["holes", "OBSERVATION_MODIFIER", 384, 389], ["Gag lattice", "OBSERVATION", 409, 420]]], ["In addition to the Gag polyprotein, the full-length viral RNA also encodes the Gag-Pol polyprotein.", [["Gag", "GENE_OR_GENE_PRODUCT", 19, 22], ["Gag", "GENE_OR_GENE_PRODUCT", 79, 82], ["Pol", "GENE_OR_GENE_PRODUCT", 83, 86], ["Gag polyprotein", "RNA", 19, 34], ["full-length viral RNA", "RNA", 40, 61], ["Gag", "PROTEIN", 79, 82], ["Pol polyprotein", "PROTEIN", 83, 98], ["the Gag polyprotein", "PROBLEM", 15, 34], ["the Gag", "TEST", 75, 82]]], ["The longer Gag-Pol protein is translated by a ribosomal frameshifting mechanism, contains the viral enzymes, and is incorporated into the nascent virion through interactions with Gag (Smith et al., 1993) .", [["ribosomal", "ANATOMY", 46, 55], ["virion", "ANATOMY", 146, 152], ["Pol", "GENE_OR_GENE_PRODUCT", 15, 18], ["ribosomal", "CELLULAR_COMPONENT", 46, 55], ["virion", "CELLULAR_COMPONENT", 146, 152], ["Gag", "GENE_OR_GENE_PRODUCT", 179, 182], ["Gag", "PROTEIN", 11, 14], ["Pol protein", "PROTEIN", 15, 26], ["viral enzymes", "PROTEIN", 94, 107], ["Gag", "PROTEIN", 179, 182], ["a ribosomal frameshifting mechanism", "PROBLEM", 44, 79], ["the viral enzymes", "TEST", 90, 107], ["ribosomal frameshifting", "OBSERVATION", 46, 69], ["nascent virion", "OBSERVATION", 138, 152]]], ["Fig. 2 The HIV-1 Gag polyprotein.", [["HIV-1", "ORGANISM", 11, 16], ["Gag", "ORGANISM", 17, 20], ["HIV-1 Gag polyprotein", "DNA", 11, 32], ["HIV-1", "SPECIES", 11, 16], ["HIV-1", "SPECIES", 11, 16], ["The HIV", "TEST", 7, 14]]], ["HIV-1 Gag comprises four functional elements connected by two spacer peptides SP1 and SP2 (gray).", [["HIV-1", "ORGANISM", 0, 5], ["Gag", "ORGANISM", 6, 9], ["SP1", "GENE_OR_GENE_PRODUCT", 78, 81], ["SP2", "GENE_OR_GENE_PRODUCT", 86, 89], ["HIV-1 Gag", "PROTEIN", 0, 9], ["SP1", "PROTEIN", 78, 81], ["SP2", "PROTEIN", 86, 89], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["two spacer peptides SP1 and SP2 (gray", "TEST", 58, 95]]], ["MA (yellow) facilitates membrane binding and Env incorporation.", [["membrane", "ANATOMY", 24, 32], ["MA", "GENE_OR_GENE_PRODUCT", 0, 2], ["membrane", "CELLULAR_COMPONENT", 24, 32], ["Env", "GENE_OR_GENE_PRODUCT", 45, 48], ["Env", "PROTEIN", 45, 48], ["membrane binding", "PROBLEM", 24, 40], ["Env incorporation", "TREATMENT", 45, 62], ["membrane binding", "OBSERVATION", 24, 40], ["Env incorporation", "OBSERVATION", 45, 62]]], ["CA (orange) mediates assembly of the immature capsid and, after proteolytic processing, forms the mature conical capsid.", [["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["immature capsid", "PROTEIN", 37, 52], ["mature conical capsid", "PROTEIN", 98, 119], ["the immature capsid", "PROBLEM", 33, 52], ["proteolytic processing", "TREATMENT", 64, 86], ["the mature conical capsid", "PROBLEM", 94, 119], ["immature", "OBSERVATION_MODIFIER", 37, 45], ["capsid", "OBSERVATION", 46, 52], ["mature", "OBSERVATION_MODIFIER", 98, 104], ["conical capsid", "OBSERVATION", 105, 119]]], ["NC (red) binds the viral RNA genome through two zinc finger motifs. p6 (brown) binds Vpr and recruits early-acting ESCRT proteins TSG101 (a subunit of the ESCRT-I complex) and ALIX to facilitate membrane fission.", [["membrane", "ANATOMY", 195, 203], ["zinc", "CHEMICAL", 48, 52], ["NC (red)", "GENE_OR_GENE_PRODUCT", 0, 8], ["p6", "GENE_OR_GENE_PRODUCT", 68, 70], ["Vpr", "GENE_OR_GENE_PRODUCT", 85, 88], ["ESCRT", "GENE_OR_GENE_PRODUCT", 115, 120], ["TSG101", "GENE_OR_GENE_PRODUCT", 130, 136], ["ESCRT-I", "GENE_OR_GENE_PRODUCT", 155, 162], ["ALIX", "GENE_OR_GENE_PRODUCT", 176, 180], ["membrane", "CELLULAR_COMPONENT", 195, 203], ["viral RNA genome", "DNA", 19, 35], ["zinc finger motifs", "PROTEIN", 48, 66], ["p6 (brown)", "PROTEIN", 68, 78], ["Vpr", "PROTEIN", 85, 88], ["ESCRT proteins", "PROTEIN", 115, 129], ["TSG101", "PROTEIN", 130, 136], ["ESCRT-I complex", "PROTEIN", 155, 170], ["ALIX", "PROTEIN", 176, 180], ["NC (red)", "TREATMENT", 0, 8], ["the viral RNA genome", "TREATMENT", 15, 35], ["two zinc finger motifs", "TREATMENT", 44, 66], ["p6 (brown) binds Vpr", "PROBLEM", 68, 88], ["viral RNA genome", "OBSERVATION", 19, 35], ["membrane fission", "OBSERVATION", 195, 211]]], ["Pink arrowheads denote proteolytic cleavage sites during maturation.EnvelopmentThe multifunctional structural proteins that mediate assembly and membrane targeting also appear to facilitate virion envelopment by inducing membrane curvature.", [["membrane", "ANATOMY", 145, 153], ["virion", "ANATOMY", 190, 196], ["membrane", "ANATOMY", 221, 229], ["membrane", "CELLULAR_COMPONENT", 145, 153], ["membrane", "CELLULAR_COMPONENT", 221, 229], ["proteolytic cleavage sites", "PROTEIN", 23, 49], ["multifunctional structural proteins", "PROTEIN", 83, 118], ["Pink arrowheads", "PROBLEM", 0, 15], ["proteolytic cleavage sites", "PROBLEM", 23, 49], ["virion envelopment", "TREATMENT", 190, 208], ["proteolytic cleavage", "OBSERVATION", 23, 43], ["sites", "OBSERVATION_MODIFIER", 44, 49], ["membrane curvature", "OBSERVATION", 221, 239]]], ["The hexagonal HIV-1 Gag lattice contains small discontinuities that accommodate declination and allow the immature lattice to bend the membrane and create a spherical virion .", [["membrane", "ANATOMY", 135, 143], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["virion", "CELLULAR_COMPONENT", 167, 173], ["HIV-1", "SPECIES", 14, 19], ["The hexagonal HIV", "TEST", 0, 17], ["small discontinuities", "PROBLEM", 41, 62], ["hexagonal", "OBSERVATION_MODIFIER", 4, 13], ["HIV", "OBSERVATION", 14, 17], ["Gag lattice", "OBSERVATION", 20, 31], ["small discontinuities", "OBSERVATION", 41, 62], ["spherical virion", "OBSERVATION", 157, 173]]], ["The host factor angiomotin (AMOT) has also been implicated in HIV-1 virion envelopment because fully enveloped spherical particles are not formed efficiently in the absence of AMOT (Mercenne et al., 2015) .", [["angiomotin", "GENE_OR_GENE_PRODUCT", 16, 26], ["AMOT", "GENE_OR_GENE_PRODUCT", 28, 32], ["HIV-1", "ORGANISM", 62, 67], ["virion", "ORGANISM", 68, 74], ["host factor", "PROTEIN", 4, 15], ["angiomotin", "PROTEIN", 16, 26], ["AMOT", "PROTEIN", 28, 32], ["HIV-1", "SPECIES", 62, 67], ["HIV-1", "SPECIES", 62, 67], ["spherical particles", "OBSERVATION", 111, 130]]], ["The Bar domain of AMOT likely contributes to this activity as this domain has been shown to bend and tubulate membranes in other contexts (Nishimura et al., 2018) .", [["tubulate membranes", "ANATOMY", 101, 119], ["AMOT", "CHEMICAL", 18, 22], ["AMOT", "GENE_OR_GENE_PRODUCT", 18, 22], ["membranes", "CELLULAR_COMPONENT", 110, 119], ["Bar domain", "PROTEIN", 4, 14], ["AMOT", "PROTEIN", 18, 22], ["likely contributes to", "UNCERTAINTY", 23, 44], ["tubulate membranes", "OBSERVATION", 101, 119]]], ["Unlike HIV-1, betaretroviruses and spumaviruses assemble in the cytoplasm before being trafficked to the plasma membrane.", [["cytoplasm", "ANATOMY", 64, 73], ["plasma membrane", "ANATOMY", 105, 120], ["HIV-1", "ORGANISM", 7, 12], ["betaretroviruses", "GENE_OR_GENE_PRODUCT", 14, 30], ["spumaviruses", "GENE_OR_GENE_PRODUCT", 35, 47], ["cytoplasm", "ORGANISM_SUBSTANCE", 64, 73], ["plasma membrane", "CELLULAR_COMPONENT", 105, 120], ["spumaviruses", "PROTEIN", 35, 47], ["HIV-1", "SPECIES", 7, 12], ["HIV-1", "SPECIES", 7, 12], ["HIV", "PROBLEM", 7, 10], ["betaretroviruses", "PROBLEM", 14, 30], ["spumaviruses", "TREATMENT", 35, 47], ["HIV", "OBSERVATION", 7, 10]]], ["Thus, assembly and budding are spatially and temporally separated in these viruses.", [["budding", "CELLULAR_COMPONENT", 19, 26], ["viruses", "OBSERVATION", 75, 82]]], ["For example, Gag proteins from prototypical foamy virus, Mason-Pfizer monkey virus, and mouse mammary tumor virus preassemble into immature virions near the pericentriolar region and are then trafficked on microtubules to associate with membranes and the viral Env protein (M\u00fcllers, 2013; H\u00fctter et al., 2013; Swanstrom and Wills, 1997) .", [["mammary tumor", "ANATOMY", 94, 107], ["virions", "ANATOMY", 140, 147], ["pericentriolar region", "ANATOMY", 157, 178], ["microtubules", "ANATOMY", 206, 218], ["membranes", "ANATOMY", 237, 246], ["mammary tumor", "DISEASE", 94, 107], ["Gag", "GENE_OR_GENE_PRODUCT", 13, 16], ["prototypical foamy virus", "ORGANISM", 31, 55], ["Mason-Pfizer monkey virus", "ORGANISM", 57, 82], ["mouse mammary tumor virus", "ORGANISM", 88, 113], ["pericentriolar region", "CELLULAR_COMPONENT", 157, 178], ["microtubules", "CELLULAR_COMPONENT", 206, 218], ["membranes", "CELLULAR_COMPONENT", 237, 246], ["Gag proteins", "PROTEIN", 13, 25], ["viral Env protein", "PROTEIN", 255, 272], ["Pfizer monkey virus", "SPECIES", 63, 82], ["mouse", "SPECIES", 88, 93], ["foamy virus", "SPECIES", 44, 55], ["Mason-Pfizer monkey virus", "SPECIES", 57, 82], ["mouse mammary tumor virus", "SPECIES", 88, 113], ["Gag proteins", "PROBLEM", 13, 25], ["prototypical foamy virus", "PROBLEM", 31, 55], ["Mason-Pfizer monkey virus", "TREATMENT", 57, 82], ["mouse mammary tumor virus", "PROBLEM", 88, 113], ["Gag proteins", "OBSERVATION", 13, 25], ["foamy virus", "OBSERVATION", 44, 55], ["mammary", "ANATOMY", 94, 101], ["tumor", "OBSERVATION", 102, 107], ["immature virions", "OBSERVATION", 131, 147], ["pericentriolar", "ANATOMY_MODIFIER", 157, 171], ["region", "ANATOMY_MODIFIER", 172, 178]]], ["Hepatitis B virus (HBV), a hepadnavirus, similarly forms capsids in the cytoplasm, which then associate with envelope proteins in cellular membranes to mediate particle envelopment and budding (Prange, 2012; Blondot et al., 2016) .EnvelopmentMore broadly, most enveloped viruses have multifunctional structural proteins that mediate assembly and envelopment.", [["cytoplasm", "ANATOMY", 72, 81], ["cellular membranes", "ANATOMY", 130, 148], ["Hepatitis B", "DISEASE", 0, 11], ["Hepatitis B virus", "ORGANISM", 0, 17], ["HBV", "ORGANISM", 19, 22], ["cytoplasm", "ORGANISM_SUBSTANCE", 72, 81], ["cellular membranes", "CELLULAR_COMPONENT", 130, 148], ["envelope proteins", "PROTEIN", 109, 126], ["multifunctional structural proteins", "PROTEIN", 284, 319], ["Hepatitis B virus", "SPECIES", 0, 17], ["Hepatitis B virus", "SPECIES", 0, 17], ["HBV", "SPECIES", 19, 22], ["Hepatitis B virus", "PROBLEM", 0, 17], ["HBV", "PROBLEM", 19, 22], ["a hepadnavirus", "PROBLEM", 25, 39], ["capsids in the cytoplasm", "PROBLEM", 57, 81], ["envelope proteins in cellular membranes", "PROBLEM", 109, 148], ["multifunctional structural proteins", "PROBLEM", 284, 319], ["cellular membranes", "OBSERVATION", 130, 148], ["particle", "OBSERVATION_MODIFIER", 160, 168], ["structural proteins", "OBSERVATION", 300, 319]]], ["Often, this role is fulfilled by matrix proteins that bind to the viral membrane, assemble into higher-order structures, and link internal ribonucleoprotein complexes to external envelope glycoproteins.", [["membrane", "ANATOMY", 72, 80], ["matrix", "CELLULAR_COMPONENT", 33, 39], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["matrix proteins", "PROTEIN", 33, 48], ["internal ribonucleoprotein complexes", "PROTEIN", 130, 166], ["external envelope glycoproteins", "PROTEIN", 170, 201], ["link internal ribonucleoprotein complexes", "PROBLEM", 125, 166], ["external envelope glycoproteins", "PROBLEM", 170, 201], ["viral membrane", "OBSERVATION", 66, 80], ["internal", "ANATOMY", 130, 138], ["ribonucleoprotein complexes", "OBSERVATION", 139, 166], ["envelope glycoproteins", "OBSERVATION", 179, 201]]], ["In viruses that lack classical matrix proteins, such as hantaviruses (Hepojoki et al., 2012; Cifuentes-Munoz et al., 2014; Muyangwa et al., 2015) and alphaviruses (Brown et al., 2018) , cytoplasmic tails of envelope glycoproteins act as matrix protein surrogates by directly interacting with nucleoproteins.", [["cytoplasmic", "ANATOMY", 186, 197], ["matrix", "CELLULAR_COMPONENT", 31, 37], ["cytoplasmic", "ORGANISM_SUBSTANCE", 186, 197], ["matrix", "CELLULAR_COMPONENT", 237, 243], ["nucleoproteins", "GENE_OR_GENE_PRODUCT", 292, 306], ["classical matrix proteins", "PROTEIN", 21, 46], ["cytoplasmic tails", "PROTEIN", 186, 203], ["envelope glycoproteins", "PROTEIN", 207, 229], ["nucleoproteins", "PROTEIN", 292, 306], ["lack classical matrix proteins", "PROBLEM", 16, 46], ["Cifuentes", "TEST", 93, 102], ["alphaviruses", "PROBLEM", 150, 162], ["envelope glycoproteins act", "TREATMENT", 207, 233]]], ["Larger, more complex DNA viruses such as pox viruses (Roberts and Smith, 2008; Liu et al., 2014) and herpes viruses (Lv et al., 2019) divide these functions between multiple viral proteins (see Table 1 ).", [["pox viruses", "DISEASE", 41, 52], ["herpes viruses", "DISEASE", 101, 115], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["pox viruses", "ORGANISM", 41, 52], ["herpes viruses", "ORGANISM", 101, 115], ["viral proteins", "PROTEIN", 174, 188], ["pox", "SPECIES", 41, 44], ["pox viruses", "SPECIES", 41, 52], ["Larger, more complex DNA viruses", "PROBLEM", 0, 32], ["pox viruses", "PROBLEM", 41, 52], ["herpes viruses", "PROBLEM", 101, 115], ["multiple viral proteins", "PROBLEM", 165, 188], ["more complex", "OBSERVATION_MODIFIER", 8, 20], ["DNA viruses", "OBSERVATION", 21, 32], ["pox viruses", "OBSERVATION", 41, 52]]], ["BuddingESCRT-dependent buddingAs membrane envelopment proceeds, the membrane is constricted until nascent virions are connected to the plasma membrane by a thin stalk that must be severed to separate the viral and cellular membranes.", [["membrane", "ANATOMY", 33, 41], ["membrane", "ANATOMY", 68, 76], ["virions", "ANATOMY", 106, 113], ["plasma membrane", "ANATOMY", 135, 150], ["cellular membranes", "ANATOMY", 214, 232], ["BuddingESCRT", "GENE_OR_GENE_PRODUCT", 0, 12], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["virions", "CELLULAR_COMPONENT", 106, 113], ["plasma membrane", "CELLULAR_COMPONENT", 135, 150], ["cellular membranes", "CELLULAR_COMPONENT", 214, 232], ["BuddingESCRT", "PROTEIN", 0, 12], ["BuddingESCRT", "TEST", 0, 12], ["dependent budding", "PROBLEM", 13, 30], ["nascent virions", "PROBLEM", 98, 113], ["a thin stalk", "PROBLEM", 154, 166], ["dependent", "OBSERVATION_MODIFIER", 13, 22], ["budding", "OBSERVATION", 23, 30], ["constricted", "OBSERVATION", 80, 91], ["viral", "OBSERVATION", 204, 209], ["cellular membranes", "OBSERVATION", 214, 232]]], ["Many enveloped viruses accomplish membrane constriction and fission by recruiting the machinery of the cellular ESCRT pathway (Votteler and Sundquist, 2013) .", [["membrane", "ANATOMY", 34, 42], ["cellular", "ANATOMY", 103, 111], ["membrane", "CELLULAR_COMPONENT", 34, 42], ["cellular", "CELL", 103, 111], ["ESCRT", "PROTEIN", 112, 117], ["membrane constriction", "TREATMENT", 34, 55], ["enveloped", "OBSERVATION_MODIFIER", 5, 14], ["viruses", "OBSERVATION", 15, 22], ["membrane constriction", "OBSERVATION", 34, 55]]], ["ESCRT-independent enveloped viruses also exist, however, and these viruses must therefore either recruit other, as yet unidentified, host factors or encode viral proteins that mediate budding.", [["ESCRT", "GENE_OR_GENE_PRODUCT", 0, 5], ["budding", "CELLULAR_COMPONENT", 184, 191], ["ESCRT", "PROTEIN", 0, 5], ["host factors", "PROTEIN", 133, 145], ["viral proteins", "PROTEIN", 156, 170], ["independent enveloped viruses", "PROBLEM", 6, 35], ["these viruses", "PROBLEM", 61, 74], ["encode viral proteins", "PROBLEM", 149, 170], ["enveloped", "OBSERVATION_MODIFIER", 18, 27], ["viruses", "OBSERVATION", 28, 35], ["viruses", "OBSERVATION", 67, 74]]], ["The ESCRT pathway mediates cellular membrane fission events throughout eukarya and also in some archaeal species (McCullough et al., 2018; Christ et al., 2017; Scourfield and Martin-Serrano, 2017; Henne et al., 2013) .", [["cellular membrane", "ANATOMY", 27, 44], ["ESCRT", "GENE_OR_GENE_PRODUCT", 4, 9], ["cellular membrane", "CELLULAR_COMPONENT", 27, 44], ["ESCRT", "PROTEIN", 4, 9], ["The ESCRT pathway", "TREATMENT", 0, 17], ["cellular membrane fission events", "PROBLEM", 27, 59], ["cellular membrane fission", "OBSERVATION", 27, 52], ["archaeal species", "OBSERVATION", 96, 112]]], ["The pathway was initially identified as the machinery that mediates intraluminal vesicle budding into specialized late endosomes, termed multivesicular bodies (MVB) (Hanson and Cashikar, 2012) , but is now known to act at many other cellular membranes, including during cytokinetic abscission (Carlton and Martin-Serrano, 2007; Morita et al., 2007) , resealing of the post-mitotic nuclear envelope (Olmos et al., 2015; Vietri et al., 2015) , membrane repair (Scheffer et al., 2014; Jimenez et al., 2014; Skowyra et al., 2018) , closure of autophagosomes (Takahashi et al., 2018; Zhou et al., 2019) , and neuronal pruning (Zhang et al., 2014; Loncle et al., 2015; Issman-Zecharya and Schuldiner, 2014) .", [["intraluminal vesicle", "ANATOMY", 68, 88], ["late endosomes", "ANATOMY", 114, 128], ["multivesicular bodies", "ANATOMY", 137, 158], ["MVB", "ANATOMY", 160, 163], ["cellular membranes", "ANATOMY", 233, 251], ["nuclear", "ANATOMY", 381, 388], ["membrane", "ANATOMY", 442, 450], ["autophagosomes", "ANATOMY", 539, 553], ["neuronal", "ANATOMY", 604, 612], ["neuronal pruning", "DISEASE", 604, 620], ["intraluminal vesicle", "CELLULAR_COMPONENT", 68, 88], ["late endosomes", "CELLULAR_COMPONENT", 114, 128], ["multivesicular bodies", "CELLULAR_COMPONENT", 137, 158], ["MVB", "CELLULAR_COMPONENT", 160, 163], ["cellular membranes", "CELLULAR_COMPONENT", 233, 251], ["nuclear", "CELLULAR_COMPONENT", 381, 388], ["membrane", "CELLULAR_COMPONENT", 442, 450], ["autophagosomes", "CELLULAR_COMPONENT", 539, 553], ["neuronal", "CELL", 604, 612], ["membrane repair", "TREATMENT", 442, 457], ["intraluminal vesicle", "ANATOMY", 68, 88], ["late endosomes", "OBSERVATION", 114, 128], ["multivesicular bodies", "OBSERVATION", 137, 158], ["cellular membranes", "OBSERVATION", 233, 251], ["cytokinetic abscission", "OBSERVATION", 270, 292], ["membrane repair", "OBSERVATION", 442, 457]]], ["Notably, all of these membrane fission events involve constricting membranes toward a cytoplasm-filled neck and are therefore topologically equivalent to virus budding from the plasma membrane.ESCRT-dependent buddingESCRT-mediated membrane fission events are catalyzed by a common core machinery (McCullough et al., 2018; Christ et al., 2017; Scourfield and Martin-Serrano, 2017; Banjade et al., 2019) , which is recruited to different membranes by adapter proteins.", [["membrane", "ANATOMY", 22, 30], ["membranes", "ANATOMY", 67, 76], ["cytoplasm", "ANATOMY", 86, 95], ["neck", "ANATOMY", 103, 107], ["plasma membrane", "ANATOMY", 177, 192], ["membrane", "ANATOMY", 231, 239], ["membranes", "ANATOMY", 436, 445], ["membrane", "CELLULAR_COMPONENT", 22, 30], ["membranes", "CELLULAR_COMPONENT", 67, 76], ["cytoplasm", "ORGANISM_SUBSTANCE", 86, 95], ["neck", "ORGAN", 103, 107], ["plasma membrane", "CELLULAR_COMPONENT", 177, 192], ["ESCRT", "GENE_OR_GENE_PRODUCT", 193, 198], ["buddingESCRT", "GENE_OR_GENE_PRODUCT", 209, 221], ["membrane", "CELLULAR_COMPONENT", 231, 239], ["membranes", "CELLULAR_COMPONENT", 436, 445], ["ESCRT", "PROTEIN", 193, 198], ["buddingESCRT", "PROTEIN", 209, 221], ["adapter proteins", "PROTEIN", 449, 465], ["constricting membranes", "PROBLEM", 54, 76], ["a cytoplasm-filled neck", "PROBLEM", 84, 107], ["dependent buddingESCRT", "PROBLEM", 199, 221], ["membrane fission", "OBSERVATION", 22, 38], ["constricting membranes", "OBSERVATION", 54, 76], ["neck", "ANATOMY", 103, 107], ["plasma membrane", "OBSERVATION", 177, 192], ["dependent", "OBSERVATION_MODIFIER", 199, 208]]], ["These membrane-specific adapters recruit early-acting ESCRT proteins, which help to stabilize membrane curvature and also nucleate assembly of late-acting ESCRT-III proteins, which form the core fission machinery.", [["membrane", "ANATOMY", 6, 14], ["membrane", "ANATOMY", 94, 102], ["membrane", "CELLULAR_COMPONENT", 6, 14], ["ESCRT", "GENE_OR_GENE_PRODUCT", 54, 59], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 155, 164], ["early-acting ESCRT proteins", "PROTEIN", 41, 68], ["late-acting ESCRT-III proteins", "PROTEIN", 143, 173], ["membrane curvature", "PROBLEM", 94, 112]]], ["ESCRT-III proteins can be recruited by three known mechanisms: (1) Adapters can recruit Bro1 domain-containing proteins such as ALIX, which serves as a bridge to the ESCRT-III proteins, (2) Adapters can bind the ESCRT-I complex, which in turn recruits ESCRT-III proteins via intermediate ESCRT-II complexes, and (3) The nuclear LEM2 adapter binds CHMP7, a hybrid ESCRT-II/ESCRT-III protein, which then binds other ESCRT-III proteins.ESCRT-dependent buddingHumans express 12 related ESCRT-III proteins that are divided into eight subfamilies, CHMP1-7 and IST1, with some subfamilies comprising several homologs.", [["nuclear", "ANATOMY", 320, 327], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 0, 9], ["Bro1", "GENE_OR_GENE_PRODUCT", 88, 92], ["ALIX", "GENE_OR_GENE_PRODUCT", 128, 132], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 166, 175], ["ESCRT-I", "GENE_OR_GENE_PRODUCT", 212, 219], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 252, 261], ["ESCRT-II", "GENE_OR_GENE_PRODUCT", 288, 296], ["nuclear", "CELLULAR_COMPONENT", 320, 327], ["LEM2", "GENE_OR_GENE_PRODUCT", 328, 332], ["CHMP7", "GENE_OR_GENE_PRODUCT", 347, 352], ["ESCRT-II", "GENE_OR_GENE_PRODUCT", 363, 371], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 372, 381], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 414, 423], ["ESCRT", "GENE_OR_GENE_PRODUCT", 433, 438], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 482, 491], ["CHMP1-7", "GENE_OR_GENE_PRODUCT", 542, 549], ["IST1", "GENE_OR_GENE_PRODUCT", 554, 558], ["ESCRT-III proteins", "PROTEIN", 0, 18], ["Bro1 domain-containing proteins", "PROTEIN", 88, 119], ["ALIX", "PROTEIN", 128, 132], ["ESCRT-III proteins", "PROTEIN", 166, 184], ["Adapters", "PROTEIN", 190, 198], ["ESCRT-I complex", "PROTEIN", 212, 227], ["ESCRT-III proteins", "PROTEIN", 252, 270], ["intermediate ESCRT-II complexes", "PROTEIN", 275, 306], ["nuclear LEM2 adapter", "PROTEIN", 320, 340], ["CHMP7", "PROTEIN", 347, 352], ["hybrid ESCRT-II/ESCRT-III protein", "PROTEIN", 356, 389], ["ESCRT-III proteins", "PROTEIN", 414, 432], ["ESCRT", "PROTEIN", 433, 438], ["ESCRT-III proteins", "PROTEIN", 482, 500], ["CHMP1", "PROTEIN", 542, 547], ["IST1", "PROTEIN", 554, 558], ["Bro1 domain", "PROBLEM", 88, 99], ["a hybrid ESCRT", "TEST", 354, 368], ["CHMP1", "TEST", 542, 547], ["dependent", "OBSERVATION_MODIFIER", 439, 448], ["budding", "OBSERVATION", 449, 456]]], ["ESCRT-III proteins can adopt \"closed\" and \"open\" conformations.", [["ESCRT-III", "GENE_OR_GENE_PRODUCT", 0, 9], ["ESCRT-III proteins", "PROTEIN", 0, 18]]], ["In the autoinhibited closed state, ESCRT-III proteins are soluble and monomeric.", [["ESCRT-III", "GENE_OR_GENE_PRODUCT", 35, 44], ["ESCRT-III proteins", "PROTEIN", 35, 53], ["closed", "OBSERVATION", 21, 27]]], ["When autoinhibition is relieved, ESCRT-III subunits open and can then bind membranes and form curved helical filaments.", [["membranes", "ANATOMY", 75, 84], ["filaments", "ANATOMY", 109, 118], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 33, 42], ["membranes", "CELLULAR_COMPONENT", 75, 84], ["filaments", "CELLULAR_COMPONENT", 109, 118], ["ESCRT-III subunits", "PROTEIN", 33, 51]]], ["These filaments constrict membranes and recruit VPS4 AAA \u00fe ATPases.", [["filaments", "ANATOMY", 6, 15], ["membranes", "ANATOMY", 26, 35], ["membranes", "CELLULAR_COMPONENT", 26, 35], ["VPS4 AAA \u00fe ATPases", "GENE_OR_GENE_PRODUCT", 48, 66], ["VPS4 AAA \u00fe ATPases", "PROTEIN", 48, 66], ["These filaments constrict membranes", "PROBLEM", 0, 35], ["constrict membranes", "OBSERVATION", 16, 35], ["VPS4 AAA", "OBSERVATION", 48, 56]]], ["VPS4 enzymes dynamically remodel and disassemble ESCRT-III filaments, using the energy of ATP hydrolysis to extract individual ESCRT-III subunits and release them back into the cytoplasm.", [["cytoplasm", "ANATOMY", 177, 186], ["ATP", "CHEMICAL", 90, 93], ["ATP", "CHEMICAL", 90, 93], ["VPS4", "GENE_OR_GENE_PRODUCT", 0, 4], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 49, 58], ["ATP", "SIMPLE_CHEMICAL", 90, 93], ["ESCRT-III subunits", "GENE_OR_GENE_PRODUCT", 127, 145], ["cytoplasm", "ORGANISM_SUBSTANCE", 177, 186], ["VPS4 enzymes", "PROTEIN", 0, 12], ["ESCRT-III filaments", "PROTEIN", 49, 68], ["ESCRT-III subunits", "PROTEIN", 127, 145], ["VPS4 enzymes", "TEST", 0, 12], ["ATP hydrolysis", "TREATMENT", 90, 104], ["III subunits", "TREATMENT", 133, 145], ["disassemble ESCRT", "OBSERVATION", 37, 54], ["III filaments", "OBSERVATION_MODIFIER", 55, 68], ["cytoplasm", "ANATOMY", 177, 186]]], ["These enzymes thereby power the virus budding cycle, although the precise mechanism by which ESCRT-III filaments and VPS4 enzymes collaborate to mediate fission is not yet fully understood.ESCRT-dependent buddingEnveloped viral structural proteins recruit the ESCRT pathway using motifs that mimic cellular ESCRT adapters (Votteler and Sundquist, 2013; Hurley and Cada, 2018; Lippincott-Schwartz et al., 2017) .", [["cellular", "ANATOMY", 298, 306], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 93, 102], ["VPS4 enzymes", "GENE_OR_GENE_PRODUCT", 117, 129], ["ESCRT", "GENE_OR_GENE_PRODUCT", 189, 194], ["ESCRT", "GENE_OR_GENE_PRODUCT", 260, 265], ["cellular", "CELL", 298, 306], ["ESCRT-III filaments", "PROTEIN", 93, 112], ["VPS4 enzymes", "PROTEIN", 117, 129], ["ESCRT", "PROTEIN", 189, 194], ["Enveloped viral structural proteins", "PROTEIN", 212, 247], ["ESCRT", "PROTEIN", 260, 265], ["cellular ESCRT adapters", "PROTEIN", 298, 321], ["These enzymes", "TEST", 0, 13], ["VPS4 enzymes", "TEST", 117, 129], ["dependent budding", "PROBLEM", 195, 212], ["dependent budding", "OBSERVATION_MODIFIER", 195, 212], ["Enveloped", "OBSERVATION_MODIFIER", 212, 221], ["viral structural proteins", "OBSERVATION", 222, 247]]], ["These motifs were initially discovered in retroviral Gag proteins (Gottlinger et al., 1991; Huang et al., 1995; Parent et al., 1995; Xiang et al., 1996) and were termed \"late domains\" because they exerted their effects at a late stage of assembly.", [["retroviral", "ORGANISM", 42, 52], ["Gag", "GENE_OR_GENE_PRODUCT", 53, 56], ["retroviral Gag proteins", "PROTEIN", 42, 65], ["retroviral Gag", "OBSERVATION", 42, 56]]], ["Analogous late domains were subsequently identified in many other enveloped viruses.", [["Analogous late domains", "PROBLEM", 0, 22], ["enveloped", "OBSERVATION_MODIFIER", 66, 75], ["viruses", "OBSERVATION", 76, 83]]], ["Late domains can frequently function from different positions within viral structural proteins and can be swapped between viruses (Parent et al., 1995; Yuan et al., 2000) , consistent with the idea that although they have different primary binding partners, they all ultimately converge on common downstream ESCRT-III proteins.", [["ESCRT-III", "GENE_OR_GENE_PRODUCT", 308, 317], ["viral structural proteins", "PROTEIN", 69, 94], ["common downstream ESCRT-III proteins", "PROTEIN", 290, 326], ["Late domains", "PROBLEM", 0, 12], ["viral structural proteins", "PROBLEM", 69, 94], ["viral structural proteins", "OBSERVATION", 69, 94]]], ["Several different classes of late domains are now well understood, and others have been identified but remain to be linked to ESCRT binding partners.", [["ESCRT", "GENE_OR_GENE_PRODUCT", 126, 131], ["ESCRT binding partners", "PROTEIN", 126, 148], ["different", "OBSERVATION_MODIFIER", 8, 17], ["classes", "OBSERVATION_MODIFIER", 18, 25], ["late domains", "OBSERVATION_MODIFIER", 29, 41]]], ["P(S/T)AP: The P(S/T)AP late domain (where the second residue can be either a serine or a threonine) was first identified in the p6 polypeptide of HIV-1 Gag (Gottlinger et al., 1991; Huang et al., 1995) , and subsequently identified in structural proteins of other retroviruses, filoviruses, arenaviruses and reoviruses (Votteler and Sundquist, 2013) .", [["threonine", "CHEMICAL", 89, 98], ["arenaviruses", "DISEASE", 291, 303], ["serine", "CHEMICAL", 77, 83], ["threonine", "CHEMICAL", 89, 98], ["serine", "AMINO_ACID", 77, 83], ["threonine", "AMINO_ACID", 89, 98], ["HIV-1", "ORGANISM", 146, 151], ["retroviruses", "ORGANISM", 264, 276], ["filoviruses", "GENE_OR_GENE_PRODUCT", 278, 289], ["AP late domain", "PROTEIN", 20, 34], ["p6 polypeptide", "PROTEIN", 128, 142], ["structural proteins", "PROTEIN", 235, 254], ["HIV-1", "SPECIES", 146, 151], ["HIV-1", "SPECIES", 146, 151], ["The P(S/T)AP late domain", "PROBLEM", 10, 34], ["the second residue", "PROBLEM", 42, 60], ["a threonine)", "TREATMENT", 87, 99], ["other retroviruses", "PROBLEM", 258, 276], ["filoviruses", "PROBLEM", 278, 289], ["retroviruses", "OBSERVATION", 264, 276]]], ["The P(S/T)AP motif recruits the four-protein ESCRT-I complex by binding the UEV domain of the TSG101 subunit (Demirov et al., 2002; Garrus et al., 2001; VerPlank et al., 2001; Martin-Serrano et al., 2001) .", [["ESCRT-I", "GENE_OR_GENE_PRODUCT", 45, 52], ["TSG101", "GENE_OR_GENE_PRODUCT", 94, 100], ["P(S/T)AP motif", "DNA", 4, 18], ["ESCRT", "PROTEIN", 45, 50], ["I complex", "PROTEIN", 51, 60], ["UEV domain", "PROTEIN", 76, 86], ["TSG101 subunit", "PROTEIN", 94, 108], ["The P(S/T)AP motif", "TREATMENT", 0, 18]]], ["P(S/T)AP motifs are found in several cellular ESCRT adapter proteins, such as the early endosomal protein HRS (Bache et al., 2003) .", [["cellular", "ANATOMY", 37, 45], ["endosomal", "ANATOMY", 88, 97], ["cellular", "CELL", 37, 45], ["endosomal", "CELLULAR_COMPONENT", 88, 97], ["P(S/T)AP motifs", "DNA", 0, 15], ["cellular ESCRT adapter proteins", "PROTEIN", 37, 68], ["early endosomal protein HRS", "PROTEIN", 82, 109], ["AP motifs", "TEST", 6, 15], ["ESCRT adapter proteins", "OBSERVATION", 46, 68]]], ["YPX n L: YPX n L late domains (where X n can vary in sequence and length) recruit ALIX by binding the central V domain (Strack et al., 2003; Martin-Serrano et al., 2003; von Schwedler et al., 2003) .", [["ALIX", "GENE_OR_GENE_PRODUCT", 82, 86], ["YPX n L: YPX n L late domains", "DNA", 0, 29], ["ALIX", "PROTEIN", 82, 86], ["central V domain", "PROTEIN", 102, 118], ["YPX n L late domains", "PROBLEM", 9, 29], ["L", "OBSERVATION_MODIFIER", 6, 7]]], ["HIV-1 contains a YPX n L late domain, although this motif is less critical for budding than the PTAP motif in most cell types.", [["cell", "ANATOMY", 115, 119], ["HIV-1", "ORGANISM", 0, 5], ["PTAP", "GENE_OR_GENE_PRODUCT", 96, 100], ["cell", "CELL", 115, 119], ["YPX n L late domain", "DNA", 17, 36], ["PTAP motif", "DNA", 96, 106], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["a YPX n L late domain", "PROBLEM", 15, 36], ["the PTAP motif", "TREATMENT", 92, 106], ["most cell", "OBSERVATION_MODIFIER", 110, 119]]], ["Other viruses rely exclusively or primarily on YPX n L domains for budding, including other retroviruses, paramyxoviruses, flaviviruses, and possibly herpesviruses (Votteler and Sundquist, 2013) .", [["flaviviruses", "DISEASE", 123, 135], ["YPX n L domains", "GENE_OR_GENE_PRODUCT", 47, 62], ["retroviruses", "ORGANISM", 92, 104], ["herpesviruses", "ORGANISM", 150, 163], ["YPX n L domains", "DNA", 47, 62], ["Other viruses", "PROBLEM", 0, 13], ["YPX n L domains", "TREATMENT", 47, 62], ["budding", "PROBLEM", 67, 74], ["other retroviruses", "PROBLEM", 86, 104], ["paramyxoviruses", "PROBLEM", 106, 121], ["flaviviruses", "PROBLEM", 123, 135], ["herpesviruses", "PROBLEM", 150, 163], ["viruses", "OBSERVATION", 6, 13], ["retroviruses", "OBSERVATION", 92, 104], ["paramyxoviruses", "OBSERVATION", 106, 121], ["flaviviruses", "OBSERVATION", 123, 135], ["possibly", "UNCERTAINTY", 141, 149]]], ["Divergent structural proteins that lack a readily detectable YPX n L motif, yet still bind to ALIX, have also been described (Boonyaratanakornkit et al., 2013; Lee et al., 2012) , suggesting that ALIX-recruiting sequence motifs may accommodate more variability than has been documented to date.", [["ALIX", "GENE_OR_GENE_PRODUCT", 94, 98], ["ALIX", "GENE_OR_GENE_PRODUCT", 196, 200], ["structural proteins", "PROTEIN", 10, 29], ["YPX n L motif", "PROTEIN", 61, 74], ["ALIX", "PROTEIN", 94, 98], ["ALIX", "PROTEIN", 196, 200], ["Divergent structural proteins", "PROBLEM", 0, 29], ["a readily detectable YPX n L motif", "PROBLEM", 40, 74]]], ["Cellular YPX n L-containing ESCRT adapters recruit ALIX during exosome biogenesis and lysosomal sorting (Baietti et al., 2012; Dores et al., 2012) .ESCRT-dependent buddingPPXY: The PPXY late domain (where X can be any residue but is often a proline) binds WW domains in NEDD4-like HECT ubiquitin E3 ligases.", [["Cellular", "ANATOMY", 0, 8], ["exosome", "ANATOMY", 63, 70], ["lysosomal", "ANATOMY", 86, 95], ["proline", "CHEMICAL", 241, 248], ["proline", "CHEMICAL", 241, 248], ["YPX n L-containing ESCRT", "GENE_OR_GENE_PRODUCT", 9, 33], ["ALIX", "GENE_OR_GENE_PRODUCT", 51, 55], ["exosome", "CELLULAR_COMPONENT", 63, 70], ["lysosomal", "CELLULAR_COMPONENT", 86, 95], ["ESCRT", "GENE_OR_GENE_PRODUCT", 148, 153], ["NEDD4-like HECT", "GENE_OR_GENE_PRODUCT", 270, 285], ["Cellular YPX n L-containing ESCRT adapters", "PROTEIN", 0, 42], ["ALIX", "PROTEIN", 51, 55], ["ESCRT-dependent buddingPPXY", "PROTEIN", 148, 175], ["PPXY late domain", "PROTEIN", 181, 197], ["X", "PROTEIN", 205, 206], ["WW domains", "PROTEIN", 256, 266], ["NEDD4", "PROTEIN", 270, 275], ["HECT ubiquitin E3 ligases", "PROTEIN", 281, 306], ["Cellular YPX n L-containing ESCRT", "TREATMENT", 0, 33], ["dependent buddingPPXY", "PROBLEM", 154, 175], ["The PPXY late domain", "PROBLEM", 177, 197], ["any residue", "PROBLEM", 214, 225], ["a proline)", "TREATMENT", 239, 249], ["NEDD4", "TEST", 270, 275], ["ESCRT adapters", "OBSERVATION", 28, 42], ["recruit ALIX", "OBSERVATION", 43, 55], ["dependent", "OBSERVATION_MODIFIER", 154, 163], ["buddingPPXY", "OBSERVATION", 164, 175], ["E3 ligases", "OBSERVATION", 296, 306]]], ["PPXY late domains are found in retroviruses, filoviruses, arenaviruses, rhabdoviruses, and hepadnaviruses (Votteler and Sundquist, 2013) .", [["arenaviruses", "DISEASE", 58, 70], ["rhabdoviruses", "DISEASE", 72, 85], ["hepadnaviruses", "DISEASE", 91, 105], ["PPXY", "GENE_OR_GENE_PRODUCT", 0, 4], ["retroviruses", "ORGANISM", 31, 43], ["filoviruses", "GENE_OR_GENE_PRODUCT", 45, 56], ["PPXY late domains", "PROTEIN", 0, 17], ["PPXY late domains", "PROBLEM", 0, 17], ["retroviruses", "PROBLEM", 31, 43], ["filoviruses", "PROBLEM", 45, 56], ["arenaviruses", "PROBLEM", 58, 70], ["rhabdoviruses", "TREATMENT", 72, 85], ["hepadnaviruses", "TREATMENT", 91, 105], ["retroviruses", "OBSERVATION", 31, 43]]], ["HIV-1 Gag does not contain a recognized PPXY motif.", [["HIV-1", "ORGANISM", 0, 5], ["Gag", "ORGANISM", 6, 9], ["PPXY", "GENE_OR_GENE_PRODUCT", 40, 44], ["PPXY motif", "PROTEIN", 40, 50], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3]]], ["Nevertheless, overexpression of the ubiquitin E3 ligase NEDD4L induces budding of HIV-1 Gag constructs that lack PTAP and YPX n L late domains (Usami et al., 2008; Chung et al., 2008) .", [["NEDD4L", "GENE_OR_GENE_PRODUCT", 56, 62], ["HIV-1", "ORGANISM", 82, 87], ["PTAP", "GENE_OR_GENE_PRODUCT", 113, 117], ["ubiquitin E3 ligase", "PROTEIN", 36, 55], ["NEDD4L", "PROTEIN", 56, 62], ["HIV-1 Gag constructs", "DNA", 82, 102], ["PTAP", "PROTEIN", 113, 117], ["YPX", "PROTEIN", 122, 125], ["HIV-1", "SPECIES", 82, 87], ["HIV-1", "SPECIES", 82, 87], ["the ubiquitin E3 ligase NEDD4L", "TREATMENT", 32, 62], ["HIV", "PROBLEM", 82, 85]]], ["In this context, NEDD4L is recruited by a cellular PPXY-containing protein AMOT, which also binds HIV-1 Gag (Mercenne et al., 2015) .", [["cellular", "ANATOMY", 42, 50], ["NEDD4L", "GENE_OR_GENE_PRODUCT", 17, 23], ["cellular", "CELL", 42, 50], ["AMOT", "GENE_OR_GENE_PRODUCT", 75, 79], ["HIV-1", "ORGANISM", 98, 103], ["NEDD4L", "PROTEIN", 17, 23], ["PPXY", "PROTEIN", 51, 55], ["AMOT", "PROTEIN", 75, 79], ["HIV-1", "SPECIES", 98, 103], ["a cellular PPXY", "TEST", 40, 55], ["protein AMOT", "TREATMENT", 67, 79]]], ["The related angiomotin-like 1 (AMOTL-1) recruits NEDD4 family members to paramyxovirus M proteins, which also lack discernible PPXY domains (Pei et al., 2010; Ray et al., 2019) .", [["angiomotin-like 1", "GENE_OR_GENE_PRODUCT", 12, 29], ["AMOTL-1", "GENE_OR_GENE_PRODUCT", 31, 38], ["NEDD4", "GENE_OR_GENE_PRODUCT", 49, 54], ["paramyxovirus M proteins", "GENE_OR_GENE_PRODUCT", 73, 97], ["angiomotin-like 1 (AMOTL-1", "PROTEIN", 12, 38], ["NEDD4 family members", "PROTEIN", 49, 69], ["paramyxovirus M proteins", "PROTEIN", 73, 97], ["PPXY domains", "PROTEIN", 127, 139], ["The related angiomotin", "PROBLEM", 0, 22]]], ["NEDD4 E3 enzymes transfer K63-linked ubiquitin chains onto PPXY-containing cellular proteins, and they regulate endocytosis, ESCRT-dependent MVB cargo selection and protein trafficking through ubiquitination (Rotin and Kumar, 2009 ).ESCRT-dependent buddingIt is not yet fully understood how NEDD4 family members promote budding, but it has been suggested that ubiquitination of viral structural proteins, or other proteins within the budding site, recruits the ESCRT pathway because ALIX and TSG101 both contain ubiquitin-binding domains that can recognize ubiquitinated cargos for MVB incorporation and lysosomal degradation (Shields and Piper, 2011) .", [["cellular", "ANATOMY", 75, 83], ["MVB", "ANATOMY", 141, 144], ["budding site", "ANATOMY", 434, 446], ["MVB", "ANATOMY", 582, 585], ["lysosomal", "ANATOMY", 604, 613], ["NEDD4 E3", "GENE_OR_GENE_PRODUCT", 0, 8], ["K63", "GENE_OR_GENE_PRODUCT", 26, 29], ["PPXY", "GENE_OR_GENE_PRODUCT", 59, 63], ["cellular", "CELL", 75, 83], ["ESCRT", "GENE_OR_GENE_PRODUCT", 125, 130], ["MVB", "CELLULAR_COMPONENT", 141, 144], ["ESCRT", "GENE_OR_GENE_PRODUCT", 233, 238], ["NEDD4", "GENE_OR_GENE_PRODUCT", 291, 296], ["ESCRT", "GENE_OR_GENE_PRODUCT", 461, 466], ["ALIX", "GENE_OR_GENE_PRODUCT", 483, 487], ["TSG101", "GENE_OR_GENE_PRODUCT", 492, 498], ["MVB", "CELLULAR_COMPONENT", 582, 585], ["lysosomal", "CELLULAR_COMPONENT", 604, 613], ["NEDD4 E3 enzymes", "PROTEIN", 0, 16], ["K63", "PROTEIN", 26, 29], ["ubiquitin chains", "PROTEIN", 37, 53], ["PPXY", "PROTEIN", 59, 63], ["cellular proteins", "PROTEIN", 75, 92], ["ESCRT", "PROTEIN", 125, 130], ["ESCRT", "PROTEIN", 233, 238], ["NEDD4 family members", "PROTEIN", 291, 311], ["viral structural proteins", "PROTEIN", 378, 403], ["budding site", "PROTEIN", 434, 446], ["ESCRT", "PROTEIN", 461, 466], ["ALIX", "PROTEIN", 483, 487], ["TSG101", "PROTEIN", 492, 498], ["ubiquitin-binding domains", "PROTEIN", 512, 537], ["ubiquitinated cargos", "PROTEIN", 557, 577], ["K63", "TEST", 26, 29], ["PPXY", "TEST", 59, 63], ["cellular proteins", "PROBLEM", 75, 92], ["dependent budding", "PROBLEM", 239, 256], ["viral structural proteins", "PROBLEM", 378, 403], ["other proteins within the budding site", "PROBLEM", 408, 446], ["TSG101", "TEST", 492, 498], ["ubiquitin-binding domains", "PROBLEM", 512, 537], ["MVB incorporation", "TREATMENT", 582, 599], ["cellular proteins", "OBSERVATION", 75, 92], ["cargo selection", "OBSERVATION", 145, 160], ["dependent budding", "OBSERVATION_MODIFIER", 239, 256]]], ["Consistent with this idea, retroviral Gag proteins are typically ubiquitinated (although this requirement is not absolute (Zhadina et al., 2007) ), and ubiquitin depletion or mutations that prevent ubiquitin ligase recruitment inhibit retrovirus budding (Patnaik et al., 2000; Strack et al., 2000) .ESCRT-dependent buddingFPIV: The paramyxovirus SV5 employs an FPIV motif to facilitate budding.", [["retroviral", "ORGANISM", 27, 37], ["Gag", "GENE_OR_GENE_PRODUCT", 38, 41], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 152, 161], ["retrovirus", "ORGANISM", 235, 245], ["ESCRT", "GENE_OR_GENE_PRODUCT", 299, 304], ["buddingFPIV", "GENE_OR_GENE_PRODUCT", 315, 326], ["paramyxovirus SV5", "ORGANISM", 332, 349], ["retroviral Gag proteins", "PROTEIN", 27, 50], ["ubiquitin", "PROTEIN", 152, 161], ["ubiquitin ligase", "PROTEIN", 198, 214], ["ESCRT-dependent buddingFPIV", "PROTEIN", 299, 326], ["paramyxovirus SV5", "PROTEIN", 332, 349], ["FPIV motif", "DNA", 361, 371], ["retroviral Gag proteins", "PROBLEM", 27, 50], ["ubiquitin depletion", "PROBLEM", 152, 171], ["mutations", "PROBLEM", 175, 184], ["ubiquitin ligase recruitment", "TREATMENT", 198, 226], ["dependent buddingFPIV", "PROBLEM", 305, 326], ["The paramyxovirus SV5", "TREATMENT", 328, 349], ["an FPIV motif", "TREATMENT", 358, 371], ["retroviral Gag", "OBSERVATION", 27, 41], ["ubiquitin depletion", "OBSERVATION", 152, 171], ["ubiquitin ligase", "OBSERVATION", 198, 214]]], ["SV5 release is ESCRT-dependent and is augmented by AMOTL1, but the binding partner for the FPIV motif remains to be defined (El Najjar et al., 2014) .", [["SV5", "GENE_OR_GENE_PRODUCT", 0, 3], ["ESCRT", "GENE_OR_GENE_PRODUCT", 15, 20], ["AMOTL1", "GENE_OR_GENE_PRODUCT", 51, 57], ["FPIV", "GENE_OR_GENE_PRODUCT", 91, 95], ["SV5", "PROTEIN", 0, 3], ["ESCRT", "PROTEIN", 15, 20], ["AMOTL1", "PROTEIN", 51, 57], ["FPIV motif", "DNA", 91, 101], ["SV5 release", "PROBLEM", 0, 11], ["the FPIV motif", "TREATMENT", 87, 101], ["ESCRT", "OBSERVATION", 15, 20], ["dependent", "OBSERVATION_MODIFIER", 21, 30]]], ["Viral structural proteins typically encode multiple late domains that function in synergy.", [["Viral structural proteins", "PROTEIN", 0, 25], ["Viral structural proteins", "PROBLEM", 0, 25], ["multiple late domains", "PROBLEM", 43, 64], ["multiple", "OBSERVATION_MODIFIER", 43, 51], ["late domains", "OBSERVATION_MODIFIER", 52, 64]]], ["For example, HIV-1 p6 Gag contains both a P(S/ T)AP and a YPX n L motif, the HTLV-I Gag and Ebola virus (EBOV) structural protein VP40 proteins contain adjacent PPPY and PTAP late domains that bind both TSG101 and NEDD4, and murine leukemia virus Gag contains all three canonical late domains (Votteler and Sundquist, 2013) .", [["HIV-1", "ORGANISM", 13, 18], ["p6", "ORGANISM", 19, 21], ["HTLV-I Gag", "ORGANISM", 77, 87], ["Ebola virus", "ORGANISM", 92, 103], ["EBOV", "ORGANISM", 105, 109], ["VP40", "GENE_OR_GENE_PRODUCT", 130, 134], ["PPPY", "GENE_OR_GENE_PRODUCT", 161, 165], ["TSG101", "GENE_OR_GENE_PRODUCT", 203, 209], ["NEDD4", "GENE_OR_GENE_PRODUCT", 214, 219], ["murine leukemia virus", "ORGANISM", 225, 246], ["HIV-1 p6 Gag", "PROTEIN", 13, 25], ["YPX n L motif", "DNA", 58, 71], ["HTLV-I Gag", "PROTEIN", 77, 87], ["Ebola virus (EBOV) structural protein", "PROTEIN", 92, 129], ["VP40 proteins", "PROTEIN", 130, 143], ["PPPY", "PROTEIN", 161, 165], ["PTAP late domains", "PROTEIN", 170, 187], ["TSG101", "PROTEIN", 203, 209], ["NEDD4", "PROTEIN", 214, 219], ["murine leukemia virus Gag", "PROTEIN", 225, 250], ["canonical late domains", "PROTEIN", 270, 292], ["HIV-1", "SPECIES", 13, 18], ["Ebola virus", "SPECIES", 92, 103], ["murine", "SPECIES", 225, 231], ["HIV-1", "SPECIES", 13, 18], ["HTLV-I", "SPECIES", 77, 83], ["Ebola virus", "SPECIES", 92, 103], ["EBOV", "SPECIES", 105, 109], ["murine leukemia virus", "SPECIES", 225, 246], ["HIV", "TEST", 13, 16], ["AP", "TEST", 49, 51], ["a YPX n L motif", "TREATMENT", 56, 71], ["the HTLV", "TEST", 73, 81], ["Ebola virus", "PROBLEM", 92, 103], ["structural protein VP40 proteins", "TEST", 111, 143], ["adjacent PPPY", "PROBLEM", 152, 165], ["PTAP late domains", "PROBLEM", 170, 187], ["TSG101", "TEST", 203, 209], ["NEDD4", "TEST", 214, 219], ["murine leukemia virus Gag", "PROBLEM", 225, 250], ["leukemia virus", "OBSERVATION", 232, 246]]], ["Nevertheless, some viruses contain a single (or at least dominant), late domain.", [["late domain", "PROTEIN", 68, 79], ["some viruses", "PROBLEM", 14, 26], ["viruses", "OBSERVATION", 19, 26], ["single", "OBSERVATION_MODIFIER", 37, 43]]], ["For example, the retroviral EIAV Gag protein appears to recruit ALIX exclusively through a single YPX n L motif (Votteler and Sundquist, 2013) .ESCRT-dependent buddingAll modes of viral ESCRT pathway recruitment ultimately converge on ESCRT-III, the machinery that catalyzes membrane fission.", [["membrane", "ANATOMY", 275, 283], ["retroviral", "ORGANISM", 17, 27], ["EIAV", "ORGANISM", 28, 32], ["Gag", "GENE_OR_GENE_PRODUCT", 33, 36], ["ALIX", "GENE_OR_GENE_PRODUCT", 64, 68], ["ESCRT", "GENE_OR_GENE_PRODUCT", 144, 149], ["ESCRT", "GENE_OR_GENE_PRODUCT", 186, 191], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 235, 244], ["membrane", "CELLULAR_COMPONENT", 275, 283], ["retroviral EIAV Gag protein", "PROTEIN", 17, 44], ["ALIX", "PROTEIN", 64, 68], ["YPX n L motif", "DNA", 98, 111], ["ESCRT", "PROTEIN", 144, 149], ["viral ESCRT", "PROTEIN", 180, 191], ["ESCRT-III", "PROTEIN", 235, 244], ["EIAV", "SPECIES", 28, 32], ["the retroviral EIAV Gag protein", "PROBLEM", 13, 44], ["a single YPX n L motif (Votteler and Sundquist", "TREATMENT", 89, 135], ["dependent budding", "PROBLEM", 150, 167], ["viral ESCRT pathway", "TREATMENT", 180, 199], ["retroviral EIAV", "OBSERVATION", 17, 32], ["Gag protein", "OBSERVATION", 33, 44], ["dependent budding", "OBSERVATION_MODIFIER", 150, 167], ["All modes", "OBSERVATION_MODIFIER", 167, 176], ["viral ESCRT", "OBSERVATION", 180, 191], ["membrane fission", "OBSERVATION", 275, 291]]], ["In the best-studied cases such as HIV-1, multiple different mammalian ESCRT-III proteins have been shown to localize to the bud neck (Jouvenet et al., 2011) , but only CHMP2 and CHMP4 family members seem to perform indispensable functional roles (Sandrin and Sundquist, 2013; Morita et al., 2011) .", [["bud neck", "ANATOMY", 124, 132], ["HIV-1", "ORGANISM", 34, 39], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 70, 79], ["bud neck", "MULTI-TISSUE_STRUCTURE", 124, 132], ["CHMP2", "GENE_OR_GENE_PRODUCT", 168, 173], ["CHMP4", "GENE_OR_GENE_PRODUCT", 178, 183], ["mammalian ESCRT-III proteins", "PROTEIN", 60, 88], ["CHMP2", "PROTEIN", 168, 173], ["CHMP4 family members", "PROTEIN", 178, 198], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 34, 39], ["HIV", "TEST", 34, 37], ["bud", "ANATOMY_MODIFIER", 124, 127], ["neck", "ANATOMY", 128, 132]]], ["ESCRT-III proteins form helical filaments in the bud neck and progressively constrict it with the help of VPS4 enzymes, as described above.", [["filaments", "ANATOMY", 32, 41], ["bud neck", "ANATOMY", 49, 57], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 0, 9], ["bud neck", "ORGAN", 49, 57], ["VPS4", "GENE_OR_GENE_PRODUCT", 106, 110], ["ESCRT-III proteins", "PROTEIN", 0, 18], ["VPS4 enzymes", "PROTEIN", 106, 118], ["helical filaments in the bud neck", "PROBLEM", 24, 57], ["VPS4 enzymes", "TEST", 106, 118], ["III proteins", "OBSERVATION_MODIFIER", 6, 18], ["helical filaments", "OBSERVATION_MODIFIER", 24, 41], ["bud", "ANATOMY_MODIFIER", 49, 52], ["neck", "ANATOMY", 53, 57]]], ["Ultimately, a membrane fission reaction severs the neck, releasing the virion from the cell.ESCRT-independent buddingSome enveloped viruses bud independently of the ESCRT pathway, including alphaviruses (Brown et al., 2018), some paramyxoviruses (Salditt et al., 2010; Utley et al., 2008) , and influenza A virus (Rossman and Lamb, 2011) .", [["membrane", "ANATOMY", 14, 22], ["neck", "ANATOMY", 51, 55], ["cell", "ANATOMY", 87, 91], ["bud", "ANATOMY", 140, 143], ["influenza A virus", "DISEASE", 295, 312], ["membrane", "CELLULAR_COMPONENT", 14, 22], ["neck", "ORGANISM_SUBDIVISION", 51, 55], ["virion", "CELLULAR_COMPONENT", 71, 77], ["cell", "CELL", 87, 91], ["ESCRT", "GENE_OR_GENE_PRODUCT", 92, 97], ["ESCRT", "GENE_OR_GENE_PRODUCT", 165, 170], ["influenza A virus", "ORGANISM", 295, 312], ["ESCRT", "PROTEIN", 92, 97], ["influenza A virus", "SPECIES", 295, 312], ["influenza A virus", "SPECIES", 295, 312], ["a membrane fission reaction", "PROBLEM", 12, 39], ["alphaviruses", "PROBLEM", 190, 202], ["some paramyxoviruses", "PROBLEM", 225, 245], ["influenza A virus", "PROBLEM", 295, 312], ["membrane", "OBSERVATION", 14, 22], ["fission reaction", "OBSERVATION", 23, 39], ["neck", "ANATOMY", 51, 55], ["cell", "ANATOMY", 87, 91], ["enveloped", "OBSERVATION_MODIFIER", 122, 131], ["viruses", "OBSERVATION", 132, 139]]], ["ESCRT-independent membrane scission mechanisms are generally not well understood, but appear to involve as yet unidentified cellular factors, virally encoded proteins, or a combination.ESCRT-independent buddingSome RNA viruses, such as alphaviruses, contain an outer glycoprotein shell that completely covers the exterior of the viral membrane.", [["membrane", "ANATOMY", 18, 26], ["cellular", "ANATOMY", 124, 132], ["membrane", "ANATOMY", 335, 343], ["ESCRT", "GENE_OR_GENE_PRODUCT", 0, 5], ["membrane", "CELLULAR_COMPONENT", 18, 26], ["cellular", "CELL", 124, 132], ["ESCRT", "GENE_OR_GENE_PRODUCT", 185, 190], ["viral membrane", "CELLULAR_COMPONENT", 329, 343], ["ESCRT", "PROTEIN", 0, 5], ["cellular factors", "PROTEIN", 124, 140], ["virally encoded proteins", "PROTEIN", 142, 166], ["ESCRT", "PROTEIN", 185, 190], ["virally encoded proteins", "PROBLEM", 142, 166], ["Some RNA viruses", "PROBLEM", 210, 226], ["alphaviruses", "PROBLEM", 236, 248], ["an outer glycoprotein shell", "TREATMENT", 258, 285], ["Some", "OBSERVATION_MODIFIER", 210, 214], ["RNA viruses", "OBSERVATION", 215, 226], ["outer", "OBSERVATION_MODIFIER", 261, 266], ["glycoprotein shell", "OBSERVATION", 267, 285], ["exterior", "ANATOMY_MODIFIER", 313, 321], ["viral membrane", "OBSERVATION", 329, 343]]], ["The formation of this external protein coat has been suggested to play a role in virus budding, both in ESCRTindependent and ESCRT-dependent viruses.", [["ESCRT", "GENE_OR_GENE_PRODUCT", 125, 130], ["external protein coat", "PROTEIN", 22, 43], ["ESCRT", "PROTEIN", 125, 130], ["this external protein coat", "TREATMENT", 17, 43], ["a role in virus budding", "PROBLEM", 71, 94], ["dependent viruses", "PROBLEM", 131, 148], ["dependent", "OBSERVATION_MODIFIER", 131, 140], ["viruses", "OBSERVATION", 141, 148]]], ["The alphaviral transmembrane glycoproteins E1 and E2 are embedded in the viral lipid envelope and form heterodimers that further trimerize into a continuous icosahedral lattice.", [["E2", "CHEMICAL", 50, 52], ["E1", "GENE_OR_GENE_PRODUCT", 43, 45], ["E2", "GENE_OR_GENE_PRODUCT", 50, 52], ["alphaviral transmembrane glycoproteins", "PROTEIN", 4, 42], ["E1", "PROTEIN", 43, 45], ["E2", "PROTEIN", 50, 52], ["heterodimers", "PROTEIN", 103, 115], ["The alphaviral transmembrane glycoproteins E1", "TREATMENT", 0, 45], ["E2", "TREATMENT", 50, 52], ["the viral lipid envelope", "TREATMENT", 69, 93], ["heterodimers", "TREATMENT", 103, 115], ["a continuous icosahedral lattice", "TREATMENT", 144, 176], ["viral lipid envelope", "OBSERVATION", 73, 93]]], ["These interactions are required to complete the budding step, and completion of the E1-E2 protein lattice, together with the nucleocapsid interactions across the viral membrane may be sufficient to drive both membrane curvature and fission (Brown et al., 2018; Weissenhorn et al., 2013) .", [["membrane", "ANATOMY", 168, 176], ["membrane", "ANATOMY", 209, 217], ["E2", "CHEMICAL", 87, 89], ["E1-E2", "GENE_OR_GENE_PRODUCT", 84, 89], ["membrane", "CELLULAR_COMPONENT", 168, 176], ["membrane", "CELLULAR_COMPONENT", 209, 217], ["E1", "PROTEIN", 84, 86], ["the E1-E2 protein lattice", "TREATMENT", 80, 105], ["the nucleocapsid interactions", "PROBLEM", 121, 150], ["viral membrane", "OBSERVATION", 162, 176]]], ["In contrast, flaviviruses and hepaciviruses also contain an outer protein coat, but still depend on the ESCRT pathway to complete their replication cycle (see below).", [["hepaciviruses", "GENE_OR_GENE_PRODUCT", 30, 43], ["ESCRT", "GENE_OR_GENE_PRODUCT", 104, 109], ["outer protein coat", "PROTEIN", 60, 78], ["ESCRT", "PROTEIN", 104, 109], ["flaviviruses", "PROBLEM", 13, 25], ["hepaciviruses", "TREATMENT", 30, 43], ["an outer protein coat", "PROBLEM", 57, 78], ["flaviviruses", "OBSERVATION", 13, 25], ["outer", "OBSERVATION_MODIFIER", 60, 65], ["protein coat", "OBSERVATION", 66, 78]]], ["Thus, external protein coats can apparently either replace or act in concert with the ESCRT pathway.ESCRT-independent buddingInfluenza A is another ESCRT-independent virus (Bruce et al., 2009; Watanabe and Lamb, 2010; Chen et al., 2007) , but in this case, the viral transmembrane protein M2 appears to mediate membrane fission (Rossman et al., 2010) .", [["membrane", "ANATOMY", 311, 319], ["ESCRT", "GENE_OR_GENE_PRODUCT", 86, 91], ["ESCRT", "GENE_OR_GENE_PRODUCT", 100, 105], ["Influenza A", "ORGANISM", 125, 136], ["ESCRT", "GENE_OR_GENE_PRODUCT", 148, 153], ["M2", "GENE_OR_GENE_PRODUCT", 289, 291], ["membrane", "CELLULAR_COMPONENT", 311, 319], ["ESCRT", "PROTEIN", 86, 91], ["ESCRT", "PROTEIN", 100, 105], ["viral transmembrane protein M2", "PROTEIN", 261, 291], ["Influenza A", "SPECIES", 125, 136], ["external protein coats", "TREATMENT", 6, 28], ["the viral transmembrane protein M2", "PROBLEM", 257, 291], ["protein coats", "OBSERVATION", 15, 28]]], ["During particle assembly, the hemagglutinin (HA) and neuraminidase (NA) glycoproteins are targeted to the plasma membrane and cluster in lipid rafts.", [["plasma membrane", "ANATOMY", 106, 121], ["lipid rafts", "ANATOMY", 137, 148], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 30, 43], ["HA", "GENE_OR_GENE_PRODUCT", 45, 47], ["neuraminidase (NA) glycoproteins", "GENE_OR_GENE_PRODUCT", 53, 85], ["plasma membrane", "CELLULAR_COMPONENT", 106, 121], ["lipid rafts", "CELLULAR_COMPONENT", 137, 148], ["hemagglutinin", "PROTEIN", 30, 43], ["HA", "PROTEIN", 45, 47], ["neuraminidase (NA) glycoproteins", "PROTEIN", 53, 85], ["the hemagglutinin (HA)", "TREATMENT", 26, 48], ["neuraminidase (NA) glycoproteins", "TREATMENT", 53, 85], ["lipid rafts", "OBSERVATION", 137, 148]]], ["The matrix protein M1 interacts with the cytoplasmic tails of HA and NA, polymerizes against the membrane, and apparently acts in concert with HA to induce membrane curvature.", [["cytoplasmic", "ANATOMY", 41, 52], ["membrane", "ANATOMY", 97, 105], ["membrane", "ANATOMY", 156, 164], ["NA", "CHEMICAL", 69, 71], ["matrix", "CELLULAR_COMPONENT", 4, 10], ["cytoplasmic", "ORGANISM_SUBSTANCE", 41, 52], ["HA", "GENE_OR_GENE_PRODUCT", 62, 64], ["NA", "SIMPLE_CHEMICAL", 69, 71], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["HA", "GENE_OR_GENE_PRODUCT", 143, 145], ["membrane", "CELLULAR_COMPONENT", 156, 164], ["matrix protein M1", "PROTEIN", 4, 21], ["cytoplasmic tails", "PROTEIN", 41, 58], ["HA", "PROTEIN", 62, 64], ["The matrix protein M1", "TREATMENT", 0, 21], ["HA", "PROBLEM", 62, 64], ["NA", "TEST", 69, 71], ["HA", "PROBLEM", 143, 145], ["protein M1", "OBSERVATION", 11, 21], ["membrane curvature", "OBSERVATION", 156, 174]]], ["M1 also recruits M2 to the bud neck, and an amphipathic helix in the cytoplasmic M2 tail inserts, deforms and promotes plasma membrane fission (Martyna and Rossman, 2014; Chlanda and Zimmerberg, 2016) .", [["bud neck", "ANATOMY", 27, 35], ["cytoplasmic", "ANATOMY", 69, 80], ["plasma membrane", "ANATOMY", 119, 134], ["M2", "GENE_OR_GENE_PRODUCT", 17, 19], ["bud neck", "MULTI-TISSUE_STRUCTURE", 27, 35], ["cytoplasmic", "ORGANISM_SUBSTANCE", 69, 80], ["plasma membrane", "CELLULAR_COMPONENT", 119, 134], ["M1", "PROTEIN", 0, 2], ["M2", "PROTEIN", 17, 19], ["amphipathic helix", "PROTEIN", 44, 61], ["cytoplasmic M2 tail inserts", "PROTEIN", 69, 96], ["an amphipathic helix", "PROBLEM", 41, 61], ["the cytoplasmic M2 tail inserts", "TREATMENT", 65, 96], ["M2", "OBSERVATION_MODIFIER", 17, 19], ["bud", "ANATOMY_MODIFIER", 27, 30], ["neck", "ANATOMY", 31, 35], ["amphipathic helix", "OBSERVATION", 44, 61], ["cytoplasmic", "OBSERVATION", 69, 80], ["M2 tail", "ANATOMY", 81, 88], ["plasma membrane fission", "OBSERVATION", 119, 142]]], ["M2 also functions as a pH-regulated ion channel that facilitates the release of viral ribonucleoprotein complexes from the endosome into the cytoplasm, but ion channel and membrane fission appear to be independent activities (Rossman et al., 2010) .Intracellular buddingSome viral families envelop and bud into internal cellular membranes rather than at the plasma membrane.", [["endosome", "ANATOMY", 123, 131], ["cytoplasm", "ANATOMY", 141, 150], ["membrane", "ANATOMY", 172, 180], ["Intracellular", "ANATOMY", 249, 262], ["bud", "ANATOMY", 302, 305], ["cellular membranes", "ANATOMY", 320, 338], ["plasma membrane", "ANATOMY", 358, 373], ["M2", "GENE_OR_GENE_PRODUCT", 0, 2], ["endosome", "CELLULAR_COMPONENT", 123, 131], ["cytoplasm", "ORGANISM_SUBSTANCE", 141, 150], ["membrane", "CELLULAR_COMPONENT", 172, 180], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 249, 262], ["cellular membranes", "CELLULAR_COMPONENT", 320, 338], ["plasma membrane", "CELLULAR_COMPONENT", 358, 373], ["M2", "PROTEIN", 0, 2], ["pH-regulated ion channel", "PROTEIN", 23, 47], ["viral ribonucleoprotein complexes", "PROTEIN", 80, 113], ["a pH", "TEST", 21, 25], ["viral ribonucleoprotein complexes", "PROBLEM", 80, 113], ["Intracellular budding", "PROBLEM", 249, 270], ["ion channel", "OBSERVATION_MODIFIER", 36, 47], ["viral ribonucleoprotein complexes", "OBSERVATION", 80, 113], ["Some", "OBSERVATION_MODIFIER", 270, 274], ["viral", "OBSERVATION", 275, 280], ["internal", "ANATOMY_MODIFIER", 311, 319], ["cellular membranes", "OBSERVATION", 320, 338], ["plasma membrane", "ANATOMY", 358, 373]]], ["Budding into the lumen of a cellular organelle is topologically equivalent to budding from the plasma membrane, but in these cases the viral particle is temporarily surrounded by two membranes, the viral envelope and the organelle membrane.", [["lumen", "ANATOMY", 17, 22], ["cellular organelle", "ANATOMY", 28, 46], ["plasma membrane", "ANATOMY", 95, 110], ["membranes", "ANATOMY", 183, 192], ["organelle membrane", "ANATOMY", 221, 239], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 22], ["cellular organelle", "CELLULAR_COMPONENT", 28, 46], ["plasma membrane", "CELLULAR_COMPONENT", 95, 110], ["membranes", "CELLULAR_COMPONENT", 183, 192], ["organelle membrane", "CELLULAR_COMPONENT", 221, 239], ["the viral envelope and the organelle membrane", "PROBLEM", 194, 239], ["lumen", "ANATOMY_MODIFIER", 17, 22], ["cellular organelle", "OBSERVATION", 28, 46], ["topologically equivalent", "OBSERVATION", 50, 74], ["plasma membrane", "OBSERVATION", 95, 110], ["viral particle", "OBSERVATION", 135, 149], ["two membranes", "OBSERVATION", 179, 192], ["viral envelope", "OBSERVATION", 198, 212], ["organelle membrane", "OBSERVATION", 221, 239]]], ["Virion release into the extracellular space therefore requires transport to and fusion of the virion-containing organelle with the plasma membrane.Intracellular buddingOne such case is the hepatitis B virus (HBV), which co-opts the MVB pathway for egress (Prange, 2012; Blondot et al., 2016; Patient et al., 2009) .", [["extracellular space", "ANATOMY", 24, 43], ["organelle", "ANATOMY", 112, 121], ["plasma membrane", "ANATOMY", 131, 146], ["Intracellular", "ANATOMY", 147, 160], ["MVB", "ANATOMY", 232, 235], ["hepatitis B", "DISEASE", 189, 200], ["Virion", "GENE_OR_GENE_PRODUCT", 0, 6], ["extracellular space", "CELLULAR_COMPONENT", 24, 43], ["virion", "CELLULAR_COMPONENT", 94, 100], ["organelle", "CELLULAR_COMPONENT", 112, 121], ["plasma membrane", "CELLULAR_COMPONENT", 131, 146], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 147, 160], ["hepatitis B virus", "ORGANISM", 189, 206], ["HBV", "ORGANISM", 208, 211], ["MVB", "CELLULAR_COMPONENT", 232, 235], ["hepatitis B virus", "SPECIES", 189, 206], ["hepatitis B virus", "SPECIES", 189, 206], ["HBV", "SPECIES", 208, 211], ["Virion release into the extracellular space", "PROBLEM", 0, 43], ["the plasma membrane", "TREATMENT", 127, 146], ["Intracellular budding", "PROBLEM", 147, 168], ["the hepatitis B virus", "PROBLEM", 185, 206], ["extracellular space", "OBSERVATION", 24, 43], ["plasma membrane", "OBSERVATION", 131, 146], ["budding", "OBSERVATION", 161, 168]]], ["The three viral envelope proteins S, M, and L form budding sites at the MVB membrane that recruit mature cytoplasmic nucleocapsids.", [["sites", "ANATOMY", 59, 64], ["MVB membrane", "ANATOMY", 72, 84], ["cytoplasmic nucleocapsids", "ANATOMY", 105, 130], ["budding sites", "CELLULAR_COMPONENT", 51, 64], ["MVB membrane", "CELLULAR_COMPONENT", 72, 84], ["cytoplasmic", "ORGANISM_SUBSTANCE", 105, 116], ["nucleocapsids", "CELLULAR_COMPONENT", 117, 130], ["viral envelope proteins", "PROTEIN", 10, 33], ["S, M, and L", "PROTEIN", 34, 45], ["budding sites", "PROTEIN", 51, 64], ["The three viral envelope proteins S", "PROBLEM", 0, 35], ["budding sites", "PROBLEM", 51, 64], ["mature cytoplasmic nucleocapsids", "PROBLEM", 98, 130], ["MVB membrane", "ANATOMY", 72, 84], ["mature", "OBSERVATION_MODIFIER", 98, 104], ["cytoplasmic nucleocapsids", "OBSERVATION", 105, 130]]], ["The assembling HBV particles bud into the MVB lumen in an ESCRT-dependent reaction that creates intraluminal virions.", [["MVB lumen", "ANATOMY", 42, 51], ["intraluminal virions", "ANATOMY", 96, 116], ["HBV", "ORGANISM", 15, 18], ["MVB lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 51], ["HBV", "SPECIES", 15, 18], ["The assembling HBV particles", "PROBLEM", 0, 28], ["an ESCRT", "PROBLEM", 55, 63], ["dependent reaction", "PROBLEM", 64, 82], ["intraluminal virions", "PROBLEM", 96, 116], ["HBV", "OBSERVATION", 15, 18], ["MVB lumen", "OBSERVATION", 42, 51], ["ESCRT", "OBSERVATION", 58, 63], ["dependent", "OBSERVATION_MODIFIER", 64, 73], ["reaction", "OBSERVATION", 74, 82], ["intraluminal virions", "OBSERVATION", 96, 116]]], ["MVBs then fuse with the plasma membrane to release the enveloped viral particles from the cell, a process that resembles exosome release.Intracellular buddingHerpesviruses are released via the secretory pathway in a complex series of events that requires several viral and cellular proteins (Lv et al., 2019; Fradkin and Budnik, 2016; Owen et al., 2015) .", [["MVBs", "ANATOMY", 0, 4], ["plasma membrane", "ANATOMY", 24, 39], ["cell", "ANATOMY", 90, 94], ["exosome", "ANATOMY", 121, 128], ["Intracellular", "ANATOMY", 137, 150], ["cellular", "ANATOMY", 273, 281], ["MVBs", "CELLULAR_COMPONENT", 0, 4], ["plasma membrane", "CELLULAR_COMPONENT", 24, 39], ["cell", "CELL", 90, 94], ["exosome", "CELLULAR_COMPONENT", 121, 128], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 137, 150], ["Herpesviruses", "GENE_OR_GENE_PRODUCT", 158, 171], ["cellular", "CELL", 273, 281], ["viral and cellular proteins", "PROTEIN", 263, 290], ["MVBs", "PROBLEM", 0, 4], ["the plasma membrane", "TREATMENT", 20, 39], ["the enveloped viral particles", "PROBLEM", 51, 80], ["Intracellular buddingHerpesviruses", "PROBLEM", 137, 171], ["viral particles", "OBSERVATION", 65, 80], ["cell", "OBSERVATION", 90, 94], ["exosome release", "OBSERVATION", 121, 136], ["buddingHerpesviruses", "OBSERVATION", 151, 171]]], ["Herpesviral genome replication, capsid assembly, and genome packaging all take place in the nucleus.", [["nucleus", "ANATOMY", 92, 99], ["capsid", "CELLULAR_COMPONENT", 32, 38], ["nucleus", "CELLULAR_COMPONENT", 92, 99], ["Herpesviral genome replication", "PROBLEM", 0, 30], ["genome packaging", "TREATMENT", 53, 69], ["genome replication", "OBSERVATION", 12, 30], ["nucleus", "ANATOMY", 92, 99]]], ["The fully assembled nucleocapsids are too large to escape into the cytoplasm through nuclear pores and instead exit the nucleus and cell by undergoing several steps of envelopment and de-envelopment at multiple cellular membranes.", [["nucleocapsids", "ANATOMY", 20, 33], ["cytoplasm", "ANATOMY", 67, 76], ["nuclear pores", "ANATOMY", 85, 98], ["nucleus", "ANATOMY", 120, 127], ["cell", "ANATOMY", 132, 136], ["cellular membranes", "ANATOMY", 211, 229], ["nucleocapsids", "CELLULAR_COMPONENT", 20, 33], ["cytoplasm", "ORGANISM_SUBSTANCE", 67, 76], ["nuclear pores", "CELLULAR_COMPONENT", 85, 98], ["nucleus", "CELLULAR_COMPONENT", 120, 127], ["cell", "CELL", 132, 136], ["cellular membranes", "CELLULAR_COMPONENT", 211, 229], ["The fully assembled nucleocapsids", "PROBLEM", 0, 33], ["de-envelopment at multiple cellular membranes", "PROBLEM", 184, 229], ["nucleocapsids", "OBSERVATION", 20, 33], ["too large", "OBSERVATION_MODIFIER", 38, 47], ["cytoplasm", "ANATOMY_MODIFIER", 67, 76], ["nuclear pores", "OBSERVATION_MODIFIER", 85, 98], ["nucleus", "ANATOMY", 120, 127], ["multiple", "OBSERVATION_MODIFIER", 202, 210], ["cellular membranes", "OBSERVATION", 211, 229]]], ["During primary envelopment, the nucleocapsids bud through the inner nuclear membrane into the perinuclear space, thereby acquiring a lipid envelope.", [["bud", "ANATOMY", 46, 49], ["inner nuclear membrane", "ANATOMY", 62, 84], ["perinuclear space", "ANATOMY", 94, 111], ["inner nuclear membrane", "CELLULAR_COMPONENT", 62, 84], ["perinuclear space", "CELLULAR_COMPONENT", 94, 111], ["lipid envelope", "CELLULAR_COMPONENT", 133, 147], ["the nucleocapsids bud", "PROBLEM", 28, 49], ["a lipid envelope", "TREATMENT", 131, 147], ["inner", "ANATOMY_MODIFIER", 62, 67], ["nuclear membrane", "ANATOMY", 68, 84], ["perinuclear space", "OBSERVATION", 94, 111], ["lipid envelope", "OBSERVATION", 133, 147]]], ["This process requires the virus to remodel the nuclear lamina.", [["nuclear lamina", "ANATOMY", 47, 61], ["nuclear lamina", "CELLULAR_COMPONENT", 47, 61], ["the virus", "PROBLEM", 22, 31], ["virus", "OBSERVATION", 26, 31], ["nuclear lamina", "ANATOMY", 47, 61]]], ["Cellular and viral kinases phosphorylate components of the nuclear lamina, leading to its disassembly.", [["Cellular", "ANATOMY", 0, 8], ["nuclear lamina", "ANATOMY", 59, 73], ["Cellular", "CELL", 0, 8], ["nuclear lamina", "CELLULAR_COMPONENT", 59, 73], ["Cellular and viral kinases", "PROTEIN", 0, 26], ["Cellular and viral kinases phosphorylate components", "TREATMENT", 0, 51], ["viral kinases", "OBSERVATION", 13, 26], ["phosphorylate components", "OBSERVATION", 27, 51], ["nuclear lamina", "ANATOMY", 59, 73]]], ["Two viral proteins, pUL31 and pUL34, then assemble into a cage-like nuclear egress complex, that carries the virion across the inner nuclear membrane (Bigalke and Heldwein, 2015) .", [["nuclear", "ANATOMY", 68, 75], ["inner nuclear membrane", "ANATOMY", 127, 149], ["pUL31", "GENE_OR_GENE_PRODUCT", 20, 25], ["pUL34", "GENE_OR_GENE_PRODUCT", 30, 35], ["virion", "CELLULAR_COMPONENT", 109, 115], ["inner nuclear membrane", "CELLULAR_COMPONENT", 127, 149], ["viral proteins", "PROTEIN", 4, 18], ["pUL31", "PROTEIN", 20, 25], ["pUL34", "PROTEIN", 30, 35], ["cage-like nuclear egress complex", "PROTEIN", 58, 90], ["Two viral proteins", "TEST", 0, 18], ["pUL31", "TEST", 20, 25], ["pUL34", "TEST", 30, 35], ["viral proteins", "OBSERVATION", 4, 18], ["egress complex", "OBSERVATION", 76, 90], ["inner", "ANATOMY_MODIFIER", 127, 132], ["nuclear membrane", "ANATOMY", 133, 149]]], ["There is some evidence that the ESCRT machinery may also be involved in facilitating the membrane fission step required to release the enveloped virion into the intermembrane space (Arii et al., 2018) .", [["membrane", "ANATOMY", 89, 97], ["intermembrane space", "ANATOMY", 161, 180], ["ESCRT", "GENE_OR_GENE_PRODUCT", 32, 37], ["membrane", "CELLULAR_COMPONENT", 89, 97], ["intermembrane", "CELLULAR_COMPONENT", 161, 174], ["the ESCRT machinery", "TREATMENT", 28, 47], ["the membrane fission step", "TREATMENT", 85, 110], ["may also be", "UNCERTAINTY", 48, 59], ["intermembrane space", "OBSERVATION", 161, 180]]], ["The primary envelope then fuses with the outer nuclear membrane in a process termed de-envelopment.", [["nuclear membrane", "ANATOMY", 47, 63], ["outer nuclear membrane", "CELLULAR_COMPONENT", 41, 63], ["the outer nuclear membrane", "TREATMENT", 37, 63], ["nuclear membrane", "OBSERVATION", 47, 63]]], ["The viral glycoproteins are necessary for de-envelopment, likely because they mediate fusion with the outer nuclear membrane.", [["outer nuclear membrane", "ANATOMY", 102, 124], ["outer nuclear membrane", "CELLULAR_COMPONENT", 102, 124], ["viral glycoproteins", "PROTEIN", 4, 23], ["The viral glycoproteins", "TREATMENT", 0, 23], ["de-envelopment", "TREATMENT", 42, 56], ["viral glycoproteins", "OBSERVATION", 4, 23], ["fusion", "OBSERVATION", 86, 92], ["outer", "ANATOMY_MODIFIER", 102, 107], ["nuclear membrane", "ANATOMY", 108, 124]]], ["Once in the cytoplasm, nucleocapsids associate with tegument proteins, which in the mature virion occupy the space between the nucleocapsid and the envelope.", [["cytoplasm", "ANATOMY", 12, 21], ["nucleocapsids", "ANATOMY", 23, 36], ["cytoplasm", "ORGANISM_SUBSTANCE", 12, 21], ["nucleocapsids", "CELLULAR_COMPONENT", 23, 36], ["nucleocapsid", "CELLULAR_COMPONENT", 127, 139], ["envelope", "CELLULAR_COMPONENT", 148, 156], ["tegument proteins", "PROTEIN", 52, 69], ["tegument proteins", "PROBLEM", 52, 69], ["tegument proteins", "OBSERVATION", 52, 69], ["mature", "OBSERVATION_MODIFIER", 84, 90], ["virion", "OBSERVATION", 91, 97], ["nucleocapsid", "OBSERVATION", 127, 139], ["envelope", "OBSERVATION_MODIFIER", 148, 156]]], ["The nucleocapsids then bud into vesicles, whose origins have been variously described as the trans-Golgi network, endosomes, or autophagic membranes.", [["nucleocapsids", "ANATOMY", 4, 17], ["vesicles", "ANATOMY", 32, 40], ["Golgi network", "ANATOMY", 99, 112], ["endosomes", "ANATOMY", 114, 123], ["autophagic membranes", "ANATOMY", 128, 148], ["nucleocapsids", "CELLULAR_COMPONENT", 4, 17], ["vesicles", "CELLULAR_COMPONENT", 32, 40], ["Golgi network", "CELLULAR_COMPONENT", 99, 112], ["endosomes", "CELLULAR_COMPONENT", 114, 123], ["autophagic membranes", "CELLULAR_COMPONENT", 128, 148], ["autophagic membranes", "PROBLEM", 128, 148], ["nucleocapsids", "OBSERVATION", 4, 17], ["vesicles", "ANATOMY_MODIFIER", 32, 40], ["autophagic membranes", "OBSERVATION", 128, 148]]], ["Recruitment to sites of secondary envelopment is promoted by tegument proteins through interactions with vesicle membranes and viral glycoproteins.", [["vesicle membranes", "ANATOMY", 105, 122], ["tegument proteins", "GENE_OR_GENE_PRODUCT", 61, 78], ["vesicle membranes", "CELLULAR_COMPONENT", 105, 122], ["tegument proteins", "PROTEIN", 61, 78], ["viral glycoproteins", "PROTEIN", 127, 146], ["secondary envelopment", "PROBLEM", 24, 45], ["vesicle membranes", "TREATMENT", 105, 122], ["viral glycoproteins", "PROBLEM", 127, 146], ["secondary envelopment", "OBSERVATION", 24, 45], ["viral glycoproteins", "OBSERVATION", 127, 146]]], ["Early-acting ESCRT proteins are not required for this process, but there are reports that ESCRT-III and VPS4 activity are required for virion release (Crump et al., 2007; Calistri et al., 2007; Pawliczek and Crump, 2009) , and an exciting new structure of the herpes simplex virus pUL7: pUL51 complex, which is required for efficient virion assembly, reveals that the N-terminal region of pUL51 adopts a CHMP4B-like fold that may function as a viral ESCRT-III-like protein (Butt et al., 2020).", [["virion", "ANATOMY", 334, 340], ["herpes simplex", "DISEASE", 260, 274], ["N", "CHEMICAL", 368, 369], ["ESCRT", "GENE_OR_GENE_PRODUCT", 13, 18], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 90, 99], ["VPS4", "GENE_OR_GENE_PRODUCT", 104, 108], ["herpes simplex virus", "ORGANISM", 260, 280], ["pUL7", "ORGANISM", 281, 285], ["pUL51", "GENE_OR_GENE_PRODUCT", 287, 292], ["virion", "CELLULAR_COMPONENT", 334, 340], ["pUL51", "GENE_OR_GENE_PRODUCT", 389, 394], ["CHMP4B", "GENE_OR_GENE_PRODUCT", 404, 410], ["ESCRT-III", "GENE_OR_GENE_PRODUCT", 450, 459], ["Early-acting ESCRT proteins", "PROTEIN", 0, 27], ["ESCRT", "PROTEIN", 90, 95], ["VPS4", "PROTEIN", 104, 108], ["herpes simplex virus pUL7: pUL51 complex", "PROTEIN", 260, 300], ["N-terminal region", "PROTEIN", 368, 385], ["pUL51", "PROTEIN", 389, 394], ["CHMP4B", "PROTEIN", 404, 410], ["viral ESCRT-III-like protein", "PROTEIN", 444, 472], ["herpes simplex virus", "SPECIES", 260, 280], ["herpes simplex virus", "SPECIES", 260, 280], ["Early-acting ESCRT proteins", "PROBLEM", 0, 27], ["virion release", "TREATMENT", 135, 149], ["the herpes simplex virus", "PROBLEM", 256, 280], ["a CHMP4B-like fold", "PROBLEM", 402, 420], ["a viral ESCRT", "TEST", 442, 455], ["herpes simplex", "OBSERVATION", 260, 274], ["terminal", "ANATOMY_MODIFIER", 370, 378]]], ["Following membrane fission, the enveloped virions end up inside intracellular vesicles and are released into the extracellular space when the vesicles fuse with the plasma membrane.Intracellular buddingIn a related process, flaviviruses and hepaciviruses are released through the secretory pathway (Chatel-Chaix and Bartenschlager, 2014; Falcon et al., 2017; Gerold et al., 2017) .", [["membrane", "ANATOMY", 10, 18], ["virions", "ANATOMY", 42, 49], ["intracellular vesicles", "ANATOMY", 64, 86], ["extracellular space", "ANATOMY", 113, 132], ["vesicles", "ANATOMY", 142, 150], ["plasma membrane", "ANATOMY", 165, 180], ["Intracellular", "ANATOMY", 181, 194], ["membrane", "CELLULAR_COMPONENT", 10, 18], ["intracellular vesicles", "CELLULAR_COMPONENT", 64, 86], ["extracellular space", "CELLULAR_COMPONENT", 113, 132], ["vesicles", "CELLULAR_COMPONENT", 142, 150], ["plasma membrane", "CELLULAR_COMPONENT", 165, 180], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 181, 194], ["flaviviruses", "ORGANISM", 224, 236], ["hepaciviruses", "GENE_OR_GENE_PRODUCT", 241, 254], ["membrane fission", "TREATMENT", 10, 26], ["the enveloped virions", "TREATMENT", 28, 49], ["Intracellular budding", "PROBLEM", 181, 202], ["flaviviruses", "PROBLEM", 224, 236], ["membrane fission", "OBSERVATION", 10, 26], ["enveloped", "OBSERVATION_MODIFIER", 32, 41], ["virions", "OBSERVATION", 42, 49], ["intracellular vesicles", "OBSERVATION", 64, 86], ["extracellular", "ANATOMY_MODIFIER", 113, 126], ["vesicles fuse", "OBSERVATION", 142, 155], ["plasma membrane", "OBSERVATION", 165, 180], ["budding", "OBSERVATION", 195, 202], ["flaviviruses", "OBSERVATION", 224, 236]]], ["Both genera of viruses induce extensive remodeling of endoplasmic reticulum (ER) membranes to form replication compartments.", [["endoplasmic reticulum", "ANATOMY", 54, 75], ["ER) membranes", "ANATOMY", 77, 90], ["compartments", "ANATOMY", 111, 123], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 54, 75], ["ER", "GENE_OR_GENE_PRODUCT", 77, 79], ["membranes", "CELLULAR_COMPONENT", 81, 90], ["viruses", "PROBLEM", 15, 22], ["extensive remodeling of endoplasmic reticulum", "PROBLEM", 30, 75], ["genera", "OBSERVATION_MODIFIER", 5, 11], ["viruses", "OBSERVATION", 15, 22], ["extensive", "OBSERVATION_MODIFIER", 30, 39], ["remodeling", "OBSERVATION", 40, 50], ["endoplasmic reticulum", "OBSERVATION", 54, 75], ["replication", "OBSERVATION_MODIFIER", 99, 110], ["compartments", "OBSERVATION_MODIFIER", 111, 123]]], ["These vesicle-like structures remain connected to the ER, enclose viral proteins and the viral genome, and serve as protected compartments where almost all steps of the life cycle are carried out.", [["vesicle-like structures", "ANATOMY", 6, 29], ["ER", "ANATOMY", 54, 56], ["vesicle", "CELLULAR_COMPONENT", 6, 13], ["ER", "GENE_OR_GENE_PRODUCT", 54, 56], ["ER", "PROTEIN", 54, 56], ["viral proteins", "PROTEIN", 66, 80], ["viral genome", "DNA", 89, 101], ["vesicle", "OBSERVATION", 6, 13], ["viral proteins", "OBSERVATION", 66, 80], ["viral genome", "OBSERVATION", 89, 101]]], ["Assembled nucleocapsids then bud into the ER lumen and are released through the secretory pathway.Quasi-enveloped virusesHistorically, viruses have been divided into enveloped and non-enveloped classes based on the presence or absence of a hostderived membrane envelope, and it was thought that non-enveloped viruses were released exclusively by host cell lysis.", [["nucleocapsids", "ANATOMY", 10, 23], ["bud", "ANATOMY", 29, 32], ["ER lumen", "ANATOMY", 42, 50], ["membrane envelope", "ANATOMY", 252, 269], ["cell", "ANATOMY", 351, 355], ["nucleocapsids", "CELLULAR_COMPONENT", 10, 23], ["ER lumen", "CELLULAR_COMPONENT", 42, 50], ["membrane", "CELLULAR_COMPONENT", 252, 260], ["host cell", "CELL", 346, 355], ["Assembled nucleocapsids", "PROBLEM", 0, 23], ["Quasi-enveloped virusesHistorically", "PROBLEM", 98, 133], ["viruses", "PROBLEM", 135, 142], ["a hostderived membrane envelope", "PROBLEM", 238, 269], ["non-enveloped viruses", "PROBLEM", 295, 316], ["host cell lysis", "TREATMENT", 346, 361], ["nucleocapsids", "OBSERVATION", 10, 23], ["lumen", "ANATOMY_MODIFIER", 45, 50], ["viruses", "OBSERVATION", 135, 142], ["non-enveloped", "OBSERVATION_MODIFIER", 295, 308], ["viruses", "OBSERVATION", 309, 316], ["host cell lysis", "OBSERVATION", 346, 361]]], ["This simple paradigm has now been overturned by studies showing that many different classes of non-enveloped viruses can acquire hostderived lipid envelopes and exit cells within vesicles.", [["cells", "ANATOMY", 166, 171], ["vesicles", "ANATOMY", 179, 187], ["cells", "CELL", 166, 171], ["vesicles", "CELLULAR_COMPONENT", 179, 187], ["exit cells", "CELL_TYPE", 161, 171], ["non-enveloped viruses", "PROBLEM", 95, 116], ["hostderived lipid envelopes", "PROBLEM", 129, 156], ["exit cells within vesicles", "PROBLEM", 161, 187], ["non-enveloped viruses", "OBSERVATION", 95, 116], ["lipid envelopes", "OBSERVATION", 141, 156], ["exit cells", "OBSERVATION", 161, 171]]], ["These extracellular vesicles resemble exosomes, and viruses that use this egress method are termed \"quasi-enveloped\" (Feng et al., 2014) .Quasi-enveloped virusesThe picornavirus hepatitis A virus (HAV) was the first virus definitively shown to be quasi-enveloped (Feng et al., 2013) , and HAV still serves as a paradigm for the process.", [["extracellular vesicles", "ANATOMY", 6, 28], ["exosomes", "ANATOMY", 38, 46], ["picornavirus hepatitis A", "DISEASE", 165, 189], ["extracellular vesicles", "CELLULAR_COMPONENT", 6, 28], ["exosomes", "CELL", 38, 46], ["viruses", "ORGANISM", 154, 161], ["picornavirus hepatitis A virus", "ORGANISM", 165, 195], ["HAV", "ORGANISM", 197, 200], ["HAV", "ORGANISM", 289, 292], ["exosomes", "CELL_TYPE", 38, 46], ["picornavirus hepatitis A virus", "SPECIES", 165, 195], ["hepatitis A virus", "SPECIES", 178, 195], ["HAV", "SPECIES", 197, 200], ["HAV", "SPECIES", 289, 292], ["viruses", "PROBLEM", 52, 59], ["The picornavirus hepatitis A virus (HAV", "PROBLEM", 161, 200], ["the first virus", "PROBLEM", 206, 221], ["exosomes", "OBSERVATION", 38, 46], ["enveloped viruses", "OBSERVATION", 144, 161], ["picornavirus hepatitis", "OBSERVATION", 165, 187]]], ["Quasi-enveloped HAV particles (eHAV) are released in exosome-like vesicles that typically contain 1-4 particles per vesicle.", [["exosome-like vesicles", "ANATOMY", 53, 74], ["vesicle", "ANATOMY", 116, 123], ["HAV particles", "ORGANISM", 16, 29], ["eHAV", "GENE_OR_GENE_PRODUCT", 31, 35], ["vesicles", "CELLULAR_COMPONENT", 66, 74], ["vesicle", "CELLULAR_COMPONENT", 116, 123], ["exosome", "PROTEIN", 53, 60], ["HAV", "SPECIES", 16, 19], ["eHAV", "SPECIES", 31, 35], ["Quasi-enveloped HAV particles", "PROBLEM", 0, 29], ["particles", "OBSERVATION_MODIFIER", 20, 29], ["1-4 particles", "OBSERVATION_MODIFIER", 98, 111], ["vesicle", "ANATOMY", 116, 123]]], ["These vesicles are formed when HAV capsids bud into endosomes in an ESCRT-dependent manner.", [["vesicles", "ANATOMY", 6, 14], ["endosomes", "ANATOMY", 52, 61], ["vesicles", "CELLULAR_COMPONENT", 6, 14], ["endosomes", "CELLULAR_COMPONENT", 52, 61], ["ESCRT", "GENE_OR_GENE_PRODUCT", 68, 73], ["ESCRT", "PROTEIN", 68, 73], ["HAV", "SPECIES", 31, 34], ["vesicles", "OBSERVATION", 6, 14], ["endosomes", "OBSERVATION_MODIFIER", 52, 61], ["ESCRT-dependent", "OBSERVATION_MODIFIER", 68, 83]]], ["To promote budding, the VP2 capsid protein recruits ALIX, apparently using tandem YPX 3 L domains that become buried in the fully assembled virion (Gonzalez-Lopez et al., 2018; McKnight et al., 2017) .", [["budding", "CELLULAR_COMPONENT", 11, 18], ["VP2", "GENE_OR_GENE_PRODUCT", 24, 27], ["ALIX", "GENE_OR_GENE_PRODUCT", 52, 56], ["virion", "CELLULAR_COMPONENT", 140, 146], ["VP2 capsid protein", "PROTEIN", 24, 42], ["ALIX", "PROTEIN", 52, 56], ["tandem YPX 3 L domains", "PROTEIN", 75, 97], ["tandem YPX 3 L domains", "TREATMENT", 75, 97], ["buried", "OBSERVATION", 110, 116]]], ["Virion-containing multivesicular bodies then fuse with the plasma membrane and release eHAV particles into the extracellular space.", [["multivesicular bodies", "ANATOMY", 18, 39], ["plasma membrane", "ANATOMY", 59, 74], ["extracellular space", "ANATOMY", 111, 130], ["Virion", "SIMPLE_CHEMICAL", 0, 6], ["multivesicular bodies", "CELLULAR_COMPONENT", 18, 39], ["plasma membrane", "CELLULAR_COMPONENT", 59, 74], ["eHAV particles", "CELLULAR_COMPONENT", 87, 101], ["extracellular space", "CELLULAR_COMPONENT", 111, 130], ["Virion", "PROTEIN", 0, 6], ["Virion", "TREATMENT", 0, 6], ["multivesicular bodies", "PROBLEM", 18, 39], ["the plasma membrane", "TREATMENT", 55, 74], ["multivesicular bodies", "OBSERVATION", 18, 39], ["extracellular space", "ANATOMY", 111, 130]]], ["There is now good evidence that this is the primary mode of HAV release from hepatocytes in vivo, and that HAV circulates in the blood exclusively within small vesicles (Feng et al., 2013) .", [["hepatocytes", "ANATOMY", 77, 88], ["blood", "ANATOMY", 129, 134], ["small vesicles", "ANATOMY", 154, 168], ["HAV", "ORGANISM", 60, 63], ["hepatocytes", "CELL", 77, 88], ["HAV", "ORGANISM", 107, 110], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["small vesicles", "CELLULAR_COMPONENT", 154, 168], ["hepatocytes", "CELL_TYPE", 77, 88], ["HAV", "SPECIES", 60, 63], ["HAV", "SPECIES", 107, 110], ["HAV circulates in the blood", "PROBLEM", 107, 134], ["good", "OBSERVATION_MODIFIER", 13, 17], ["hepatocytes", "ANATOMY", 77, 88], ["blood", "ANATOMY", 129, 134], ["small vesicles", "ANATOMY", 154, 168]]], ["HAV can then shed its envelope in the biliary tract, which produces a non-enveloped particle that may be more stable in harsher environmental conditions (Feng et al., 2014) .", [["biliary tract", "ANATOMY", 38, 51], ["HAV", "ORGANISM", 0, 3], ["biliary tract", "ORGANISM_SUBDIVISION", 38, 51], ["HAV", "SPECIES", 0, 3], ["a non-enveloped particle", "PROBLEM", 68, 92], ["biliary tract", "ANATOMY", 38, 51], ["non-enveloped particle", "OBSERVATION", 70, 92], ["may be", "UNCERTAINTY", 98, 104], ["more", "OBSERVATION_MODIFIER", 105, 109], ["stable", "OBSERVATION_MODIFIER", 110, 116]]], ["Importantly, HAV is highly infectious in both its enveloped and non-enveloped states.Quasi-enveloped virusesThe capacity for quasi-envelopment has since been described for several other viruses that were traditionally considered to be non-enveloped, including many other picornaviruses (Chen et al., 2015; Mutsafi and Altan-Bonnet, 2018) , Hepatitis E virus (Qi et al., 2015) , rotaviruses and noroviruses (Santiana et al., 2018) .", [["Hepatitis E", "DISEASE", 340, 351], ["rotaviruses and noroviruses", "DISEASE", 378, 405], ["HAV", "ORGANISM", 13, 16], ["Hepatitis E virus", "ORGANISM", 340, 357], ["rotaviruses", "ORGANISM", 378, 389], ["Hepatitis E virus", "SPECIES", 340, 357], ["rotaviruses", "SPECIES", 378, 389], ["HAV", "SPECIES", 13, 16], ["Hepatitis E virus", "SPECIES", 340, 357], ["Quasi-enveloped viruses", "PROBLEM", 85, 108], ["quasi-envelopment", "TREATMENT", 125, 142], ["several other viruses", "PROBLEM", 172, 193], ["Hepatitis E virus", "TREATMENT", 340, 357], ["rotaviruses", "PROBLEM", 378, 389], ["noroviruses", "PROBLEM", 394, 405], ["highly", "OBSERVATION_MODIFIER", 20, 26], ["infectious", "OBSERVATION", 27, 37], ["enveloped", "OBSERVATION_MODIFIER", 50, 59], ["non-enveloped", "OBSERVATION_MODIFIER", 64, 77], ["viruses", "OBSERVATION", 101, 108], ["viruses", "OBSERVATION", 186, 193]]], ["Furthermore, some picornaviruses, including poliovirus and coxsackievirus, differ from the HAV paradigm in that they form quasi-enveloped virions by subverting the autophagy pathway.", [["virions", "ANATOMY", 138, 145], ["poliovirus", "ORGANISM", 44, 54], ["coxsackievirus", "ORGANISM", 59, 73], ["HAV", "ORGANISM", 91, 94], ["HAV", "SPECIES", 91, 94], ["some picornaviruses", "PROBLEM", 13, 32], ["poliovirus", "PROBLEM", 44, 54], ["coxsackievirus", "PROBLEM", 59, 73], ["picornaviruses", "OBSERVATION", 18, 32], ["poliovirus", "OBSERVATION", 44, 54], ["coxsackievirus", "OBSERVATION", 59, 73]]], ["In these cases, double-membraned autophagosomes engulf multiple naked viral particles, which then release quasi-enveloped viruses when the outer autophagosomal membrane fuses with the plasma membrane (Mutsafi and Altan-Bonnet, 2018; Bird et al., 2014) .", [["autophagosomes", "ANATOMY", 33, 47], ["autophagosomal membrane", "ANATOMY", 145, 168], ["plasma membrane", "ANATOMY", 184, 199], ["autophagosomes", "CELLULAR_COMPONENT", 33, 47], ["outer", "CELLULAR_COMPONENT", 139, 144], ["autophagosomal membrane", "CELLULAR_COMPONENT", 145, 168], ["plasma membrane", "CELLULAR_COMPONENT", 184, 199], ["double-membraned autophagosomes", "CELL_LINE", 16, 47], ["double-membraned autophagosomes", "PROBLEM", 16, 47], ["multiple naked viral particles", "PROBLEM", 55, 85], ["viral particles", "OBSERVATION", 70, 85], ["autophagosomal membrane", "OBSERVATION", 145, 168]]], ["A final variation on this theme is the exosomal transfer of viral nucleic acids between cells, which apparently can, in some viruses like hepatitis C, spread productive infections without requiring full viral assembly (Ramakrishnaiah et al., 2013; Bukong et al., 2014) .Quasi-enveloped virusesThe membrane appears to perform several important functions for quasi-enveloped viruses, including protecting the capsid from antibody-mediated neutralization (Feng et al., 2013) , and clustering together of multiple virions so that they can enter target cells as a swarm or \"quasi-species\" that can cooperate genetically through cross-complementation.", [["exosomal", "ANATOMY", 39, 47], ["cells", "ANATOMY", 88, 93], ["membrane", "ANATOMY", 297, 305], ["cells", "ANATOMY", 548, 553], ["nucleic acids", "CHEMICAL", 66, 79], ["hepatitis C", "DISEASE", 138, 149], ["infections", "DISEASE", 169, 179], ["cells", "CELL", 88, 93], ["hepatitis C", "ORGANISM", 138, 149], ["viruses", "ORGANISM", 286, 293], ["membrane", "CELLULAR_COMPONENT", 297, 305], ["cells", "CELL", 548, 553], ["target cells", "CELL_TYPE", 541, 553], ["hepatitis C", "SPECIES", 138, 149], ["viral nucleic acids between cells", "PROBLEM", 60, 93], ["some viruses", "PROBLEM", 120, 132], ["hepatitis C", "PROBLEM", 138, 149], ["spread productive infections", "PROBLEM", 151, 179], ["quasi-enveloped viruses", "PROBLEM", 357, 380], ["multiple virions", "PROBLEM", 501, 517], ["viruses", "OBSERVATION", 125, 132], ["hepatitis", "OBSERVATION", 138, 147], ["spread", "OBSERVATION_MODIFIER", 151, 157], ["productive", "OBSERVATION_MODIFIER", 158, 168], ["infections", "OBSERVATION", 169, 179], ["enveloped viruses", "OBSERVATION", 276, 293]]], ["The later activity may be most important for enteroviruses, whose larger vesicles can each contain tens or even hundreds of viral particles (Chen et al., 2015; Santiana et al., 2018) .Quasi-enveloped virusesThe outer membranes of quasi-enveloped viruses lack viral glycoproteins, and therefore cannot fuse with target cell membranes.", [["vesicles", "ANATOMY", 73, 81], ["outer membranes", "ANATOMY", 211, 226], ["cell membranes", "ANATOMY", 318, 332], ["enteroviruses", "ORGANISM", 45, 58], ["vesicles", "CELLULAR_COMPONENT", 73, 81], ["viruses", "ORGANISM", 200, 207], ["outer membranes", "CELLULAR_COMPONENT", 211, 226], ["cell membranes", "CELLULAR_COMPONENT", 318, 332], ["viral glycoproteins", "PROTEIN", 259, 278], ["enteroviruses", "PROBLEM", 45, 58], ["quasi-enveloped viruses lack viral glycoproteins", "PROBLEM", 230, 278], ["enveloped viruses", "OBSERVATION", 190, 207], ["outer membranes", "OBSERVATION_MODIFIER", 211, 226], ["viral glycoproteins", "OBSERVATION", 259, 278], ["cell membranes", "OBSERVATION", 318, 332]]], ["Instead, eHAV particles are taken up into the host cells by endocytosis and trafficked toward the lysosome, where the membrane is degraded, and the released naked virions can cross into the cytoplasm by disrupting the endolysosomal membrane (Rivera-Serrano et al., 2019) .MaturationMost enveloped viruses undergo additional maturation steps during and after budding.", [["cells", "ANATOMY", 51, 56], ["lysosome", "ANATOMY", 98, 106], ["membrane", "ANATOMY", 118, 126], ["virions", "ANATOMY", 163, 170], ["cytoplasm", "ANATOMY", 190, 199], ["endolysosomal membrane", "ANATOMY", 218, 240], ["cells", "CELL", 51, 56], ["lysosome", "CELLULAR_COMPONENT", 98, 106], ["membrane", "CELLULAR_COMPONENT", 118, 126], ["cytoplasm", "ORGANISM_SUBSTANCE", 190, 199], ["endolysosomal membrane", "CELLULAR_COMPONENT", 218, 240], ["host cells", "CELL_TYPE", 46, 56], ["eHAV particles", "TREATMENT", 9, 23], ["the released naked virions", "PROBLEM", 144, 170], ["host cells", "OBSERVATION", 46, 56], ["endolysosomal membrane", "OBSERVATION", 218, 240]]], ["Before maturation, the virion functions as an assembly machinery that can package components and leave the producer cell.", [["cell", "ANATOMY", 116, 120], ["cell", "CELL", 116, 120], ["producer cell", "CELL_TYPE", 107, 120], ["producer cell", "OBSERVATION", 107, 120]]], ["Conformational changes, typically triggered by proteolytic cleavage or pH changes, then convert the virion into a particle that is capable of entering and replicating in a new target cell (Veesler and Johnson, 2012; Steven et al., 2005) .MaturationIn the case of HIV-1, the viral protease (PR) is activated by autoproteolysis as the virus assembles and buds, and it cleaves the Gag polyprotein at five different sites, producing three new proteins (MA, CA and NC) and three smaller peptides (SP1, SP2, and p6).", [["cell", "ANATOMY", 183, 187], ["buds", "ANATOMY", 353, 357], ["cell", "CELL", 183, 187], ["HIV-1", "ORGANISM", 263, 268], ["PR", "GENE_OR_GENE_PRODUCT", 290, 292], ["Gag", "GENE_OR_GENE_PRODUCT", 378, 381], ["MA", "GENE_OR_GENE_PRODUCT", 449, 451], ["CA", "GENE_OR_GENE_PRODUCT", 453, 455], ["SP1", "GENE_OR_GENE_PRODUCT", 492, 495], ["SP2", "GENE_OR_GENE_PRODUCT", 497, 500], ["p6", "GENE_OR_GENE_PRODUCT", 506, 508], ["viral protease", "PROTEIN", 274, 288], ["PR", "PROTEIN", 290, 292], ["Gag polyprotein", "PROTEIN", 378, 393], ["MA", "PROTEIN", 449, 451], ["CA", "PROTEIN", 453, 455], ["NC", "PROTEIN", 460, 462], ["SP1", "PROTEIN", 492, 495], ["SP2", "PROTEIN", 497, 500], ["p6", "PROTEIN", 506, 508], ["HIV-1", "SPECIES", 263, 268], ["HIV-1", "SPECIES", 263, 268], ["Conformational changes", "PROBLEM", 0, 22], ["proteolytic cleavage", "PROBLEM", 47, 67], ["pH changes", "PROBLEM", 71, 81], ["HIV", "PROBLEM", 263, 266], ["the viral protease", "PROBLEM", 270, 288], ["the virus assembles", "PROBLEM", 329, 348], ["the Gag polyprotein", "PROBLEM", 374, 393], ["CA and NC", "TREATMENT", 453, 462], ["SP1", "TEST", 492, 495], ["SP2", "TEST", 497, 500], ["Gag polyprotein", "OBSERVATION", 378, 393]]], ["Gag processing drives a series of major rearrangements in which the CA protein forms a conical internal capsid that surrounds viral RNA in complex with NC protein and viral enzymes.", [["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["CA", "GENE_OR_GENE_PRODUCT", 68, 70], ["NC", "GENE_OR_GENE_PRODUCT", 152, 154], ["CA protein", "PROTEIN", 68, 78], ["conical internal capsid", "PROTEIN", 87, 110], ["viral RNA", "RNA", 126, 135], ["NC protein", "PROTEIN", 152, 162], ["viral enzymes", "PROTEIN", 167, 180], ["major rearrangements", "PROBLEM", 34, 54], ["the CA protein", "TEST", 64, 78], ["a conical internal capsid", "PROBLEM", 85, 110], ["viral RNA", "PROBLEM", 126, 135], ["NC protein", "TEST", 152, 162], ["viral enzymes", "TEST", 167, 180], ["viral RNA", "OBSERVATION", 126, 135]]], ["Gag cleavage is a sequential, ordered process, and each processing event appears to perform a different function.", [["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["Gag cleavage", "PROBLEM", 0, 12], ["cleavage", "OBSERVATION", 4, 12]]], ["Cleavage at the SP1-NC junction releases the NC-RNA complex to condense to the center of the virion, cleavage at the MA-CA junction promotes folding of the CA N-terminus into a b-hairpin that will ultimately form an NTP-permeable pore in the assembled capsid, and cleavage at the CA-SP1 junction destabilizes the immature lattice and promotes formation of the mature capsid lattice.", [["NTP", "CHEMICAL", 216, 219], ["N", "CHEMICAL", 159, 160], ["NTP", "CHEMICAL", 216, 219], ["SP1", "GENE_OR_GENE_PRODUCT", 16, 19], ["virion", "CELLULAR_COMPONENT", 93, 99], ["NTP", "SIMPLE_CHEMICAL", 216, 219], ["pore", "CELLULAR_COMPONENT", 230, 234], ["capsid", "CELLULAR_COMPONENT", 252, 258], ["CA", "GENE_OR_GENE_PRODUCT", 280, 282], ["SP1", "GENE_OR_GENE_PRODUCT", 283, 286], ["SP1", "PROTEIN", 16, 19], ["NC-RNA complex", "PROTEIN", 45, 59], ["MA", "PROTEIN", 117, 119], ["CA N-terminus", "PROTEIN", 156, 169], ["b-hairpin", "PROTEIN", 177, 186], ["NTP-permeable pore", "PROTEIN", 216, 234], ["CA", "PROTEIN", 280, 282], ["SP1", "PROTEIN", 283, 286], ["Cleavage at the SP1-NC junction", "TREATMENT", 0, 31], ["cleavage at the MA-CA junction", "TREATMENT", 101, 131], ["an NTP-permeable pore", "TREATMENT", 213, 234], ["cleavage at the CA-SP1 junction", "TREATMENT", 264, 295], ["NC junction", "ANATOMY", 20, 31], ["NC", "ANATOMY", 45, 47], ["virion", "OBSERVATION", 93, 99], ["permeable pore", "OBSERVATION_MODIFIER", 220, 234], ["capsid", "OBSERVATION", 252, 258], ["immature lattice", "OBSERVATION", 313, 329], ["mature", "OBSERVATION_MODIFIER", 360, 366], ["capsid lattice", "OBSERVATION", 367, 381]]], ["The NC-SP2 and SP2-p6 cleavages are also required for infectivity, as is cleavage of the longer Gag-Pol polyprotein, which liberates the viral enzymes.", [["NC-SP2", "GENE_OR_GENE_PRODUCT", 4, 10], ["SP2-p6", "GENE_OR_GENE_PRODUCT", 15, 21], ["Pol", "GENE_OR_GENE_PRODUCT", 100, 103], ["NC-SP2 and SP2-p6 cleavages", "DNA", 4, 31], ["Gag", "PROTEIN", 96, 99], ["Pol polyprotein", "PROTEIN", 100, 115], ["viral enzymes", "PROTEIN", 137, 150], ["The NC", "TREATMENT", 0, 6], ["SP2-p6 cleavages", "TREATMENT", 15, 31], ["infectivity", "PROBLEM", 54, 65], ["the viral enzymes", "TEST", 133, 150], ["NC", "ANATOMY", 4, 6]]], ["The mature conical capsid is a fullerene cone, with a curved hexagonal lattice comprising CA hexamers, and the cone ends closed through the incorporation of 12 CA pentamers.", [["fullerene", "CHEMICAL", 31, 40], ["CA", "GENE_OR_GENE_PRODUCT", 90, 92], ["CA", "GENE_OR_GENE_PRODUCT", 160, 162], ["CA hexamers", "PROTEIN", 90, 101], ["CA pentamers", "PROTEIN", 160, 172], ["a curved hexagonal lattice comprising CA hexamers", "TREATMENT", 52, 101], ["the incorporation of 12 CA pentamers", "TREATMENT", 136, 172], ["mature", "OBSERVATION_MODIFIER", 4, 10], ["conical capsid", "OBSERVATION", 11, 25]]], ["CA hexamers are stabilized by binding IP 6 (Dick et al., 2018; Mallery et al., 2018) , and differential placement of the hexamers and pentamers produces a variety of related capsid structures that each differ slightly in length and shape (Sundquist and Krausslich, 2012; Mattei et al., 2016; Freed, 2015) .", [["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["CA hexamers", "PROTEIN", 0, 11], ["CA hexamers", "TEST", 0, 11], ["the hexamers and pentamers", "TREATMENT", 117, 143], ["related capsid structures", "PROBLEM", 166, 191], ["capsid structures", "OBSERVATION", 174, 191], ["shape", "OBSERVATION_MODIFIER", 232, 237]]], ["Viral glycoproteins and their fusion peptides that enable entry into target cells must also typically be proteolytically processed to be functional.", [["cells", "ANATOMY", 76, 81], ["cells", "CELL", 76, 81], ["Viral glycoproteins", "PROTEIN", 0, 19], ["target cells", "CELL_TYPE", 69, 81], ["Viral glycoproteins", "TREATMENT", 0, 19], ["their fusion peptides", "TREATMENT", 24, 45]]], ["For example, the HIV-1 Env glycoprotein is synthesized as a polyprotein precursor (gp160), which is inserted into the endoplasmic reticulum membrane co-translationally.", [["endoplasmic reticulum membrane", "ANATOMY", 118, 148], ["HIV-1", "ORGANISM", 17, 22], ["Env", "ORGANISM", 23, 26], ["gp160", "GENE_OR_GENE_PRODUCT", 83, 88], ["endoplasmic reticulum membrane", "CELLULAR_COMPONENT", 118, 148], ["HIV-1 Env glycoprotein", "PROTEIN", 17, 39], ["polyprotein precursor", "PROTEIN", 60, 81], ["gp160", "PROTEIN", 83, 88], ["HIV-1", "SPECIES", 17, 22], ["HIV-1", "SPECIES", 17, 22], ["the HIV", "TEST", 13, 20], ["a polyprotein precursor", "TREATMENT", 58, 81], ["endoplasmic reticulum", "ANATOMY", 118, 139], ["membrane co-translationally", "OBSERVATION", 140, 167]]], ["Env is glycosylated and then proteolytically cleaved by the host Golgiassociated protease furin as it traffics through the secretory pathway, producing the mature surface gp120 and transmembrane gp41 glycoprotein subunits, which remain non-covalently associated as heterotrimeric spikes.", [["surface", "ANATOMY", 163, 170], ["Env", "GENE_OR_GENE_PRODUCT", 0, 3], ["furin", "GENE_OR_GENE_PRODUCT", 90, 95], ["gp120", "GENE_OR_GENE_PRODUCT", 171, 176], ["transmembrane", "CELLULAR_COMPONENT", 181, 194], ["Env", "PROTEIN", 0, 3], ["Golgiassociated protease", "PROTEIN", 65, 89], ["furin", "PROTEIN", 90, 95], ["gp120", "PROTEIN", 171, 176], ["transmembrane gp41 glycoprotein subunits", "PROTEIN", 181, 221], ["glycosylated", "TREATMENT", 7, 19], ["the host Golgiassociated protease furin", "TREATMENT", 56, 95], ["transmembrane gp41 glycoprotein subunits", "TREATMENT", 181, 221], ["heterotrimeric spikes", "PROBLEM", 265, 286]]], ["Proteolytic processing exposes the fusion peptide at the gp41 N-terminus and is required for fusogenic activity (Checkley et al., 2011) .MaturationIn other viruses, proteolytic activation of viral fusion proteins can occur following entry into the target cell.", [["cell", "ANATOMY", 255, 259], ["N", "CHEMICAL", 62, 63], ["cell", "CELL", 255, 259], ["gp41 N-terminus", "PROTEIN", 57, 72], ["viral fusion proteins", "PROTEIN", 191, 212], ["target cell", "CELL_TYPE", 248, 259], ["Proteolytic processing", "TREATMENT", 0, 22], ["the fusion peptide", "TREATMENT", 31, 49], ["MaturationIn other viruses", "PROBLEM", 137, 163], ["viral fusion proteins", "PROBLEM", 191, 212], ["fusion", "OBSERVATION", 35, 41], ["viruses", "OBSERVATION", 156, 163], ["viral fusion", "OBSERVATION", 191, 203], ["target cell", "OBSERVATION", 248, 259]]], ["Activation of the EBOV glycoprotein is a particularly well-understood case.", [["EBOV", "ORGANISM", 18, 22], ["EBOV glycoprotein", "PROTEIN", 18, 35], ["EBOV", "SPECIES", 18, 22], ["the EBOV glycoprotein", "TREATMENT", 14, 35]]], ["EBOV particles associate with the host cell surface by interactions with host receptors that bind to glycans on the viral glycoprotein GP and phosphatidylserine in the viral envelope.", [["cell surface", "ANATOMY", 39, 51], ["phosphatidylserine", "CHEMICAL", 142, 160], ["phosphatidylserine", "CHEMICAL", 142, 160], ["EBOV", "ORGANISM", 0, 4], ["cell surface", "CELLULAR_COMPONENT", 39, 51], ["GP", "GENE_OR_GENE_PRODUCT", 135, 137], ["phosphatidylserine", "AMINO_ACID", 142, 160], ["host receptors", "PROTEIN", 73, 87], ["viral glycoprotein GP", "PROTEIN", 116, 137], ["EBOV", "SPECIES", 0, 4], ["EBOV particles", "PROBLEM", 0, 14], ["host receptors", "TREATMENT", 73, 87], ["the viral glycoprotein GP", "TREATMENT", 112, 137], ["phosphatidylserine", "TREATMENT", 142, 160], ["host cell", "OBSERVATION", 34, 43], ["surface", "OBSERVATION_MODIFIER", 44, 51], ["viral envelope", "OBSERVATION", 168, 182]]], ["After internalization through macropinocytosis, endosomal cysteine proteases such as cathepsins L and B proteolytically process GP to remove a mucinlike subdomain and the glycan cap and expose the receptor-binding site (RBS).", [["endosomal", "ANATOMY", 48, 57], ["cysteine", "CHEMICAL", 58, 66], ["endosomal", "CELLULAR_COMPONENT", 48, 57], ["cathepsins L", "GENE_OR_GENE_PRODUCT", 85, 97], ["B", "GENE_OR_GENE_PRODUCT", 102, 103], ["GP", "GENE_OR_GENE_PRODUCT", 128, 130], ["endosomal cysteine proteases", "PROTEIN", 48, 76], ["cathepsins L and B", "PROTEIN", 85, 103], ["GP", "PROTEIN", 128, 130], ["mucinlike subdomain", "PROTEIN", 143, 162], ["glycan cap", "PROTEIN", 171, 181], ["receptor-binding site", "PROTEIN", 197, 218], ["RBS", "DNA", 220, 223], ["internalization through macropinocytosis", "TREATMENT", 6, 46], ["endosomal cysteine proteases", "TREATMENT", 48, 76], ["cathepsins L and B proteolytically process", "TREATMENT", 85, 127], ["a mucinlike subdomain", "TREATMENT", 141, 162], ["the glycan cap", "TREATMENT", 167, 181], ["macropinocytosis", "OBSERVATION", 30, 46], ["endosomal cysteine", "OBSERVATION", 48, 66], ["glycan cap", "OBSERVATION", 171, 181]]], ["The RBS binds the late endosomal/lysosomal protein NPC1, which induces a conformational change in GP, insertion of a fusion loop into the endosomal membrane, fusion of viral and endosomal membranes and release of the nucleocapsid into the cytoplasm (Lee and Saphire, 2009; Carette et al., 2011; Cote et al., 2011; Gong et al., 2016; Wang et al., 2016) .Cell-to-Cell TransmissionAfter budding, viruses can spread in two different ways; through cell-free transmission and cell-to-cell transmission.", [["endosomal", "ANATOMY", 23, 32], ["lysosomal", "ANATOMY", 33, 42], ["endosomal membrane", "ANATOMY", 138, 156], ["endosomal membranes", "ANATOMY", 178, 197], ["cytoplasm", "ANATOMY", 239, 248], ["Cell", "ANATOMY", 353, 357], ["Cell", "ANATOMY", 361, 365], ["cell", "ANATOMY", 443, 447], ["cell", "ANATOMY", 470, 474], ["cell", "ANATOMY", 478, 482], ["RBS", "GENE_OR_GENE_PRODUCT", 4, 7], ["late endosomal", "CELLULAR_COMPONENT", 18, 32], ["lysosomal", "CELLULAR_COMPONENT", 33, 42], ["NPC1", "GENE_OR_GENE_PRODUCT", 51, 55], ["GP", "GENE_OR_GENE_PRODUCT", 98, 100], ["endosomal membrane", "CELLULAR_COMPONENT", 138, 156], ["endosomal membranes", "CELLULAR_COMPONENT", 178, 197], ["nucleocapsid", "CELLULAR_COMPONENT", 217, 229], ["cytoplasm", "ORGANISM_SUBSTANCE", 239, 248], ["Cell", "CELL", 353, 357], ["Cell", "CELL", 361, 365], ["cell", "CELL", 443, 447], ["cell", "CELL", 470, 474], ["cell", "CELL", 478, 482], ["RBS", "DNA", 4, 7], ["lysosomal protein", "PROTEIN", 33, 50], ["NPC1", "PROTEIN", 51, 55], ["GP", "PROTEIN", 98, 100], ["fusion loop", "PROTEIN", 117, 128], ["The RBS", "TEST", 0, 7], ["a conformational change in GP", "PROBLEM", 71, 100], ["a fusion loop into the endosomal membrane", "TREATMENT", 115, 156], ["fusion of viral and endosomal membranes", "TREATMENT", 158, 197], ["Cell", "TEST", 353, 357], ["viruses", "PROBLEM", 393, 400], ["cell", "TEST", 470, 474], ["late", "OBSERVATION_MODIFIER", 18, 22], ["endosomal", "OBSERVATION_MODIFIER", 23, 32], ["lysosomal protein NPC1", "OBSERVATION", 33, 55], ["fusion loop", "OBSERVATION", 117, 128], ["endosomal membrane", "OBSERVATION", 138, 156], ["viral", "OBSERVATION", 168, 173], ["endosomal membranes", "OBSERVATION", 178, 197], ["viruses", "OBSERVATION", 393, 400], ["cell", "OBSERVATION", 478, 482]]], ["Cell-free virions diffuse freely through the extracellular space, and even between organisms, before entering target cells.", [["Cell", "ANATOMY", 0, 4], ["virions", "ANATOMY", 10, 17], ["extracellular space", "ANATOMY", 45, 64], ["cells", "ANATOMY", 117, 122], ["Cell", "CELL", 0, 4], ["extracellular space", "CELLULAR_COMPONENT", 45, 64], ["cells", "CELL", 117, 122], ["target cells", "CELL_TYPE", 110, 122], ["free virions", "OBSERVATION", 5, 17], ["diffuse", "OBSERVATION_MODIFIER", 18, 25], ["extracellular space", "ANATOMY", 45, 64], ["target cells", "OBSERVATION", 110, 122]]], ["This process can promote dissemination over long distances, to new tissues, and between hosts.", [["tissues", "ANATOMY", 67, 74], ["tissues", "TISSUE", 67, 74], ["dissemination", "OBSERVATION_MODIFIER", 25, 38]]], ["However, untargeted diffusion through aqueous media is relatively inefficient, and free viruses are susceptible to immune recognition.", [["untargeted diffusion through aqueous media", "PROBLEM", 9, 51], ["free viruses", "PROBLEM", 83, 95], ["free viruses", "OBSERVATION", 83, 95]]], ["In contrast, viral spread through direct sites of cell-to-cell contact increases transmission efficiency and can help evade antibody recognition.", [["sites", "ANATOMY", 41, 46], ["cell", "ANATOMY", 50, 54], ["cell", "ANATOMY", 58, 62], ["cell", "CELL", 50, 54], ["cell", "CELL", 58, 62], ["viral spread", "PROBLEM", 13, 25], ["cell", "TEST", 50, 54], ["transmission efficiency", "PROBLEM", 81, 104], ["viral spread", "OBSERVATION", 13, 25]]], ["To promote cell-to-cell transmission, viruses often subvert cellular structures that are normally used for cell-cell communication or cargo transfer.Cell-to-Cell TransmissionRetroviruses such as HIV-1 and MLV actively promote the formation of adhesive structures between donor and target cells.", [["cell", "ANATOMY", 11, 15], ["cell", "ANATOMY", 19, 23], ["cellular structures", "ANATOMY", 60, 79], ["cell", "ANATOMY", 107, 111], ["cell", "ANATOMY", 112, 116], ["Cell", "ANATOMY", 149, 153], ["Cell", "ANATOMY", 157, 161], ["adhesive structures", "ANATOMY", 243, 262], ["cells", "ANATOMY", 288, 293], ["cell", "CELL", 11, 15], ["cell", "CELL", 19, 23], ["cellular", "CELL", 60, 68], ["cell", "CELL", 107, 111], ["cell", "CELL", 112, 116], ["Cell", "CELL", 149, 153], ["Cell", "CELL", 157, 161], ["HIV-1", "ORGANISM", 195, 200], ["MLV", "ORGANISM", 205, 208], ["cells", "CELL", 288, 293], ["donor and target cells", "CELL_TYPE", 271, 293], ["HIV-1", "SPECIES", 195, 200], ["HIV-1", "SPECIES", 195, 200], ["MLV", "SPECIES", 205, 208], ["cell-cell communication", "TREATMENT", 107, 130], ["Cell", "TEST", 149, 153], ["Retroviruses", "PROBLEM", 174, 186], ["HIV", "TEST", 195, 198], ["MLV", "TREATMENT", 205, 208], ["adhesive structures", "PROBLEM", 243, 262], ["donor and target cells", "TREATMENT", 271, 293], ["cellular structures", "OBSERVATION", 60, 79], ["adhesive structures", "OBSERVATION", 243, 262], ["target cells", "OBSERVATION", 281, 293]]], ["These stable contact sites are termed virological synapses because they resemble the immunological synapses that mediate antigen presentation, and even employ some of the same molecular components.", [["termed virological synapses", "PROBLEM", 31, 58], ["the immunological synapses", "PROBLEM", 81, 107], ["stable", "OBSERVATION_MODIFIER", 6, 12]]], ["Virological synapse formation requires interactions between the viral glycoprotein on the donor cell and its cognate target cell receptor.", [["synapse", "ANATOMY", 12, 19], ["donor cell", "ANATOMY", 90, 100], ["cell", "ANATOMY", 124, 128], ["donor cell", "CELL", 90, 100], ["target cell receptor", "GENE_OR_GENE_PRODUCT", 117, 137], ["viral glycoprotein", "PROTEIN", 64, 82], ["donor cell", "CELL_TYPE", 90, 100], ["cognate target cell receptor", "PROTEIN", 109, 137], ["Virological synapse formation", "PROBLEM", 0, 29], ["the viral glycoprotein", "TREATMENT", 60, 82], ["the donor cell", "TREATMENT", 86, 100]]], ["Coreceptors and adhesion molecules are then recruited to stabilize and further organize these contact sites, and the producer cell cytoskeleton is repolarized towards the synapse to promote directional viral assembly and release.", [["sites", "ANATOMY", 102, 107], ["cell cytoskeleton", "ANATOMY", 126, 143], ["synapse", "ANATOMY", 171, 178], ["Coreceptors", "GENE_OR_GENE_PRODUCT", 0, 11], ["cell cytoskeleton", "CELLULAR_COMPONENT", 126, 143], ["synapse", "CELLULAR_COMPONENT", 171, 178], ["Coreceptors", "PROTEIN", 0, 11], ["adhesion molecules", "PROTEIN", 16, 34], ["Coreceptors and adhesion molecules", "TREATMENT", 0, 34], ["adhesion molecules", "OBSERVATION", 16, 34], ["producer cell cytoskeleton", "OBSERVATION", 117, 143]]], ["Virions bud directly into the intersynaptic space and are transferred efficiently to the closely opposed target cell (Agosto et al., 2015; Bracq et al., 2018; Dufloo et al., 2018; Nejmeddine and Bangham, 2010) .Cell-to-Cell TransmissionOther viruses hijack existing cell-cell contacts for transmission.", [["intersynaptic space", "ANATOMY", 30, 49], ["cell", "ANATOMY", 112, 116], ["Cell", "ANATOMY", 211, 215], ["Cell", "ANATOMY", 219, 223], ["cell-cell contacts", "ANATOMY", 266, 284], ["cell", "CELL", 112, 116], ["Cell", "CELL", 211, 215], ["Cell", "CELL", 219, 223], ["cell", "CELL", 266, 270], ["cell", "CELL", 271, 275], ["Virions bud", "PROBLEM", 0, 11], ["Cell", "TEST", 211, 215], ["cell-cell contacts", "OBSERVATION", 266, 284]]], ["For example, neurotropic viruses such as herpesviruses and rabies viruses are transported along axons and spread across synaptic contacts (Koyuncu et al., 2013) .", [["axons", "ANATOMY", 96, 101], ["synaptic contacts", "ANATOMY", 120, 137], ["rabies viruses", "DISEASE", 59, 73], ["neurotropic viruses", "ORGANISM", 13, 32], ["herpesviruses", "ORGANISM", 41, 54], ["rabies viruses", "ORGANISM", 59, 73], ["axons", "CELLULAR_COMPONENT", 96, 101], ["synaptic contacts", "CELLULAR_COMPONENT", 120, 137], ["rabies viruses", "SPECIES", 59, 73], ["neurotropic viruses", "PROBLEM", 13, 32], ["herpesviruses", "PROBLEM", 41, 54], ["rabies viruses", "PROBLEM", 59, 73], ["neurotropic viruses", "OBSERVATION", 13, 32]]], ["Viruses can also achieve targeted release by exploiting membrane protrusions such as nanotubes and filopodia, which normally transmit information and cargoes between cells (Agosto et al., 2015; Bracq et al., 2018; Dufloo et al., 2018) .ConclusionsThe principles of enveloped virus budding are remarkably conserved between different virus families, presumably owing to evolutionary history and common functional requirements.", [["membrane", "ANATOMY", 56, 64], ["filopodia", "ANATOMY", 99, 108], ["cells", "ANATOMY", 166, 171], ["membrane", "CELLULAR_COMPONENT", 56, 64], ["nanotubes", "CELLULAR_COMPONENT", 85, 94], ["filopodia", "CELLULAR_COMPONENT", 99, 108], ["cells", "CELL", 166, 171], ["enveloped virus", "ORGANISM", 265, 280], ["Viruses", "PROBLEM", 0, 7], ["exploiting membrane protrusions", "PROBLEM", 45, 76], ["enveloped virus budding", "PROBLEM", 265, 288], ["common functional requirements", "PROBLEM", 393, 423], ["membrane protrusions", "OBSERVATION", 56, 76], ["enveloped virus", "OBSERVATION", 265, 280]]], ["Viral egress is typically orchestrated by multifunctional structural proteins that recruit components, assemble the virion, bend host membranes, and facilitate membrane fission.", [["virion", "ANATOMY", 116, 122], ["membranes", "ANATOMY", 134, 143], ["membrane", "ANATOMY", 160, 168], ["virion", "CELLULAR_COMPONENT", 116, 122], ["membranes", "CELLULAR_COMPONENT", 134, 143], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["multifunctional structural proteins", "PROTEIN", 42, 77], ["Viral egress", "PROBLEM", 0, 12], ["multifunctional structural proteins", "PROBLEM", 42, 77], ["bend host membranes", "PROBLEM", 124, 143], ["facilitate membrane fission", "PROBLEM", 149, 176], ["egress", "OBSERVATION", 6, 12], ["structural proteins", "OBSERVATION", 58, 77], ["host membranes", "OBSERVATION", 129, 143], ["membrane fission", "OBSERVATION", 160, 176]]], ["In many, but not all cases, the cellular ESCRT pathway is recruited to mediate the final membrane fission step.", [["cellular", "ANATOMY", 32, 40], ["membrane", "ANATOMY", 89, 97], ["cellular", "CELL", 32, 40], ["membrane", "CELLULAR_COMPONENT", 89, 97], ["ESCRT", "PROTEIN", 41, 46]]], ["Recent studies have also revealed that many traditional \"non-enveloped\" viruses can be released within vesicles as quasi-enveloped viruses and that viruses frequently alter cellular pathways to promote directional release and synapse formation.ConclusionsAlthough the general strategies for enveloped virus egress are increasingly well understood, important challenges remain, including characterizing the release mechanisms of ESCRT-independent viruses, the biology and entry mechanisms of quasienveloped viruses, and the molecular mechanisms and pathogenesis associated with cell-to-cell viral spread.", [["vesicles", "ANATOMY", 103, 111], ["cellular", "ANATOMY", 173, 181], ["synapse", "ANATOMY", 226, 233], ["cell", "ANATOMY", 577, 581], ["cell", "ANATOMY", 585, 589], ["vesicles", "CELLULAR_COMPONENT", 103, 111], ["cellular", "CELL", 173, 181], ["synapse", "CELLULAR_COMPONENT", 226, 233], ["ESCRT", "GENE_OR_GENE_PRODUCT", 428, 433], ["cell", "CELL", 577, 581], ["cell", "CELL", 585, 589], ["Recent studies", "TEST", 0, 14], ["many traditional \"non-enveloped\" viruses", "PROBLEM", 39, 79], ["quasi-enveloped viruses", "PROBLEM", 115, 138], ["viruses", "PROBLEM", 148, 155], ["enveloped virus egress", "PROBLEM", 291, 313], ["independent viruses", "PROBLEM", 434, 453], ["quasienveloped viruses", "PROBLEM", 491, 513], ["the molecular mechanisms", "PROBLEM", 519, 543], ["pathogenesis", "PROBLEM", 548, 560], ["cell", "TEST", 577, 581], ["cell viral spread", "PROBLEM", 585, 602], ["cell", "OBSERVATION", 585, 589], ["viral spread", "OBSERVATION", 590, 602]]], ["These and other advances will help reveal the best approaches for inhibiting virus release for therapeutic benefit and harnessing release activities in new systems that can be used to deliver biomolecular cargoes into target cells in vivo.", [["cells", "ANATOMY", 225, 230], ["cells", "CELL", 225, 230], ["target cells", "CELL_TYPE", 218, 230], ["inhibiting virus release", "TREATMENT", 66, 90], ["therapeutic benefit", "TREATMENT", 95, 114], ["harnessing release activities", "TREATMENT", 119, 148]]]], "PMC7191553": [["To date, the whole population is at risk of infection with the coronavirus COVID-19 (SARS-CoV-2); in particular, older people, often frail and subject to multimorbidity, are at highest risk for severe and fatal disease.", [["infection", "DISEASE", 44, 53], ["multimorbidity", "DISEASE", 154, 168], ["coronavirus COVID-19", "ORGANISM", 63, 83], ["SARS-CoV-2", "ORGANISM", 85, 95], ["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125], ["infection", "PROBLEM", 44, 53], ["the coronavirus COVID", "TEST", 59, 80], ["severe and fatal disease", "PROBLEM", 194, 218], ["infection", "OBSERVATION", 44, 53], ["severe", "OBSERVATION_MODIFIER", 194, 200], ["fatal disease", "OBSERVATION", 205, 218]]]], "f3cacad9438bcac1c219b1e4675c99a867bf3e7c": [["EditorSince the first case of SARS-CoV-2 was confirmed, lives were altered in many ways, elective surgery was discontinued and outpatient clinics were cancelled or altered to phone consultations 1-5 .", [["SARS", "DISEASE", 30, 34], ["SARS", "PROBLEM", 30, 34], ["elective surgery", "TREATMENT", 89, 105]]], ["Anecdotal evidence suggests a reduction of acute surgical admissions, however there is paucity of studies looking into the causative factors.", [["reduction", "OBSERVATION_MODIFIER", 30, 39], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["surgical", "OBSERVATION", 49, 57]]], ["It was anticipated by some that as a result of the 'lock-down' patients would deteriorate at home without access to hospital treatment, leading to late presentations.EditorWe performed a multicentre study at sixteen hospitals aiming to evaluate the patients with acute surgical inflammatory processes (ASIP) (appendicitis, cholecystitis, diverticulitis and perianal abscesses) during the COVID-19 outbreak and compare it with the same timeframe in 2019.", [["perianal abscesses", "ANATOMY", 357, 375], ["ASIP", "DISEASE", 302, 306], ["appendicitis", "DISEASE", 309, 321], ["cholecystitis", "DISEASE", 323, 336], ["diverticulitis", "DISEASE", 338, 352], ["abscesses", "DISEASE", 366, 375], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 249, 257], ["perianal abscesses", "PATHOLOGICAL_FORMATION", 357, 375], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 249, 257], ["the 'lock", "TREATMENT", 47, 56], ["hospital treatment", "TREATMENT", 116, 134], ["a multicentre study", "TEST", 185, 204], ["acute surgical inflammatory processes", "PROBLEM", 263, 300], ["ASIP)", "PROBLEM", 302, 307], ["appendicitis", "PROBLEM", 309, 321], ["cholecystitis", "PROBLEM", 323, 336], ["diverticulitis", "PROBLEM", 338, 352], ["perianal abscesses", "PROBLEM", 357, 375], ["the COVID", "TEST", 384, 393], ["acute", "OBSERVATION_MODIFIER", 263, 268], ["surgical", "OBSERVATION_MODIFIER", 269, 277], ["inflammatory", "OBSERVATION", 278, 290], ["appendicitis", "OBSERVATION", 309, 321], ["cholecystitis", "OBSERVATION", 323, 336], ["diverticulitis", "OBSERVATION", 338, 352], ["perianal", "ANATOMY", 357, 365], ["abscesses", "OBSERVATION", 366, 375]]], ["Consecutive patients from March 14th 2020 (date of the declaration of the state of alarm by Spanish Government) until the May 2th 2020 (beginning of the gradual de-escalation plan) were included.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["the gradual de-escalation plan", "TREATMENT", 149, 179]]], ["In total, 521 patients were treated for ASIP in 2020 (cases) and 822 in 2019 (controls).", [["ASIP", "DISEASE", 40, 44], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["ASIP", "TREATMENT", 40, 44]]], ["This represents a 36\u22c56% (appendicitis -33\u22c54%, cholecystitis -22\u22c59%, diverticulitis -60% anal perianal abscesses -41%) reduction.", [["anal perianal abscesses", "ANATOMY", 88, 111], ["appendicitis", "DISEASE", 25, 37], ["cholecystitis", "DISEASE", 46, 59], ["diverticulitis", "DISEASE", 68, 82], ["abscesses", "DISEASE", 102, 111], ["anal", "PATHOLOGICAL_FORMATION", 88, 92], ["perianal abscesses", "PATHOLOGICAL_FORMATION", 93, 111], ["appendicitis", "TEST", 25, 37], ["cholecystitis", "TEST", 46, 59], ["diverticulitis", "PROBLEM", 68, 82], ["anal perianal abscesses", "PROBLEM", 88, 111], ["appendicitis", "OBSERVATION", 25, 37], ["cholecystitis", "OBSERVATION", 46, 59], ["diverticulitis", "OBSERVATION", 68, 82], ["anal perianal", "ANATOMY", 88, 101], ["abscesses", "OBSERVATION", 102, 111]]], ["The higher reduction was observed in mild and moderate cases (-49\u22c53% and -19\u22c55%, respectively), with a similar number of severe cases (86 vs. 97; variation -11\u22c53% Our conclusion is that, whilst the COVID-19 outbreak led to delayed presentations and selected more severe ASIP cases, the positive COVID-19 status itself did not have a direct impact on either mor-bidity or mortality.", [["ASIP", "DISEASE", 270, 274], ["ASIP", "CANCER", 270, 274], ["The higher reduction", "TREATMENT", 0, 20], ["mild and moderate cases", "PROBLEM", 37, 60], ["severe cases", "PROBLEM", 121, 133], ["variation", "TEST", 146, 155], ["the COVID", "TEST", 194, 203], ["selected more severe ASIP cases", "PROBLEM", 249, 280], ["the positive COVID", "TEST", 282, 300], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["reduction", "OBSERVATION_MODIFIER", 11, 20], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["moderate", "OBSERVATION_MODIFIER", 46, 54], ["severe", "OBSERVATION_MODIFIER", 121, 127]]], ["Based on these results, we recommend that treatment of ASIP cases to retrovert to that of pre-COVID era (i.e. surgery > conservative management).", [["ASIP", "DISEASE", 55, 59], ["treatment of ASIP cases", "TREATMENT", 42, 65], ["surgery", "TREATMENT", 110, 117], ["conservative management", "TREATMENT", 120, 143]]]], "PMC4708198": [["IntroductionCommunity-based studies are an important component of surveillance for acute respiratory infections/influenza-like illness (ARI/ILI).", [["respiratory", "ANATOMY", 89, 100], ["acute respiratory infections", "DISEASE", 83, 111], ["influenza-like illness", "DISEASE", 112, 134], ["ARI", "DISEASE", 136, 139], ["ILI", "DISEASE", 140, 143], ["surveillance", "TEST", 66, 78], ["acute respiratory infections", "PROBLEM", 83, 111], ["influenza", "PROBLEM", 112, 121], ["illness", "PROBLEM", 127, 134], ["ARI", "PROBLEM", 136, 139], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["respiratory", "ANATOMY", 89, 100], ["infections", "OBSERVATION", 101, 111], ["influenza", "OBSERVATION", 112, 121]]], ["Using nasal self-swabbing to obtain samples for laboratory analysis has advantages during outbreaks or pandemics, as this strategy would reduce the time required for health care professionals to obtain specimens, as well as lessen their risk of becoming infected.", [["nasal", "ANATOMY", 6, 11], ["samples", "ANATOMY", 36, 43], ["specimens", "ANATOMY", 202, 211], ["nasal self-swabbing", "TREATMENT", 6, 25], ["laboratory analysis", "TEST", 48, 67], ["pandemics", "PROBLEM", 103, 112], ["health care professionals", "TREATMENT", 166, 191], ["specimens", "TEST", 202, 211], ["infected", "PROBLEM", 254, 262], ["infected", "OBSERVATION", 254, 262]]], ["Furthermore, self-swabbing could be used to identify ARI/ILI etiologies in the community that might be missed from reliance on medically-attended disease surveillance.IntroductionPrevious self-swab studies for ARI/ILI have demonstrated their feasibility.1\u20133 However, few have been performed in the USA, and the use of self-swabs in a low-income, minority, urban population has not been assessed.", [["ARI", "DISEASE", 53, 56], ["ARI", "DISEASE", 210, 213], ["ILI", "DISEASE", 214, 217], ["self-swabbing", "TREATMENT", 13, 26], ["ARI/ILI etiologies", "PROBLEM", 53, 71], ["disease surveillance", "TEST", 146, 166], ["self-swab studies", "TEST", 188, 205], ["ARI", "PROBLEM", 210, 213], ["ILI", "PROBLEM", 214, 217], ["self-swabs", "TREATMENT", 318, 328]]], ["Understanding the feasibility and validity of nasal self-swabs in this population is important.", [["nasal", "ANATOMY", 46, 51], ["nasal", "ORGANISM_SUBDIVISION", 46, 51], ["nasal self-swabs", "TREATMENT", 46, 62]]], ["First, it is a population at high risk for infection and transmission due to overcrowding.4,5 Second, being low-income, Latino, publicly insured, foreign born, and having a lower education level are factors associated with lower likelihood of having a primary health care provider and seeking care for illness.6,7 Therefore, the objective of this pilot study was to assess the feasibility and validity of unsupervised self- and/or parental-swabbing for children in a low-income, urban minority population.MethodsThis pilot study was a component of an ongoing 5-year community-based ARI/ILI surveillance study, which includes a cohort of 250 households.7 Participants are from a primarily immigrant Latino population in Northern Manhattan in New York City.", [["infection", "DISEASE", 43, 52], ["illness", "DISEASE", 302, 309], ["children", "ORGANISM", 453, 461], ["children", "SPECIES", 453, 461], ["Participants", "SPECIES", 654, 666], ["infection", "PROBLEM", 43, 52], ["overcrowding", "PROBLEM", 77, 89], ["illness", "PROBLEM", 302, 309], ["this pilot study", "TEST", 342, 358], ["This pilot study", "TEST", 512, 528], ["ILI surveillance study", "TEST", 586, 608], ["infection", "OBSERVATION", 43, 52], ["foreign born", "OBSERVATION", 146, 158]]], ["Northern Manhattan is one of the most disadvantaged areas in New York City; 43.7% of the population receives federal income support.8 As part of the ongoing study, families answer twice-weekly text messages to report ARI/ILI-associated symptoms among household members.", [["ARI", "DISEASE", 217, 220], ["ILI", "DISEASE", 221, 224], ["federal income support", "TREATMENT", 109, 131], ["the ongoing study", "TEST", 145, 162], ["ARI", "PROBLEM", 217, 220], ["ILI", "PROBLEM", 221, 224], ["associated symptoms", "PROBLEM", 225, 244], ["New", "OBSERVATION_MODIFIER", 61, 64]]], ["If ARI/ILI criteria are met, a home visit is scheduled and a nasal swab is obtained from symptomatic participants by the research staff.7MethodsFrom January 7 to 23, 2014, after the swabs were collected for the primary study by the research staff, each participant was asked to obtain a nasal swab later that day, either from themselves (if they were \u226517 years old) or from their symptomatic child.", [["nasal swab", "ANATOMY", 61, 71], ["nasal swab", "ANATOMY", 287, 297], ["participants", "SPECIES", 101, 113], ["participant", "SPECIES", 253, 264], ["ARI", "PROBLEM", 3, 6], ["a nasal swab", "TEST", 59, 71], ["the swabs", "TEST", 178, 187], ["the primary study", "TEST", 207, 224], ["a nasal swab", "TEST", 285, 297]]], ["The Columbia University Medical Center Institutional Review Board approved this study with use of an information sheet and verbal consent.", [["this study", "TEST", 75, 85]]], ["For volunteers, the study team demonstrated how to obtain a nasal swab.", [["nasal swab", "ANATOMY", 60, 70], ["volunteers", "ORGANISM", 4, 14], ["the study", "TEST", 16, 25], ["a nasal swab", "TEST", 58, 70], ["nasal", "ANATOMY", 60, 65]]], ["Participants were provided with a self-swab kit and a pre-addressed, prestamped mailer that followed the US Postal Service guidelines for biological substances.9 Participants were advised that if the swab was not sent the day it was obtained, it should be stored in the refrigerator.", [["Participants", "SPECIES", 0, 12], ["Participants", "SPECIES", 162, 174], ["the swab", "TEST", 196, 204]]], ["The research staff followed up by telephone the next day to confirm that the self-swab was obtained and sent.", [["the self-swab", "TEST", 73, 86]]], ["Each participant obtaining the self-swab received a round-trip New York City MetroCard (value US$5.00) when the specimen was received.MethodsTo assess feasibility, we determined the proportion of households agreeing to perform the self-swab, the proportion returning the swab, and the number of days elapsed between when the participants received the kit and when the swab arrived in the laboratory.", [["specimen", "ANATOMY", 112, 120], ["swab", "ANATOMY", 368, 372], ["participant", "SPECIES", 5, 16], ["participants", "SPECIES", 325, 337], ["the self-swab", "TEST", 227, 240], ["the swab", "TEST", 267, 275], ["the swab", "TEST", 364, 372]]], ["All swabs obtained by research staff were analyzed by a commercially available multiplex reverse transcription polymerase chain reaction assay according to the manufacturer\u2019s instructions (BioFire Diagnostics, Inc., Salt Lake City, UT, USA).", [["swabs", "ANATOMY", 4, 9], ["All swabs", "TEST", 0, 9]]], ["The assay has a limit of detection (LOD) of 1\u2013200 tissue culture infective dose (TCID)50/mL for influenza, and an LOD of 4\u201330,000 TCID50/mL for non-influenza viral pathogens, of which only rhinovirus/enterovirus has an LOD of more than 5,000 TCID50/mL.", [["tissue", "ANATOMY", 50, 56], ["influenza", "DISEASE", 96, 105], ["rhinovirus", "ORGANISM", 189, 199], ["enterovirus", "ORGANISM", 200, 211], ["The assay", "TEST", 0, 9], ["influenza", "PROBLEM", 96, 105], ["an LOD", "TEST", 111, 117], ["non-influenza viral pathogens", "PROBLEM", 144, 173], ["rhinovirus", "PROBLEM", 189, 199], ["enterovirus", "PROBLEM", 200, 211]]], ["The LOD for bacterial respiratory pathogens ranges from 30 colony forming units (CFU)/mL to 4,000 CFU/mL.10 If the swab obtained for the primary research study was positive for a respiratory pathogen, the self-swab was also analyzed by multiplex reverse transcription polymerase chain reaction.", [["swab", "ANATOMY", 115, 119], ["The LOD", "TEST", 0, 7], ["bacterial respiratory pathogens", "PROBLEM", 12, 43], ["the swab", "TEST", 111, 119], ["the primary research study", "TEST", 133, 159], ["a respiratory pathogen", "PROBLEM", 177, 199], ["the self-swab", "TREATMENT", 201, 214], ["respiratory", "ANATOMY", 22, 33]]], ["The percent of self-swabs positive for the same pathogen as the corresponding swab obtained by research staff was calculated.", [["self-swabs", "TEST", 15, 25], ["the same pathogen", "PROBLEM", 39, 56], ["the corresponding swab", "TEST", 60, 82]]], ["Chi-square tests were used to assess if there were differences in demographic factors (age, sex, English proficiency, born in the US/elsewhere, and educational level) between those with a positive research swab who also had a positive self-swab versus a negative self-swab.", [["Chi-square tests", "TEST", 0, 16], ["a positive self-swab", "PROBLEM", 224, 244]]], ["Finally, the sensitivity of the self-swab using the research swab as the gold standard was assessed.", [["the self-swab", "TEST", 28, 41], ["the research swab", "TEST", 48, 65]]], ["All analyses were conducted using SPSS Statistics V22.0 (IBM Corporation, Armonk, NY, USA).ResultsWe approached 31 households to take part in the pilot study and 30 (96.8%) agreed (28 unique households; two households took part twice).", [["All analyses", "TEST", 0, 12], ["the pilot study", "TEST", 142, 157]]], ["These represented 15 ill adults and 15 ill children (Table 1).", [["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51]]], ["Of those who mailed the specimen, most (78.6%) reported mailing it within 1 day; all reported mailing it within 2 days.", [["specimen", "ANATOMY", 24, 32]]], ["The median time between the kit being dropped off and arrival to the laboratory was 8 days (range: 3\u201399 days).ResultsOf the 29 swabs received, 18 (62.1%, from seven adults and eleven children) had a corresponding research swab that was positive for a respiratory pathogen.", [["swabs", "ANATOMY", 127, 132], ["respiratory pathogen", "DISEASE", 251, 271], ["children", "ORGANISM", 183, 191], ["children", "SPECIES", 183, 191], ["swabs", "TEST", 127, 132], ["a corresponding research swab", "TEST", 197, 226], ["a respiratory pathogen", "PROBLEM", 249, 271], ["respiratory", "ANATOMY", 251, 262], ["pathogen", "OBSERVATION", 263, 271]]], ["Seven (87.5%) corresponding self-swabs were concordant with the positive research swabs for influenza, and eight (80.0%) corresponding self-swabs were concordant with the research swab for non-influenza pathogens (Table 2).", [["influenza", "DISEASE", 92, 101], ["self-swabs", "TEST", 28, 38], ["influenza", "PROBLEM", 92, 101], ["self-swabs", "TEST", 135, 145], ["the research swab", "TEST", 167, 184], ["non-influenza pathogens", "PROBLEM", 189, 212]]], ["The kappa statistic between research and self-swab was 0.84.", [["self-swab", "TEST", 41, 50]]], ["There were no differences in demographic variables, including education level or days between drop-off and receipt of swabs, among participants whose self- and research-staff obtained swabs correlated versus those whose swabs did not correlate (Table 1).", [["participants", "SPECIES", 131, 143], ["demographic variables", "TEST", 29, 50], ["education level", "TEST", 62, 77], ["swabs", "TREATMENT", 118, 123], ["those whose swabs", "TEST", 208, 225], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25]]], ["Of the self-swab samples that had a corresponding positive research swab, the longest time a self-swab sample took to arrive was 17 days; this swab was positive for respiratory syncytial virus and parainfluenza.", [["samples", "ANATOMY", 17, 24], ["swab", "ANATOMY", 143, 147], ["respiratory syncytial virus", "DISEASE", 165, 192], ["parainfluenza", "DISEASE", 197, 210], ["respiratory syncytial virus", "ORGANISM", 165, 192], ["parainfluenza", "ORGANISM", 197, 210], ["respiratory syncytial virus", "SPECIES", 165, 192], ["parainfluenza", "SPECIES", 197, 210], ["respiratory syncytial virus", "SPECIES", 165, 192], ["the self-swab samples", "TEST", 3, 24], ["a corresponding positive research swab", "PROBLEM", 34, 72], ["a self-swab sample", "TEST", 91, 109], ["this swab", "TEST", 138, 147], ["respiratory syncytial virus", "PROBLEM", 165, 192], ["parainfluenza", "PROBLEM", 197, 210], ["respiratory syncytial virus", "OBSERVATION", 165, 192], ["parainfluenza", "OBSERVATION", 197, 210]]], ["The research swab was positive only for respiratory syncytial virus.", [["respiratory syncytial virus", "DISEASE", 40, 67], ["respiratory syncytial virus", "ORGANISM", 40, 67], ["respiratory syncytial virus", "SPECIES", 40, 67], ["The research swab", "TEST", 0, 17], ["respiratory syncytial virus", "PROBLEM", 40, 67], ["syncytial virus", "OBSERVATION", 52, 67]]], ["Overall sensitivity for the self-swab to capture any respiratory pathogen was 83.3% (95% confidence interval [CI] 64%\u2013102%), and 87.5% (95% CI 63%\u2013112%) for influenza cases.", [["influenza", "DISEASE", 157, 166], ["Overall sensitivity", "TEST", 0, 19], ["the self-swab", "TEST", 24, 37], ["any respiratory pathogen", "TEST", 49, 73], ["CI", "TEST", 110, 112], ["CI", "TEST", 140, 142], ["influenza cases", "PROBLEM", 157, 172]]], ["Specificity was 100%, and negative and positive predictive values were 78.6% and 100%, respectively.", [["Specificity", "TEST", 0, 11]]], ["Sensitivity to capture respiratory pathogens for a person taking their own swab was 71.4% (95% CI 32%\u2013111%), and for a parent taking a swab of a child, was 90.9% (95% CI 73%\u2013109%); sensitivity for influenza was 100% for someone taking their own self-swab, and 75.0% (95% CI 63%\u2013112%) for a parent taking the swab.DiscussionIn this pilot study, we demonstrated that the use of self-swabbing for surveillance of respiratory pathogens is feasible and acceptable in a low-income, urban community.", [["swab", "ANATOMY", 308, 312], ["respiratory", "ANATOMY", 410, 421], ["influenza", "DISEASE", 197, 206], ["respiratory pathogens", "DISEASE", 410, 431], ["person", "SPECIES", 51, 57], ["Sensitivity", "TEST", 0, 11], ["capture respiratory pathogens", "PROBLEM", 15, 44], ["CI", "TEST", 95, 97], ["CI", "TEST", 167, 169], ["sensitivity", "TEST", 181, 192], ["influenza", "PROBLEM", 197, 206], ["CI", "TEST", 271, 273], ["the swab", "TREATMENT", 304, 312], ["this pilot study", "TEST", 326, 342], ["self-swabbing", "TREATMENT", 376, 389], ["respiratory pathogens", "PROBLEM", 410, 431]]], ["There was good concordance between nasal swabs obtained by research staff or by the participant.DiscussionThis study also confirmed that standard US Postal Service mailings can be used to provide viable self-swab specimens.", [["nasal swabs", "ANATOMY", 35, 46], ["specimens", "ANATOMY", 213, 222], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 35, 46], ["participant", "SPECIES", 84, 95], ["nasal swabs", "TEST", 35, 46], ["This study", "TEST", 106, 116], ["viable self-swab specimens", "TEST", 196, 222], ["good", "OBSERVATION_MODIFIER", 10, 14]]], ["The feasibility of using the postal service is important, since other commercial shipping services may be less accessible to low-income populations due to the limited availability of drop-off locations, the need for someone to be available for home pickup and, furthermore, are more costly.3 Although this study was completed during the winter, which may have reduced sample degradation, a previous study demonstrated the integrity and quality of self-swabs sent via regular mail across seasons.11DiscussionWhile the collection of self-swab samples is useful for the surveillance of ill individuals and collection of samples of nonmedically attended infections, another potential use of self-swabbing in a household is to collect samples from asymptomatic individuals in affected households.", [["swab samples", "ANATOMY", 536, 548], ["samples", "ANATOMY", 730, 737], ["infections", "DISEASE", 650, 660], ["this study", "TEST", 301, 311], ["reduced sample degradation", "PROBLEM", 360, 386], ["a previous study", "TEST", 388, 404], ["self-swabs", "TEST", 447, 457], ["self-swab samples", "TEST", 531, 548], ["ill individuals", "PROBLEM", 583, 598], ["nonmedically attended infections", "PROBLEM", 628, 660]]], ["Characterizing the level of asymptomatic infection is useful, as these individuals may also be contagious.", [["infection", "DISEASE", 41, 50], ["asymptomatic infection", "PROBLEM", 28, 50], ["asymptomatic", "OBSERVATION_MODIFIER", 28, 40], ["infection", "OBSERVATION", 41, 50], ["may also be", "UNCERTAINTY", 83, 94], ["contagious", "OBSERVATION_MODIFIER", 95, 105]]], ["In studies conducted during the 2009 influenza A H1N1 pandemic, up to 28% of those who were infected were asymptomatic.12\u201314 However, there are few data available on asymptomatic infection for seasonal influenza and other respiratory pathogens.12\u201314 Since serial swabbing would likely be needed to monitor the duration of asymptomatic shedding, it may be cost- and time-prohibitive for participants to be swabbed daily at a research site or by a health care worker in the household.DiscussionThere were limitations to this study.", [["influenza A H1N1 pandemic", "DISEASE", 37, 62], ["infection", "DISEASE", 179, 188], ["influenza", "DISEASE", 202, 211], ["respiratory pathogens", "DISEASE", 222, 243], ["influenza A H1N1", "ORGANISM", 37, 53], ["influenza A H1N1 pandemic", "SPECIES", 37, 62], ["participants", "SPECIES", 386, 398], ["2009 influenza A H1N1 pandemic", "SPECIES", 32, 62], ["A H1N1 pandemic", "PROBLEM", 47, 62], ["asymptomatic infection", "PROBLEM", 166, 188], ["seasonal influenza", "PROBLEM", 193, 211], ["other respiratory pathogens", "PROBLEM", 216, 243], ["serial swabbing", "TEST", 256, 271], ["asymptomatic shedding", "PROBLEM", 322, 343], ["this study", "TEST", 518, 528], ["infection", "OBSERVATION", 179, 188], ["respiratory pathogens", "OBSERVATION", 222, 243]]], ["Although there was high compliance with returning the self-swab samples, and all participants reported returning them within 2 days, there was wide variation in arrival time of mailed samples.", [["samples", "ANATOMY", 184, 191], ["participants", "SPECIES", 81, 93], ["wide variation", "PROBLEM", 143, 157], ["high", "OBSERVATION_MODIFIER", 19, 23], ["compliance", "OBSERVATION_MODIFIER", 24, 34], ["wide", "OBSERVATION_MODIFIER", 143, 147], ["variation", "OBSERVATION_MODIFIER", 148, 157]]], ["It is not known whether participants sent samples later than reported, whether the postal service was slow, or whether the sample was delayed in the University\u2019s central mailing office.", [["participants", "SPECIES", 24, 36], ["not known", "UNCERTAINTY", 6, 15]]], ["In addition, this pilot study was conducted concordantly with an ongoing ARI/ILI surveillance study in which participants observed the research assistant perform the nasal swab, which may have improved self-swab technique.", [["nasal swab", "ANATOMY", 166, 176], ["participants", "ORGANISM", 109, 121], ["nasal swab", "ORGANISM_SUBDIVISION", 166, 176], ["participants", "SPECIES", 109, 121], ["this pilot study", "TEST", 13, 29], ["an ongoing ARI/ILI surveillance study", "TEST", 62, 99], ["the nasal swab", "TEST", 162, 176], ["nasal", "ANATOMY", 166, 171]]], ["In this study, however, the research assistant was not present when the self-swab was taken, and it is both feasible and ideal to first instruct participants of the proper technique in a self-swab study.", [["participants", "SPECIES", 145, 157], ["this study", "TEST", 3, 13], ["the self-swab", "TEST", 68, 81], ["a self-swab study", "TEST", 185, 202]]], ["Further, participants were provided a round-trip New York City MetroCard (value US$5.00) for their time and effort; other populations might be less inclined to participate for this incentive or without an incentive.", [["participants", "SPECIES", 9, 21]]], ["However, other studies, including those from other countries, have also demonstrated high compliance with self-swabs.15\u201317 This pilot study took place in a single community and should be repeated with a larger and more diverse population within this geographical area, as well as with populations from other geographical areas.", [["other studies", "TEST", 9, 22], ["self-swabs", "TREATMENT", 106, 116], ["This pilot study", "TEST", 123, 139], ["a larger and more diverse population", "PROBLEM", 201, 237], ["high compliance", "OBSERVATION", 85, 100], ["larger", "OBSERVATION_MODIFIER", 203, 209], ["more", "OBSERVATION_MODIFIER", 214, 218], ["diverse", "OBSERVATION_MODIFIER", 219, 226], ["population", "OBSERVATION", 227, 237]]], ["A strength of this study is that there was the direct comparison of self-swab samples with research samples from the same participant.DiscussionIn conclusion, self-swabbing was acceptable and feasible in a low-income, urban minority population.", [["samples", "ANATOMY", 78, 85], ["samples", "ANATOMY", 100, 107], ["participant", "SPECIES", 122, 133], ["this study", "TEST", 14, 24], ["self-swab samples", "TEST", 68, 85], ["research samples", "TEST", 91, 107]]]], "d00733af047f08b38f17bc325d48619c1846108f": [["IntroductionThe management of mesially inclined/impacted mandibular permanent second molars is an area of significant importance to orthodontists.", [["mandibular permanent second molars", "ANATOMY", 57, 91], ["mandibular", "ORGAN", 57, 67], ["molars", "ORGAN", 85, 91], ["mesially inclined/impacted mandibular permanent second molars", "PROBLEM", 30, 91], ["impacted", "OBSERVATION_MODIFIER", 48, 56], ["mandibular", "ANATOMY", 57, 67], ["permanent", "OBSERVATION", 68, 77], ["molars", "OBSERVATION", 85, 91]]], ["However, there is little consensus on how to treat these uncommon anomalies.", [["these uncommon anomalies", "PROBLEM", 51, 75], ["little", "OBSERVATION_MODIFIER", 18, 24], ["uncommon", "OBSERVATION_MODIFIER", 57, 65], ["anomalies", "OBSERVATION", 66, 75]]], ["A survey of 12 esteemed clinicians elicited seven different treatment plans for a case with horizontally impacted second molars in a 12-year 9-month-old female patient ( Fig. 1 ) [1] .", [["molars", "ANATOMY", 121, 127], ["molars", "ORGAN", 121, 127], ["female", "ORGANISM", 153, 159], ["patient", "ORGANISM", 160, 167], ["patient", "SPECIES", 160, 167], ["horizontally impacted second molars", "PROBLEM", 92, 127]]], ["In this regard Valmaseda-Castellon et al. [2] stated \"the low prevalence of impaction of second permanent molars, and the difficulty of distinguishing between primary and secondary retention and impaction have been major factors underlying the lack of uniformity in the management of these eruption disturbances.\"", [["molars", "ANATOMY", 106, 112], ["primary and secondary retention", "DISEASE", 159, 190], ["eruption", "DISEASE", 290, 298], ["molars", "ORGAN", 106, 112], ["impaction", "PROBLEM", 76, 85], ["second permanent molars", "PROBLEM", 89, 112], ["secondary retention", "PROBLEM", 171, 190], ["impaction", "PROBLEM", 195, 204], ["these eruption disturbances", "PROBLEM", 284, 311], ["impaction", "OBSERVATION", 76, 85], ["secondary retention", "OBSERVATION", 171, 190], ["impaction", "OBSERVATION", 195, 204]]], ["This paper examines how low prevalence and proper diagnosis using clear terminology can impact our treatment decision on impacted mandibular permanent second molars.Definitions/terminologySuri et al. [3] discussed the many terms used to describe disorders of tooth eruption and pointed out the considerable confusion over their usage.", [["mandibular permanent second molars", "ANATOMY", 130, 164], ["tooth", "ANATOMY", 259, 264], ["tooth eruption", "DISEASE", 259, 273], ["confusion", "DISEASE", 307, 316], ["mandibular", "ORGAN", 130, 140], ["molars", "ORGAN", 158, 164], ["tooth", "ORGAN", 259, 264], ["our treatment decision", "TREATMENT", 95, 117], ["impacted mandibular permanent second molars", "PROBLEM", 121, 164], ["tooth eruption", "PROBLEM", 259, 273], ["the considerable confusion", "PROBLEM", 290, 316], ["mandibular", "ANATOMY", 130, 140], ["permanent second molars", "OBSERVATION", 141, 164], ["tooth", "ANATOMY", 259, 264], ["eruption", "OBSERVATION", 265, 273]]], ["To be consistent with several studies performed on prevalence and treatment outcomes the terms impaction, primary retention, and secondary retention will be used in this paper [2,4e7] .", [["primary retention", "DISEASE", 106, 123], ["several studies", "TEST", 22, 37], ["treatment", "TREATMENT", 66, 75], ["the terms impaction", "PROBLEM", 85, 104], ["primary retention", "PROBLEM", 106, 123], ["secondary retention", "PROBLEM", 129, 148], ["impaction", "OBSERVATION", 95, 104], ["primary retention", "OBSERVATION", 106, 123]]], ["Impaction is defined as the failure of tooth eruption due to a physical obstacle in the eruption path, or an abnormal eruption path of the tooth [3, 4, 7, 8] .", [["tooth", "ANATOMY", 39, 44], ["tooth", "ANATOMY", 139, 144], ["Impaction", "DISEASE", 0, 9], ["tooth eruption", "DISEASE", 39, 53], ["eruption", "DISEASE", 88, 96], ["tooth", "ORGAN", 39, 44], ["tooth", "ORGAN", 139, 144], ["Impaction", "PROBLEM", 0, 9], ["tooth eruption", "PROBLEM", 39, 53], ["a physical obstacle in the eruption path", "PROBLEM", 61, 101], ["an abnormal eruption path of the tooth", "PROBLEM", 106, 144], ["failure", "OBSERVATION_MODIFIER", 28, 35], ["tooth eruption", "OBSERVATION", 39, 53], ["abnormal", "OBSERVATION_MODIFIER", 109, 117], ["eruption", "OBSERVATION", 118, 126], ["tooth", "ANATOMY", 139, 144]]], ["Most impacted second molars occur in the mandible [2, 5] .", [["molars", "ANATOMY", 21, 27], ["mandible", "ANATOMY", 41, 49], ["molars", "ORGAN", 21, 27], ["mandible", "ORGAN", 41, 49], ["Most impacted second molars", "PROBLEM", 0, 27], ["impacted", "OBSERVATION_MODIFIER", 5, 13], ["second", "OBSERVATION_MODIFIER", 14, 20], ["molars", "OBSERVATION", 21, 27], ["mandible", "ANATOMY", 41, 49]]], ["Shpack et al. [9] , who examined 165 impacted mandibular second molars, reported most (88%) were mesially angulated, with 8% vertical, and 4% angulated distally.", [["mandibular second molars", "ANATOMY", 46, 70], ["mandibular", "ORGAN", 46, 56], ["molars", "ORGAN", 64, 70], ["impacted mandibular second molars", "PROBLEM", 37, 70], ["mesially angulated", "PROBLEM", 97, 115], ["8% vertical, and 4% angulated distally", "PROBLEM", 122, 160], ["mandibular", "ANATOMY_MODIFIER", 46, 56], ["second molars", "ANATOMY", 57, 70], ["angulated", "OBSERVATION_MODIFIER", 106, 115], ["vertical", "OBSERVATION_MODIFIER", 125, 133], ["angulated", "OBSERVATION_MODIFIER", 142, 151], ["distally", "ANATOMY_MODIFIER", 152, 160]]], ["Mesially angulated impactions have been reported to respond better to treatment than the other types [10, 11] .", [["Mesially angulated impactions", "PROBLEM", 0, 29], ["angulated", "OBSERVATION_MODIFIER", 9, 18], ["impactions", "OBSERVATION", 19, 29]]], ["Primary retention is the cessation of eruption before emergence, without a physical barrier in the eruption path and not due to abnormal position [3, 8, 12] .", [["eruption", "DISEASE", 38, 46], ["eruption", "DISEASE", 99, 107], ["eruption", "PROBLEM", 38, 46], ["a physical barrier", "TREATMENT", 73, 91], ["abnormal position", "PROBLEM", 128, 145], ["retention", "OBSERVATION", 8, 17], ["eruption", "OBSERVATION_MODIFIER", 38, 46]]], ["Primary retention is more common with upper second molars than lowers [5] .", [["upper second molars", "ANATOMY", 38, 57], ["upper", "ORGANISM_SUBDIVISION", 38, 43], ["molars", "ORGAN", 51, 57], ["upper second molars", "PROBLEM", 38, 57], ["retention", "OBSERVATION", 8, 17], ["more common", "OBSERVATION_MODIFIER", 21, 32], ["upper second", "OBSERVATION_MODIFIER", 38, 50], ["molars", "OBSERVATION", 51, 57]]], ["Secondary retention is the cessation of eruption after emergence without a physical barrier in the eruption path and not due to abnormal position.", [["eruption", "DISEASE", 40, 48], ["eruption", "DISEASE", 99, 107], ["Secondary retention", "PROBLEM", 0, 19], ["eruption", "PROBLEM", 40, 48], ["a physical barrier", "TREATMENT", 73, 91], ["abnormal position", "PROBLEM", 128, 145], ["retention", "OBSERVATION", 10, 19], ["eruption", "OBSERVATION_MODIFIER", 40, 48]]], ["Ankylosis is probably the main etiologic factor although several phenomena have been found associated with secondary retention [8, 13] .", [["Ankylosis", "DISEASE", 0, 9], ["Ankylosis", "PROBLEM", 0, 9], ["several phenomena", "PROBLEM", 57, 74], ["secondary retention", "PROBLEM", 107, 126]]], ["Secondarily retained permanent second molars seem to be the most difficult to treat [2, 6] .Definitions/terminologyEctopic eruption, a term used universally to describe the entrapment of a mesially inclined first permanent molar behind the second primary molar during its initial eruption [14] , but is not commonly used to describe a similar condition of the second permanent molar.", [["molars", "ANATOMY", 38, 44], ["molar", "ANATOMY", 223, 228], ["primary molar", "ANATOMY", 247, 260], ["Ectopic eruption", "DISEASE", 115, 131], ["molars", "ORGAN", 38, 44], ["molar", "ORGAN", 223, 228], ["molar", "ORGAN", 255, 260], ["Secondarily retained permanent second molars", "PROBLEM", 0, 44], ["Ectopic eruption", "PROBLEM", 115, 131], ["a mesially inclined first permanent molar", "PROBLEM", 187, 228], ["the second permanent molar", "PROBLEM", 356, 382], ["retained", "OBSERVATION_MODIFIER", 12, 20], ["permanent", "OBSERVATION_MODIFIER", 21, 30], ["second", "OBSERVATION_MODIFIER", 31, 37], ["molars", "OBSERVATION", 38, 44], ["eruption", "OBSERVATION", 123, 131], ["entrapment", "OBSERVATION", 173, 183], ["molar", "OBSERVATION", 223, 228], ["molar", "OBSERVATION", 377, 382]]], ["Inclusion is infrequently used to describe a tooth that remains inside the bone [2] .", [["tooth", "ANATOMY", 45, 50], ["bone", "ANATOMY", 75, 79], ["tooth", "ORGAN", 45, 50], ["bone", "TISSUE", 75, 79], ["a tooth", "PROBLEM", 43, 50], ["tooth", "ANATOMY", 45, 50], ["bone", "ANATOMY", 75, 79]]], ["Retention or inclusion have been used to indicate the molar before or after apical root closure, when the tooth was still able to erupt or not [7] .Etiologic factorsBecker [15] states \"teeth normally erupt.", [["apical root", "ANATOMY", 76, 87], ["tooth", "ANATOMY", 106, 111], ["teeth", "ANATOMY", 185, 190], ["apical root", "MULTI-TISSUE_STRUCTURE", 76, 87], ["tooth", "ORGAN", 106, 111], ["teeth", "ORGAN", 185, 190], ["Retention or inclusion", "TREATMENT", 0, 22], ["apical root closure", "TREATMENT", 76, 95], ["the tooth", "PROBLEM", 102, 111], ["teeth normally erupt", "PROBLEM", 185, 205], ["apical", "ANATOMY_MODIFIER", 76, 82], ["root", "ANATOMY", 83, 87], ["closure", "OBSERVATION", 88, 95], ["erupt", "OBSERVATION", 200, 205]]], ["In the absence, it must be assumed there is some pathologic cause.", [["some pathologic cause", "PROBLEM", 44, 65], ["pathologic", "OBSERVATION", 49, 59]]], ["The key to success in resolving.tooth impaction, is to find the cause and if possible, eliminate it.\"", [["tooth", "ANATOMY", 32, 37], ["tooth impaction", "DISEASE", 32, 47], ["tooth", "ORGAN", 32, 37], ["tooth impaction", "PROBLEM", 32, 47], ["success", "OBSERVATION", 11, 18], ["resolving", "OBSERVATION_MODIFIER", 22, 31], ["impaction", "OBSERVATION", 38, 47]]], ["Andreasen et al. [12] pointed out three main causes for second molar disturbances: ectopic position, obstacles in the eruption path or failures in the eruption mechanism.", [["eruption", "DISEASE", 118, 126], ["eruption", "DISEASE", 151, 159], ["second molar disturbances", "PROBLEM", 56, 81], ["ectopic position", "PROBLEM", 83, 99], ["the eruption path", "PROBLEM", 114, 131], ["failures in the eruption mechanism", "PROBLEM", 135, 169], ["ectopic", "OBSERVATION", 83, 90], ["eruption", "OBSERVATION", 118, 126], ["failures", "OBSERVATION", 135, 143]]], ["The abnormal eruption of mandibular second molars appears to be related to genetics [4,16e18] .", [["mandibular second molars", "ANATOMY", 25, 49], ["abnormal eruption", "DISEASE", 4, 21], ["mandibular", "ORGAN", 25, 35], ["molars", "ORGAN", 43, 49], ["The abnormal eruption of mandibular second molars", "PROBLEM", 0, 49], ["abnormal", "OBSERVATION_MODIFIER", 4, 12], ["eruption", "OBSERVATION", 13, 21], ["mandibular", "ANATOMY", 25, 35], ["second molars", "OBSERVATION", 36, 49]]], ["Craniofacial morphology including Class II malocclusion, reduced mandibular gonial angle, vertical condylar growth, and decreased distance from first molar to mandibular ramus were found to be associated with abnormal second molar eruption [19e21] .", [["Craniofacial", "ANATOMY", 0, 12], ["mandibular gonial", "ANATOMY", 65, 82], ["condylar", "ANATOMY", 99, 107], ["mandibular ramus", "ANATOMY", 159, 175], ["molar", "ANATOMY", 225, 230], ["Class II malocclusion", "DISEASE", 34, 55], ["abnormal second molar eruption", "DISEASE", 209, 239], ["condylar", "MULTI-TISSUE_STRUCTURE", 99, 107], ["mandibular", "ORGAN", 159, 169], ["ramus", "ORGAN", 170, 175], ["Class II malocclusion", "PROBLEM", 34, 55], ["reduced mandibular gonial angle", "PROBLEM", 57, 88], ["vertical condylar growth", "PROBLEM", 90, 114], ["decreased distance", "PROBLEM", 120, 138], ["abnormal second molar eruption", "PROBLEM", 209, 239], ["malocclusion", "OBSERVATION", 43, 55], ["reduced", "OBSERVATION_MODIFIER", 57, 64], ["mandibular gonial", "ANATOMY", 65, 82], ["angle", "ANATOMY_MODIFIER", 83, 88], ["vertical", "OBSERVATION_MODIFIER", 90, 98], ["condylar", "OBSERVATION_MODIFIER", 99, 107], ["growth", "OBSERVATION_MODIFIER", 108, 114], ["decreased", "OBSERVATION_MODIFIER", 120, 129], ["molar", "ANATOMY_MODIFIER", 150, 155], ["mandibular ramus", "ANATOMY", 159, 175], ["abnormal", "OBSERVATION_MODIFIER", 209, 217], ["second", "OBSERVATION_MODIFIER", 218, 224], ["molar", "OBSERVATION_MODIFIER", 225, 230], ["eruption", "OBSERVATION", 231, 239]]], ["An abnormal eruption mechanism was considered by Palma et al. [4] .Etiologic factorsInsufficient space in the dental arches has been shown related to the impaction of lower second molars [4, 10, 18] .", [["dental arches", "ANATOMY", 110, 123], ["lower second molars", "ANATOMY", 167, 186], ["abnormal eruption", "DISEASE", 3, 20], ["dental arches", "MULTI-TISSUE_STRUCTURE", 110, 123], ["molars", "ORGAN", 180, 186], ["An abnormal eruption mechanism", "PROBLEM", 0, 30], ["Etiologic factors", "PROBLEM", 67, 84], ["Insufficient space in the dental arches", "PROBLEM", 84, 123], ["the impaction of lower second molars", "PROBLEM", 150, 186], ["abnormal", "OBSERVATION_MODIFIER", 3, 11], ["eruption", "OBSERVATION", 12, 20], ["Insufficient space", "OBSERVATION", 84, 102], ["dental arches", "ANATOMY", 110, 123], ["impaction", "OBSERVATION", 154, 163], ["lower", "ANATOMY_MODIFIER", 167, 172], ["second molars", "ANATOMY", 173, 186]]], ["Evans [22] found that cases with impacted mandibular second molars have significantly more lower crowding compared with controls.", [["mandibular second molars", "ANATOMY", 42, 66], ["molars", "ORGAN", 60, 66], ["impacted mandibular second molars", "PROBLEM", 33, 66], ["impacted", "ANATOMY_MODIFIER", 33, 41], ["mandibular", "ANATOMY", 42, 52], ["second", "ANATOMY_MODIFIER", 53, 59], ["molars", "OBSERVATION", 60, 66], ["significantly", "OBSERVATION_MODIFIER", 72, 85], ["more", "OBSERVATION_MODIFIER", 86, 90], ["lower", "OBSERVATION_MODIFIER", 91, 96], ["crowding", "OBSERVATION", 97, 105]]], ["Appliances such as the lingual arch or lip bumper which hold or further worsen the posterior arch length deficiency are also associated with mandibular second molar impaction [23e26].", [["lingual arch", "ANATOMY", 23, 35], ["lip", "ANATOMY", 39, 42], ["posterior arch", "ANATOMY", 83, 97], ["mandibular", "ANATOMY", 141, 151], ["lingual arch", "MULTI-TISSUE_STRUCTURE", 23, 35], ["lip", "ORGAN", 39, 42], ["posterior arch", "MULTI-TISSUE_STRUCTURE", 83, 97], ["Appliances", "TREATMENT", 0, 10], ["lip bumper", "PROBLEM", 39, 49], ["the posterior arch length deficiency", "PROBLEM", 79, 115], ["mandibular second molar impaction", "PROBLEM", 141, 174], ["lingual arch", "ANATOMY", 23, 35], ["lip", "ANATOMY", 39, 42], ["bumper", "OBSERVATION", 43, 49], ["posterior", "ANATOMY_MODIFIER", 83, 92], ["arch", "ANATOMY", 93, 97], ["length deficiency", "OBSERVATION", 98, 115], ["mandibular", "ANATOMY", 141, 151], ["molar", "OBSERVATION_MODIFIER", 159, 164], ["impaction", "OBSERVATION", 165, 174]]], ["The distal overhang of bands cemented to first permanent molars may further prevent the proper eruption of the second molar.Etiologic factorsBecker [13] cites a number of unusual anomalies associated with the failure of permanent molars to erupt: dentigerous cyst (increased intracystic pressure), ankylosis (usually subjective), invasive cervical root resorption, hooked or dilacerated root (cause or effect?) [4] , primary failure of eruption (affects all teeth posterior to most anteriorly affected tooth) [27e29], pre-eruptive intracoronal resorption, and root encirclement of the inferior alveolar nerve.", [["molars", "ANATOMY", 57, 63], ["molars", "ANATOMY", 230, 236], ["dentigerous cyst", "ANATOMY", 247, 263], ["intracystic", "ANATOMY", 275, 286], ["cervical root", "ANATOMY", 339, 352], ["root", "ANATOMY", 387, 391], ["teeth", "ANATOMY", 458, 463], ["tooth", "ANATOMY", 502, 507], ["intracoronal", "ANATOMY", 531, 543], ["root", "ANATOMY", 560, 564], ["inferior alveolar nerve", "ANATOMY", 585, 608], ["dentigerous cyst", "DISEASE", 247, 263], ["ankylosis", "DISEASE", 298, 307], ["eruption", "DISEASE", 436, 444], ["molars", "ORGAN", 57, 63], ["molars", "ORGAN", 230, 236], ["dentigerous cyst", "PATHOLOGICAL_FORMATION", 247, 263], ["cervical root", "MULTI-TISSUE_STRUCTURE", 339, 352], ["root", "ORGAN", 387, 391], ["teeth", "ORGAN", 458, 463], ["tooth", "ORGAN", 502, 507], ["inferior alveolar nerve", "MULTI-TISSUE_STRUCTURE", 585, 608], ["The distal overhang of bands cemented", "TREATMENT", 0, 37], ["first permanent molars", "PROBLEM", 41, 63], ["the proper eruption of the second molar", "PROBLEM", 84, 123], ["Etiologic factorsBecker", "PROBLEM", 124, 147], ["unusual anomalies", "PROBLEM", 171, 188], ["the failure of permanent molars", "PROBLEM", 205, 236], ["dentigerous cyst", "PROBLEM", 247, 263], ["increased intracystic pressure)", "PROBLEM", 265, 296], ["ankylosis", "PROBLEM", 298, 307], ["invasive cervical root resorption", "PROBLEM", 330, 363], ["hooked or dilacerated root", "PROBLEM", 365, 391], ["primary failure of eruption", "PROBLEM", 417, 444], ["pre-eruptive intracoronal resorption", "PROBLEM", 518, 554], ["root encirclement of the inferior alveolar nerve", "PROBLEM", 560, 608], ["distal", "OBSERVATION_MODIFIER", 4, 10], ["overhang", "OBSERVATION_MODIFIER", 11, 19], ["bands cemented", "OBSERVATION", 23, 37], ["molars", "OBSERVATION", 57, 63], ["proper", "OBSERVATION_MODIFIER", 88, 94], ["eruption", "OBSERVATION", 95, 103], ["second molar", "ANATOMY_MODIFIER", 111, 123], ["anomalies", "OBSERVATION", 179, 188], ["permanent molars", "OBSERVATION", 220, 236], ["dentigerous", "OBSERVATION_MODIFIER", 247, 258], ["cyst", "OBSERVATION", 259, 263], ["increased", "OBSERVATION_MODIFIER", 265, 274], ["intracystic", "OBSERVATION_MODIFIER", 275, 286], ["pressure", "OBSERVATION_MODIFIER", 287, 295], ["ankylosis", "OBSERVATION", 298, 307], ["invasive", "OBSERVATION_MODIFIER", 330, 338], ["cervical root", "ANATOMY", 339, 352], ["resorption", "OBSERVATION", 353, 363], ["root", "ANATOMY", 387, 391], ["eruption", "OBSERVATION", 436, 444], ["anteriorly", "ANATOMY_MODIFIER", 482, 492], ["intracoronal", "OBSERVATION_MODIFIER", 531, 543], ["resorption", "OBSERVATION", 544, 554], ["root", "ANATOMY_MODIFIER", 560, 564], ["encirclement", "OBSERVATION", 565, 577], ["inferior", "ANATOMY_MODIFIER", 585, 593], ["alveolar nerve", "ANATOMY", 594, 608]]], ["In regards to a molar not erupting due to ankylosis, Becker [13] states \"ankylosis of an impacted tooth is often very casually determined on the empirical basis that the tooth has not responded to extrusive orthodontic forces.it is an entirely outcome-oriented, fall back designation.", [["tooth", "ANATOMY", 98, 103], ["tooth", "ANATOMY", 170, 175], ["ankylosis", "DISEASE", 42, 51], ["ankylosis", "DISEASE", 73, 82], ["tooth", "ORGAN", 98, 103], ["tooth", "ORGAN", 170, 175], ["a molar", "PROBLEM", 14, 21], ["ankylosis", "PROBLEM", 42, 51], ["ankylosis", "PROBLEM", 73, 82], ["an impacted tooth", "PROBLEM", 86, 103], ["fall back designation", "PROBLEM", 262, 283], ["ankylosis", "OBSERVATION", 42, 51], ["ankylosis", "OBSERVATION", 73, 82], ["impacted", "OBSERVATION", 89, 97], ["tooth", "ANATOMY", 98, 103], ["tooth", "ANATOMY", 170, 175]]], ["Unless you extract, the tooth ankylosis cannot be confirmed scientifically.\"", [["tooth", "ANATOMY", 24, 29], ["tooth ankylosis", "DISEASE", 24, 39], ["tooth", "ORGAN", 24, 29], ["the tooth ankylosis", "PROBLEM", 20, 39], ["ankylosis", "OBSERVATION", 30, 39]]], ["Becker [30, 31] reported on a large sample of failed cases of impacted teeth finding invasive cervical root resorption, pre-eruptive intra coronal resorption, inappropriate direction of traction and poorly designed auxiliaries, can all be associated with failure to resolve impaction.Etiologic factorsIn summary, vertically oriented infraoccluded molars are commonly due to primary or secondary retention, and these teeth may have limited eruption potential due to ankylosis or other factors.", [["teeth", "ANATOMY", 71, 76], ["cervical root", "ANATOMY", 94, 107], ["coronal", "ANATOMY", 139, 146], ["molars", "ANATOMY", 347, 353], ["teeth", "ANATOMY", 416, 421], ["impaction", "DISEASE", 274, 283], ["eruption", "DISEASE", 439, 447], ["ankylosis", "DISEASE", 465, 474], ["teeth", "ORGAN", 71, 76], ["cervical root", "MULTI-TISSUE_STRUCTURE", 94, 107], ["molars", "ORGAN", 347, 353], ["teeth", "ORGAN", 416, 421], ["Etiologic factors", "PROTEIN", 284, 301], ["impacted teeth", "PROBLEM", 62, 76], ["invasive cervical root resorption", "PROBLEM", 85, 118], ["pre-eruptive intra coronal resorption", "PROBLEM", 120, 157], ["traction and poorly designed auxiliaries", "PROBLEM", 186, 226], ["failure", "PROBLEM", 255, 262], ["impaction", "PROBLEM", 274, 283], ["Etiologic factors", "PROBLEM", 284, 301], ["vertically oriented infraoccluded molars", "PROBLEM", 313, 353], ["secondary retention", "PROBLEM", 385, 404], ["these teeth", "PROBLEM", 410, 421], ["ankylosis", "PROBLEM", 465, 474], ["other factors", "PROBLEM", 478, 491], ["impacted teeth", "OBSERVATION", 62, 76], ["invasive", "OBSERVATION_MODIFIER", 85, 93], ["cervical root", "ANATOMY", 94, 107], ["resorption", "OBSERVATION", 108, 118], ["resorption", "OBSERVATION", 147, 157], ["traction", "OBSERVATION", 186, 194], ["impaction", "OBSERVATION", 274, 283], ["molars", "OBSERVATION", 347, 353], ["secondary retention", "OBSERVATION", 385, 404], ["ankylosis", "OBSERVATION", 465, 474]]], ["Mesially inclined impacted molars are impacted due to an abnormal eruption path and usually have eruption potential.Incidence/prevalenceImpacted second molars have been reported to occur infrequently in the general population (0.03e1.7%) [18, 32, 33] , but are more common (1.8%e3%) in the orthodontic population [9, 17, 18] .", [["molars", "ANATOMY", 27, 33], ["molars", "ANATOMY", 152, 158], ["molars", "ORGAN", 27, 33], ["molars", "ORGAN", 152, 158], ["Mesially inclined impacted molars", "PROBLEM", 0, 33], ["an abnormal eruption path", "PROBLEM", 54, 79], ["prevalenceImpacted second molars", "PROBLEM", 126, 158], ["impacted", "OBSERVATION_MODIFIER", 18, 26], ["molars", "OBSERVATION", 27, 33], ["abnormal", "OBSERVATION_MODIFIER", 57, 65], ["eruption", "OBSERVATION", 66, 74]]], ["Some of the variation in prevalence may be due to the categorization of molars being either ectopic or impacted [5, 33] .", [["molars", "ANATOMY", 72, 78], ["molars", "ORGAN", 72, 78], ["molars", "PROBLEM", 72, 78], ["ectopic", "PROBLEM", 92, 99], ["may be due to", "UNCERTAINTY", 36, 49], ["molars", "OBSERVATION", 72, 78], ["impacted", "OBSERVATION_MODIFIER", 103, 111]]], ["This is probably the reason the incidence of impaction (0.2%) was so low in the Bondemark and Tsiopa [5] study.", [["impaction", "DISEASE", 45, 54], ["impaction", "PROBLEM", 45, 54], ["probably the reason", "UNCERTAINTY", 8, 27], ["impaction", "OBSERVATION", 45, 54]]], ["Combining teeth described as ectopic (1.5%) and impacted (0.2%) would give an incidence of impaction at 1.7%.", [["teeth", "ANATOMY", 10, 15], ["impaction", "DISEASE", 91, 100], ["teeth", "ORGAN", 10, 15], ["Combining teeth", "PROBLEM", 0, 15], ["ectopic", "PROBLEM", 29, 36], ["impaction", "PROBLEM", 91, 100], ["teeth", "OBSERVATION", 10, 15], ["ectopic", "OBSERVATION_MODIFIER", 29, 36], ["impaction", "OBSERVATION", 91, 100]]], ["Mandibular second molar impaction is more common than maxillary second molars, or either maxillary or mandibular first molars [2, 4, 5, 7] .", [["maxillary second molars", "ANATOMY", 54, 77], ["maxillary", "ANATOMY", 89, 98], ["mandibular first molars", "ANATOMY", 102, 125], ["Mandibular", "ORGAN", 0, 10], ["maxillary", "ORGAN", 54, 63], ["molars", "ORGAN", 71, 77], ["maxillary", "ORGAN", 89, 98], ["molars", "ORGAN", 119, 125], ["Mandibular second molar impaction", "PROBLEM", 0, 33], ["maxillary second molars", "PROBLEM", 54, 77], ["maxillary or mandibular first molars", "PROBLEM", 89, 125], ["molar", "OBSERVATION_MODIFIER", 18, 23], ["impaction", "OBSERVATION", 24, 33], ["more", "OBSERVATION_MODIFIER", 37, 41], ["common", "OBSERVATION_MODIFIER", 42, 48], ["molars", "OBSERVATION", 71, 77], ["maxillary", "ANATOMY", 89, 98], ["mandibular", "ANATOMY_MODIFIER", 102, 112], ["molars", "OBSERVATION", 119, 125]]], ["Horizontally impacted second molars are rare.", [["molars", "ANATOMY", 29, 35], ["molars", "ORGAN", 29, 35], ["Horizontally impacted second molars", "PROBLEM", 0, 35], ["impacted", "OBSERVATION_MODIFIER", 13, 21], ["second", "OBSERVATION_MODIFIER", 22, 28], ["molars", "OBSERVATION", 29, 35], ["rare", "OBSERVATION_MODIFIER", 40, 44]]], ["Monaca et al. [7] found only 7 of 161 impacted molars were horizontal.", [["molars", "ANATOMY", 47, 53], ["molars", "ORGAN", 47, 53], ["impacted", "OBSERVATION_MODIFIER", 38, 46], ["molars", "OBSERVATION", 47, 53]]], ["Fu et al. [33] observed only 5 of 125 impacted molars to be angulated at greater than 90%.", [["molars", "ANATOMY", 47, 53], ["molars", "ORGAN", 47, 53], ["impacted molars", "PROBLEM", 38, 53], ["molars", "OBSERVATION", 47, 53], ["angulated", "OBSERVATION_MODIFIER", 60, 69]]], ["Therefore, horizontally impacted molars may occur once in many thousands of patients meaning most practitioners might practice a lifetime without experiencing such a case.", [["molars", "ANATOMY", 33, 39], ["molars", "ORGAN", 33, 39], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["horizontally impacted molars", "PROBLEM", 11, 39], ["horizontally", "OBSERVATION_MODIFIER", 11, 23], ["impacted", "OBSERVATION_MODIFIER", 24, 32], ["molars", "OBSERVATION", 33, 39]]], ["Hence the difficulty in formulating a treatment plan when such a case presents itself.Clinical managementSeveral factors need to be considered in planning treatment.Age, eruption status, and root developmentThe first is the age of the patient.", [["root", "ANATOMY", 191, 195], ["eruption", "DISEASE", 170, 178], ["root", "ORGANISM_SUBDIVISION", 191, 195], ["patient", "ORGANISM", 235, 242], ["patient", "SPECIES", 235, 242], ["a treatment plan", "TREATMENT", 36, 52], ["Clinical management", "TREATMENT", 86, 105], ["treatment", "TREATMENT", 155, 164], ["eruption status", "PROBLEM", 170, 185]]], ["Younger patients experienced better outcomes than adults, with treatment around the age of 14 reported to be optimal [7,34e37] .", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["treatment", "TREATMENT", 63, 72]]], ["But although treatment in adolescence may be preferred, there are several case reports where horizontally impacted second molars were successfully uprighted in young adults [38e41].", [["molars", "ANATOMY", 122, 128], ["molars", "ORGAN", 122, 128], ["horizontally impacted second molars", "PROBLEM", 93, 128]]], ["Next is the eruption status of the impacted molar and the exposure, if any, of the clinical crown.", [["molar", "ANATOMY", 44, 49], ["molar", "ORGAN", 44, 49], ["the impacted molar", "PROBLEM", 31, 49], ["impacted", "OBSERVATION_MODIFIER", 35, 43], ["molar", "OBSERVATION", 44, 49]]], ["If sufficient clinical crown is visible to bond to (4 \u00c2 4 m) surgical exposure may not be necessary.", [["surgical exposure", "TREATMENT", 61, 78]]], ["The angulation or inclination of the impacted molar does not seem to be as important a factor as it might appear [4, 7] .", [["The angulation", "PROBLEM", 0, 14], ["the impacted molar", "PROBLEM", 33, 51], ["angulation", "OBSERVATION_MODIFIER", 4, 14], ["inclination", "OBSERVATION_MODIFIER", 18, 29], ["impacted", "OBSERVATION_MODIFIER", 37, 45], ["molar", "OBSERVATION", 46, 51]]], ["Other than experiencing longer treatment times [33] , horizontally impacted molars seem to respond as well as moderately inclined molars.", [["molars", "ANATOMY", 76, 82], ["molars", "ANATOMY", 130, 136], ["molars", "ORGAN", 76, 82], ["molars", "ORGAN", 130, 136], ["horizontally impacted molars", "PROBLEM", 54, 82], ["moderately inclined molars", "PROBLEM", 110, 136], ["molars", "OBSERVATION", 76, 82]]], ["The stage of root development of the second or third molar is a consideration if one is to consider either surgical uprighting of the impacted molar, or autotransplanting either the second or third molars [34, 35, 42, 43] .", [["root", "ANATOMY", 13, 17], ["molar", "ANATOMY", 143, 148], ["molars", "ANATOMY", 198, 204], ["root", "ORGAN", 13, 17], ["molar", "ORGAN", 143, 148], ["molars", "ORGAN", 198, 204], ["the second or third molar", "PROBLEM", 33, 58], ["the impacted molar", "PROBLEM", 130, 148], ["root", "OBSERVATION_MODIFIER", 13, 17], ["development", "OBSERVATION_MODIFIER", 18, 29], ["molar", "OBSERVATION", 53, 58], ["impacted", "OBSERVATION_MODIFIER", 134, 142], ["molar", "OBSERVATION", 143, 148]]], ["Root anomalies such as dilaceration, root resorption or ankylosis may prevent an impacted tooth from being repositioned.", [["Root", "ANATOMY", 0, 4], ["root", "ANATOMY", 37, 41], ["tooth", "ANATOMY", 90, 95], ["Root anomalies", "DISEASE", 0, 14], ["dilaceration", "DISEASE", 23, 35], ["ankylosis", "DISEASE", 56, 65], ["root", "MULTI-TISSUE_STRUCTURE", 37, 41], ["tooth", "ORGAN", 90, 95], ["Root anomalies", "PROBLEM", 0, 14], ["dilaceration", "PROBLEM", 23, 35], ["root resorption", "PROBLEM", 37, 52], ["ankylosis", "PROBLEM", 56, 65], ["an impacted tooth", "PROBLEM", 78, 95], ["anomalies", "OBSERVATION", 5, 14], ["root", "OBSERVATION_MODIFIER", 37, 41], ["resorption", "OBSERVATION", 42, 52], ["ankylosis", "OBSERVATION", 56, 65], ["impacted", "OBSERVATION_MODIFIER", 81, 89], ["tooth", "OBSERVATION", 90, 95]]], ["Similarly the presence and position of third molars may influence treatment options such as autotransplantation or orthodontic uprighting.Anchorage considerationsThe source of anchorage is a major consideration in planning orthodontic treatment and the myriad of designs reported in our literature speaks to the boundless imagination of clinicians.", [["third molars", "ANATOMY", 39, 51], ["molars", "ORGAN", 45, 51], ["third molars", "PROBLEM", 39, 51], ["treatment options", "TREATMENT", 66, 83], ["autotransplantation", "TREATMENT", 92, 111], ["orthodontic uprighting", "TREATMENT", 115, 137], ["planning orthodontic treatment", "TREATMENT", 214, 244], ["position", "OBSERVATION_MODIFIER", 27, 35], ["third", "OBSERVATION_MODIFIER", 39, 44], ["molars", "OBSERVATION", 45, 51], ["anchorage", "OBSERVATION", 176, 185]]], ["Various types of springs, loops, and uprighting arches can be used successfully with only minor changes to the anchorage teeth [2,9,17,33,37,38,40,44e56] .", [["teeth", "ANATOMY", 121, 126], ["arches", "ORGAN", 48, 54], ["teeth", "ORGAN", 121, 126], ["loops, and uprighting arches", "TREATMENT", 26, 54], ["springs", "OBSERVATION", 17, 24], ["loops", "OBSERVATION_MODIFIER", 26, 31]]], ["For absolute anchorage, miniscrews can be used in the retromolar area, or more anteriorly between the roots of the molar and/or premolars for either direct or indirect anchorage [9,11,39,41,57e61] .", [["miniscrews", "ANATOMY", 24, 34], ["retromolar area", "ANATOMY", 54, 69], ["roots", "ANATOMY", 102, 107], ["molar", "ANATOMY", 115, 120], ["premolars", "ANATOMY", 128, 137], ["retromolar area", "CANCER", 54, 69], ["roots", "ORGAN", 102, 107], ["molar", "ORGAN", 115, 120], ["premolars", "ORGAN", 128, 137], ["absolute anchorage", "TREATMENT", 4, 22], ["miniscrews", "TREATMENT", 24, 34], ["absolute anchorage", "OBSERVATION", 4, 22], ["miniscrews", "OBSERVATION", 24, 34], ["retromolar", "ANATOMY_MODIFIER", 54, 64], ["anteriorly", "ANATOMY_MODIFIER", 79, 89], ["roots", "ANATOMY_MODIFIER", 102, 107], ["molar", "ANATOMY", 115, 120]]], ["Miniplates have similarly been reported to provide an excellent source of anchorage [15, 62] .", [["Miniplates", "TREATMENT", 0, 10]]], ["The preferred biomechanical approach is often predicated on the experience of the clinician and the limited access in the area of the impacted tooth, especially in a younger individual.", [["tooth", "ANATOMY", 143, 148], ["tooth", "ORGAN", 143, 148], ["the impacted tooth", "PROBLEM", 130, 148], ["impacted", "OBSERVATION_MODIFIER", 134, 142], ["tooth", "OBSERVATION", 143, 148]]], ["The degree of crowding or follicular collision may be a factor, as well as the financial status of the family and whether or not they choose to pursue orthodontics as a treatment option.Treatment optionsWith some variations, there were four different treatment plans suggested for the management of horizontally impacted mandibular second molars in a 12-year 9-month-old patient [1] .", [["follicular", "ANATOMY", 26, 36], ["mandibular second molars", "ANATOMY", 321, 345], ["mandibular second molars", "DISEASE", 321, 345], ["mandibular", "ORGAN", 321, 331], ["molars", "ORGAN", 339, 345], ["patient", "ORGANISM", 371, 378], ["patient", "SPECIES", 371, 378], ["crowding", "PROBLEM", 14, 22], ["follicular collision", "PROBLEM", 26, 46], ["orthodontics", "TREATMENT", 151, 163], ["a treatment option", "TREATMENT", 167, 185], ["horizontally impacted mandibular second molars", "PROBLEM", 299, 345], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["crowding", "OBSERVATION", 14, 22], ["follicular collision", "OBSERVATION", 26, 46], ["mandibular", "ANATOMY", 321, 331]]], ["Let's examine the indications, contraindications, benefits, shortcomings, and reported success rates of these different treatment plans.Extract the third molars and surgically upright the impacted second molarsSurgical uprighting involves tipping the molar on its root apex through a gentle luxation movement.", [["molars", "ANATOMY", 154, 160], ["molars", "ANATOMY", 204, 210], ["molar", "ANATOMY", 251, 256], ["root apex", "ANATOMY", 264, 273], ["luxation", "DISEASE", 291, 299], ["molars", "ORGAN", 154, 160], ["molars", "ORGAN", 204, 210], ["root apex", "MULTI-TISSUE_STRUCTURE", 264, 273], ["these different treatment plans", "TREATMENT", 104, 135], ["Extract the third molars", "PROBLEM", 136, 160], ["surgically upright the impacted second molars", "PROBLEM", 165, 210], ["a gentle luxation movement", "TREATMENT", 282, 308], ["third", "OBSERVATION_MODIFIER", 148, 153], ["molars", "OBSERVATION", 154, 160], ["surgically", "OBSERVATION", 165, 175], ["impacted", "OBSERVATION_MODIFIER", 188, 196], ["second", "OBSERVATION_MODIFIER", 197, 203], ["molars", "OBSERVATION_MODIFIER", 204, 210], ["Surgical", "OBSERVATION", 210, 218], ["molar", "OBSERVATION_MODIFIER", 251, 256], ["root", "ANATOMY_MODIFIER", 264, 268], ["apex", "ANATOMY_MODIFIER", 269, 273], ["gentle", "OBSERVATION_MODIFIER", 284, 290], ["luxation movement", "OBSERVATION", 291, 308]]], ["Pogrel [35] describes the surgical technique carried out under local anesthesia supplemented by intravenous sedation as needed.", [["intravenous", "ANATOMY", 96, 107], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 107], ["the surgical technique", "TREATMENT", 22, 44], ["local anesthesia", "TREATMENT", 63, 79], ["intravenous sedation", "TREATMENT", 96, 116]]], ["A buccal flap is created to the distobuccal line angle of the first molar and down into the buccal sulcus.", [["buccal flap", "ANATOMY", 2, 13], ["distobuccal line", "ANATOMY", 32, 48], ["molar", "ANATOMY", 68, 73], ["buccal sulcus", "ANATOMY", 92, 105], ["buccal flap", "TISSUE", 2, 13], ["buccal sulcus", "MULTI-TISSUE_STRUCTURE", 92, 105], ["A buccal flap", "TREATMENT", 0, 13], ["buccal", "ANATOMY", 2, 8], ["flap", "OBSERVATION", 9, 13], ["distobuccal", "ANATOMY_MODIFIER", 32, 43], ["line", "ANATOMY_MODIFIER", 44, 48], ["angle", "ANATOMY_MODIFIER", 49, 54], ["first molar", "ANATOMY", 62, 73], ["buccal sulcus", "ANATOMY", 92, 105]]], ["Lower third molars are removed at this time.", [["third molars", "ANATOMY", 6, 18], ["molars", "ORGAN", 12, 18], ["Lower third molars", "PROBLEM", 0, 18], ["third", "OBSERVATION_MODIFIER", 6, 11], ["molars", "OBSERVATION", 12, 18], ["removed", "OBSERVATION", 23, 30]]], ["The distal soft tissues are reflected lingually and a lingual retractor placed over the distal bone in the second molar region to protect the lingual nerve.", [["distal soft tissues", "ANATOMY", 4, 23], ["lingual retractor", "ANATOMY", 54, 71], ["bone", "ANATOMY", 95, 99], ["lingual nerve", "ANATOMY", 142, 155], ["soft tissues", "TISSUE", 11, 23], ["lingual retractor", "TISSUE", 54, 71], ["bone", "TISSUE", 95, 99], ["lingual nerve", "MULTI-TISSUE_STRUCTURE", 142, 155], ["a lingual retractor", "TREATMENT", 52, 71], ["distal", "ANATOMY_MODIFIER", 4, 10], ["soft tissues", "ANATOMY", 11, 23], ["lingual", "OBSERVATION_MODIFIER", 54, 61], ["retractor", "OBSERVATION", 62, 71], ["distal", "ANATOMY_MODIFIER", 88, 94], ["bone", "ANATOMY", 95, 99], ["second molar", "ANATOMY_MODIFIER", 107, 119], ["region", "ANATOMY_MODIFIER", 120, 126], ["lingual nerve", "ANATOMY", 142, 155]]], ["Bone is then removed with a bur distal to the second molar leaving the crown of the tooth exposed down to its greatest concavity.", [["Bone", "ANATOMY", 0, 4], ["tooth", "ANATOMY", 84, 89], ["Bone", "TISSUE", 0, 4], ["tooth", "ORGAN", 84, 89], ["a bur distal to the second molar", "TREATMENT", 26, 58], ["bur", "OBSERVATION_MODIFIER", 28, 31], ["distal", "OBSERVATION_MODIFIER", 32, 38], ["second", "OBSERVATION_MODIFIER", 46, 52], ["molar", "OBSERVATION", 53, 58], ["crown", "OBSERVATION_MODIFIER", 71, 76], ["tooth", "ANATOMY", 84, 89], ["exposed", "OBSERVATION", 90, 97], ["greatest", "OBSERVATION_MODIFIER", 110, 118], ["concavity", "OBSERVATION_MODIFIER", 119, 128]]], ["A straight elevator is then placed mesially and the tooth surgically tipped and elevated into the correct position.Extract the third molars and surgically upright the impacted second molarsIndications for surgical uprighting include an adolescent with open apices of the molar roots (one-half to two-thirds root development preferable), no clinical crown of the impacted molar visible intraorally, a minor unfavorable axial inclination of the impacted molar, and no other orthodontic treatment needs [35, 42] .", [["tooth", "ANATOMY", 52, 57], ["molars", "ANATOMY", 133, 139], ["molars", "ANATOMY", 183, 189], ["apices", "ANATOMY", 257, 263], ["molar roots", "ANATOMY", 271, 282], ["root", "ANATOMY", 307, 311], ["molar", "ANATOMY", 371, 376], ["axial", "ANATOMY", 418, 423], ["molar", "ANATOMY", 452, 457], ["tooth", "ORGAN", 52, 57], ["molars", "ORGAN", 133, 139], ["molars", "ORGAN", 183, 189], ["roots", "ORGAN", 277, 282], ["root", "ORGAN", 307, 311], ["A straight elevator", "TREATMENT", 0, 19], ["Extract the third molars", "PROBLEM", 115, 139], ["surgically upright the impacted second molars", "PROBLEM", 144, 189], ["surgical uprighting", "TREATMENT", 205, 224], ["open apices of the molar roots", "TREATMENT", 252, 282], ["the impacted molar", "PROBLEM", 358, 376], ["a minor unfavorable axial inclination of the impacted molar", "PROBLEM", 398, 457], ["straight", "OBSERVATION_MODIFIER", 2, 10], ["tooth", "ANATOMY", 52, 57], ["surgically", "OBSERVATION", 58, 68], ["tipped", "OBSERVATION_MODIFIER", 69, 75], ["elevated", "OBSERVATION_MODIFIER", 80, 88], ["correct", "OBSERVATION_MODIFIER", 98, 105], ["position", "OBSERVATION_MODIFIER", 106, 114], ["third", "OBSERVATION_MODIFIER", 127, 132], ["molars", "OBSERVATION", 133, 139], ["apices", "ANATOMY_MODIFIER", 257, 263], ["molar roots", "ANATOMY", 271, 282], ["no", "UNCERTAINTY", 337, 339], ["impacted", "OBSERVATION_MODIFIER", 362, 370], ["molar", "OBSERVATION", 371, 376], ["minor", "OBSERVATION_MODIFIER", 400, 405], ["unfavorable", "OBSERVATION_MODIFIER", 406, 417], ["impacted", "OBSERVATION_MODIFIER", 443, 451], ["molar", "OBSERVATION", 452, 457], ["no other", "UNCERTAINTY", 463, 471]]], ["Kravitz et al. [42] recommend an angle of inclination of less than 75 to the long axis of the first molar.", [["inclination", "TEST", 42, 53], ["long axis", "OBSERVATION_MODIFIER", 77, 86], ["first molar", "ANATOMY", 94, 105]]], ["The benefits of this approach are it simplifies or eliminates the need for orthodontic treatment and is highly successful with an experienced surgeon.", [["this approach", "TREATMENT", 16, 29], ["orthodontic treatment", "TREATMENT", 75, 96]]], ["Monaca et al. [7] reported a positive outcome in all 38 treated molars in which only a minor unfavorable axial inclination existed.", [["molars", "ANATOMY", 64, 70], ["axial", "ANATOMY", 105, 110], ["molars", "ORGAN", 64, 70], ["a positive outcome", "PROBLEM", 27, 45], ["a minor unfavorable axial inclination", "PROBLEM", 85, 122]]], ["The shortcomings are possible pulp necrosis, ankylosis, root fracture or resorption [34e36,63].", [["pulp", "ANATOMY", 30, 34], ["root", "ANATOMY", 56, 60], ["necrosis", "DISEASE", 35, 43], ["ankylosis", "DISEASE", 45, 54], ["fracture", "DISEASE", 61, 69], ["pulp", "TISSUE", 30, 34], ["root", "TISSUE", 56, 60], ["pulp necrosis", "PROBLEM", 30, 43], ["ankylosis", "PROBLEM", 45, 54], ["root fracture", "PROBLEM", 56, 69], ["resorption", "PROBLEM", 73, 83], ["possible", "UNCERTAINTY", 21, 29], ["pulp", "OBSERVATION_MODIFIER", 30, 34], ["necrosis", "OBSERVATION", 35, 43], ["ankylosis", "OBSERVATION", 45, 54], ["root", "OBSERVATION_MODIFIER", 56, 60], ["fracture", "OBSERVATION", 61, 69], ["resorption", "OBSERVATION_MODIFIER", 73, 83]]], ["Pogrel [35] reported success in 21 of 22 cases, with eight cases developing asymptomatic pulpal calcification.", [["pulpal", "ANATOMY", 89, 95], ["pulpal calcification", "DISEASE", 89, 109], ["pulpal", "TISSUE", 89, 95], ["asymptomatic pulpal calcification", "PROBLEM", 76, 109], ["asymptomatic", "OBSERVATION_MODIFIER", 76, 88], ["pulpal", "ANATOMY", 89, 95], ["calcification", "OBSERVATION", 96, 109]]], ["None of the 21 cases developed either internal or external root resorption or developed periapical disease.", [["root", "ANATOMY", 59, 63], ["periapical", "ANATOMY", 88, 98], ["periapical disease", "DISEASE", 88, 106], ["root", "ORGAN", 59, 63], ["internal or external root resorption", "PROBLEM", 38, 74], ["periapical disease", "PROBLEM", 88, 106], ["internal", "OBSERVATION_MODIFIER", 38, 46], ["external root", "ANATOMY", 50, 63], ["resorption", "OBSERVATION", 64, 74], ["periapical disease", "OBSERVATION", 88, 106]]], ["One tooth was lost due to infection.", [["tooth", "ANATOMY", 4, 9], ["infection", "DISEASE", 26, 35], ["tooth", "ORGAN", 4, 9], ["infection", "PROBLEM", 26, 35], ["tooth", "ANATOMY", 4, 9], ["due to", "UNCERTAINTY", 19, 25], ["infection", "OBSERVATION", 26, 35]]], ["Kravitz et al. [42] cited the displacement of the second molar into buccal crossbite as the most common undesirable side effect.", [["buccal", "ANATOMY", 68, 74], ["buccal crossbite", "DISEASE", 68, 84], ["buccal", "ORGAN", 68, 74], ["the displacement of the second molar", "TREATMENT", 26, 62], ["buccal crossbite", "PROBLEM", 68, 84], ["buccal crossbite", "ANATOMY", 68, 84]]], ["Teeth horizontally impacted experience greater movement of the root apex and hence may have increased risk of complications.", [["root apex", "ANATOMY", 63, 72], ["root apex", "MULTI-TISSUE_STRUCTURE", 63, 72], ["Teeth horizontally impacted", "PROBLEM", 0, 27], ["complications", "PROBLEM", 110, 123], ["greater", "OBSERVATION_MODIFIER", 39, 46], ["movement", "OBSERVATION_MODIFIER", 47, 55], ["root", "ANATOMY", 63, 67], ["apex", "ANATOMY_MODIFIER", 68, 72], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["complications", "OBSERVATION", 110, 123]]], ["Teeth that undergo surgical uprighting/luxation prior to complete root formation show continuing eruption and root formation [35, 36, 64] .", [["root", "ANATOMY", 66, 70], ["root", "ANATOMY", 110, 114], ["luxation", "DISEASE", 39, 47], ["eruption", "DISEASE", 97, 105], ["root", "TISSUE", 66, 70], ["root", "TISSUE", 110, 114], ["surgical uprighting/luxation", "TREATMENT", 19, 47], ["complete root formation", "PROBLEM", 57, 80], ["continuing eruption and root formation", "PROBLEM", 86, 124], ["luxation", "OBSERVATION", 39, 47], ["eruption", "OBSERVATION", 97, 105], ["root", "ANATOMY", 110, 114]]], ["Divergent roots are reported to be a contraindication [7] .Extract the second molars, allow mesial drift of third molarsIn reviewing the results of 43 cases treated conservatively, Valmaseda-Castellon et al. [2] found only approximately 50% of teeth reached an acceptable position.", [["roots", "ANATOMY", 10, 15], ["molars", "ANATOMY", 78, 84], ["molars", "ANATOMY", 114, 120], ["teeth", "ANATOMY", 244, 249], ["roots", "ORGAN", 10, 15], ["molars", "ORGAN", 78, 84], ["molars", "ORGAN", 114, 120], ["teeth", "ORGAN", 244, 249], ["Divergent roots", "PROBLEM", 0, 15], ["Extract the second molars", "PROBLEM", 59, 84], ["mesial drift of third molars", "PROBLEM", 92, 120], ["Valmaseda", "TREATMENT", 181, 190], ["roots", "ANATOMY", 10, 15], ["molars", "ANATOMY", 78, 84], ["mesial drift", "OBSERVATION", 92, 104], ["third molars", "ANATOMY", 108, 120], ["teeth", "ANATOMY", 244, 249], ["acceptable position", "OBSERVATION", 261, 280]]], ["They concluded \"if second molar eruption is questionable, it could be wiser to perform early extraction of the second molars and allow the third molars to replace them.\"", [["molars", "ANATOMY", 118, 124], ["molars", "ANATOMY", 145, 151], ["molars", "ORGAN", 118, 124], ["molars", "ORGAN", 145, 151], ["second molar eruption", "PROBLEM", 19, 40], ["the second molars", "PROBLEM", 107, 124]]], ["Horizontally impacted second molars appear so severe that they are often considered irretrievable.", [["molars", "ANATOMY", 29, 35], ["molars", "ORGAN", 29, 35], ["Horizontally impacted second molars", "PROBLEM", 0, 35], ["impacted", "OBSERVATION_MODIFIER", 13, 21], ["second", "OBSERVATION_MODIFIER", 22, 28], ["molars", "OBSERVATION", 29, 35], ["severe", "OBSERVATION_MODIFIER", 46, 52]]], ["Hence extraction of these teeth is often recommended, with autonomous drift of the third molar observed and later orthodontic treatment a possibility to protract and align the third molar.Extract the second molars, allow mesial drift of third molarsThe indication for this treatment option is the family declining other treatment options such as orthodontic or surgical uprighting or autotransplantation.", [["teeth", "ANATOMY", 26, 31], ["third molar", "ANATOMY", 176, 187], ["molars", "ANATOMY", 207, 213], ["molars", "ANATOMY", 243, 249], ["teeth", "ORGAN", 26, 31], ["molars", "ORGAN", 207, 213], ["molars", "ORGAN", 243, 249], ["these teeth", "PROBLEM", 20, 31], ["autonomous drift of the third molar", "PROBLEM", 59, 94], ["orthodontic treatment", "TREATMENT", 114, 135], ["Extract the second molars", "PROBLEM", 188, 213], ["mesial drift of third molars", "PROBLEM", 221, 249], ["this treatment option", "TREATMENT", 268, 289], ["other treatment options", "TREATMENT", 314, 337], ["orthodontic", "TREATMENT", 346, 357], ["surgical uprighting", "TREATMENT", 361, 380], ["autotransplantation", "TREATMENT", 384, 403], ["teeth", "ANATOMY", 26, 31], ["third molar", "ANATOMY", 83, 94], ["third molar", "ANATOMY", 176, 187], ["molars", "ANATOMY", 207, 213], ["mesial drift", "OBSERVATION", 221, 233], ["third molars", "ANATOMY", 237, 249]]], ["The presence of advanced caries or ankylosis of the second molar would be another indication for extraction.", [["caries", "DISEASE", 25, 31], ["ankylosis", "DISEASE", 35, 44], ["advanced caries", "PROBLEM", 16, 31], ["ankylosis of the second molar", "PROBLEM", 35, 64], ["extraction", "TREATMENT", 97, 107], ["advanced", "OBSERVATION_MODIFIER", 16, 24], ["caries", "OBSERVATION", 25, 31], ["ankylosis", "OBSERVATION", 35, 44]]], ["Although several authors suggest autonomous movement of the third molar seems to be best when the tooth bud of the third molar is in the \"full crown\" stage (no root) of development [65e67].", [["third molar", "ANATOMY", 60, 71], ["tooth bud", "ANATOMY", 98, 107], ["third molar", "ANATOMY", 115, 126], ["root", "ANATOMY", 160, 164], ["third molar", "ORGAN", 60, 71], ["tooth bud", "MULTI-TISSUE_STRUCTURE", 98, 107], ["third molar", "ORGAN", 115, 126], ["root", "ORGAN", 160, 164], ["autonomous movement of the third molar", "PROBLEM", 33, 71], ["autonomous movement", "OBSERVATION", 33, 52], ["third molar", "ANATOMY", 115, 126], ["no", "UNCERTAINTY", 157, 159], ["root", "ANATOMY", 160, 164]]], ["Richardson and Richardson [68] found the timing of second molar extraction has little effect on the final third molar position.", [["second molar extraction", "TREATMENT", 51, 74], ["little effect", "OBSERVATION", 79, 92]]], ["The major benefit of this approach is that orthodontic treatment may be avoided.", [["this approach", "TREATMENT", 21, 34], ["orthodontic treatment", "TREATMENT", 43, 64]]], ["The major shortcoming is that orthodontic treatment may be required later to protract and align the third molar (Figs.", [["third molar", "ANATOMY", 100, 111], ["orthodontic treatment", "TREATMENT", 30, 51], ["third molar", "ANATOMY", 100, 111]]], ["2e4) .", [["2e4", "CELL_LINE", 0, 3]]], ["Overeruption of the opposing second molar also is a potential problem.Extract the second molars, allow mesial drift of third molarsIn the study by Monaca et al. [7] \"second molar extraction was carried out when the tooth was not retrievable owing to severe abnormalities of their location and/or inclination.\"", [["molars", "ANATOMY", 89, 95], ["molars", "ANATOMY", 125, 131], ["tooth", "ANATOMY", 215, 220], ["molars", "ORGAN", 89, 95], ["molars", "ORGAN", 125, 131], ["tooth", "ORGAN", 215, 220], ["the opposing second molar", "PROBLEM", 16, 41], ["Extract the second molars", "PROBLEM", 70, 95], ["mesial drift of third molars", "PROBLEM", 103, 131], ["the study", "TEST", 134, 143], ["\"second molar extraction", "TREATMENT", 165, 189], ["the tooth", "PROBLEM", 211, 220], ["severe abnormalities", "PROBLEM", 250, 270], ["opposing", "OBSERVATION_MODIFIER", 20, 28], ["second", "OBSERVATION_MODIFIER", 29, 35], ["molar", "OBSERVATION", 36, 41], ["molars", "ANATOMY", 89, 95], ["mesial drift", "OBSERVATION", 103, 115], ["third molars", "ANATOMY", 119, 131]]], ["No further explanation was given as to whether horizontal impaction may have fallen into this category.", [["horizontal impaction", "PROBLEM", 47, 67], ["impaction", "OBSERVATION", 58, 67]]], ["The eruption of third molars after the extraction of second molars has been the subject of numerous studies [67e75], Orton-Gibbs et al. [66] examined this phenomenon in 63 patients and found all third molars erupted; none became impacted [66] .", [["third molars", "ANATOMY", 16, 28], ["molars", "ANATOMY", 60, 66], ["molars", "ANATOMY", 201, 207], ["eruption", "DISEASE", 4, 12], ["molars", "ORGAN", 22, 28], ["molars", "ORGAN", 60, 66], ["patients", "ORGANISM", 172, 180], ["molars", "ORGAN", 201, 207], ["patients", "SPECIES", 172, 180], ["third molars", "PROBLEM", 16, 28], ["the extraction", "TREATMENT", 35, 49], ["second molars", "PROBLEM", 53, 66], ["numerous studies", "TEST", 91, 107], ["eruption", "OBSERVATION_MODIFIER", 4, 12], ["third", "OBSERVATION_MODIFIER", 16, 21], ["molars", "OBSERVATION", 22, 28]]], ["They presented a summary table of studies reporting excellent or satisfactory position of mandibular third molars in 75% to 96% of cases.", [["mandibular third molars", "ANATOMY", 90, 113], ["mandibular third", "MULTI-TISSUE_STRUCTURE", 90, 106], ["molars", "ORGAN", 107, 113], ["studies", "TEST", 34, 41], ["mandibular third molars", "PROBLEM", 90, 113], ["mandibular", "ANATOMY", 90, 100]]], ["The exception was the study by Gooris et al. [76] who reported only 46% had a satisfactory contact with the first molar.", [["the study", "TEST", 18, 27]]], ["Other studies however report a difference in the response between upper and lower third molars.", [["upper", "ANATOMY", 66, 71], ["lower third molars", "ANATOMY", 76, 94], ["upper", "ORGANISM_SUBDIVISION", 66, 71], ["molars", "ORGAN", 88, 94], ["Other studies", "TEST", 0, 13], ["a difference in the response between upper and lower third molars", "PROBLEM", 29, 94], ["upper", "ANATOMY_MODIFIER", 66, 71], ["lower", "ANATOMY_MODIFIER", 76, 81], ["third molars", "ANATOMY", 82, 94]]], ["De-la-Rosa et al. [65] found 96% of maxillary, but only 66% of mandibular third molars erupt in good position.", [["maxillary", "ANATOMY", 36, 45], ["mandibular third molars", "ANATOMY", 63, 86], ["maxillary", "ORGAN", 36, 45], ["molars", "ORGAN", 80, 86], ["mandibular third molars", "PROBLEM", 63, 86], ["maxillary", "ANATOMY", 36, 45], ["mandibular", "ANATOMY", 63, 73], ["third", "ANATOMY_MODIFIER", 74, 79], ["molars", "OBSERVATION", 80, 86], ["good position", "OBSERVATION", 96, 109]]], ["But these studies examined the extraction of second permanent molars for the relief of crowding, cases in which the axial inclination of the second molar was within normal limits.", [["molars", "ANATOMY", 62, 68], ["axial", "ANATOMY", 116, 121], ["molars", "ORGAN", 62, 68], ["these studies", "TEST", 4, 17], ["the extraction", "TREATMENT", 27, 41], ["second permanent molars", "PROBLEM", 45, 68], ["crowding", "PROBLEM", 87, 95], ["crowding", "OBSERVATION", 87, 95], ["within normal limits", "OBSERVATION", 158, 178]]], ["When impacted second molars are extracted, the response of the third molars does not seem to be as favorable.", [["molars", "ANATOMY", 21, 27], ["third molars", "ANATOMY", 63, 75], ["molars", "ORGAN", 21, 27], ["molars", "ORGAN", 69, 75], ["impacted second molars", "PROBLEM", 5, 27], ["impacted", "OBSERVATION_MODIFIER", 5, 13], ["second", "OBSERVATION_MODIFIER", 14, 20], ["molars", "OBSERVATION", 21, 27]]], ["Monaca et al. [7] found \"the extraction of first or second irretrievable molars performed to enable the mesial shifting of the subsequent molar was associated with a lower prevalence of a positive outcome (17/22 molars, 77%).", [["molars", "ANATOMY", 73, 79], ["molars", "ANATOMY", 212, 218], ["molars", "ORGAN", 73, 79], ["molars", "ORGAN", 212, 218], ["the extraction", "TREATMENT", 25, 39], ["second irretrievable molars", "PROBLEM", 52, 79], ["the subsequent molar", "PROBLEM", 123, 143], ["a positive outcome", "PROBLEM", 186, 204], ["molar", "OBSERVATION", 138, 143], ["positive", "OBSERVATION_MODIFIER", 188, 196]]], ["Magnusson and Kjellberg [6] observed the extraction of the second molar replaced by the third molar to be the most common treatment, but the least successful (11%) of the treatment options.", [["Magnusson", "TREATMENT", 0, 9], ["the extraction", "TREATMENT", 37, 51], ["the second molar", "TREATMENT", 55, 71], ["the treatment options", "TREATMENT", 167, 188]]], ["They further concluded \"the few third molars that did erupt were all malpositioned\" and \"extraction of the second molar with no further intervention should be avoided.\"Extract the impacted second molars and autotransplant the third molarsA third treatment option is to extract the impacted second molar and autotransplant either a maxillary or mandibular third molar into the second molar position.", [["molars", "ANATOMY", 38, 44], ["molars", "ANATOMY", 196, 202], ["molars", "ANATOMY", 232, 238], ["molar", "ANATOMY", 297, 302], ["maxillary", "ANATOMY", 331, 340], ["mandibular third molar", "ANATOMY", 344, 366], ["molar", "ANATOMY", 383, 388], ["molars", "ORGAN", 38, 44], ["molars", "ORGAN", 196, 202], ["molars", "ORGAN", 232, 238], ["molar", "ORGAN", 297, 302], ["maxillary", "ORGAN", 331, 340], ["mandibular", "ORGAN", 344, 354], ["the few third molars", "PROBLEM", 24, 44], ["extraction", "TREATMENT", 89, 99], ["the second molar", "PROBLEM", 103, 119], ["further intervention", "TREATMENT", 128, 148], ["Extract the impacted second molars", "PROBLEM", 168, 202], ["autotransplant the third molars", "TREATMENT", 207, 238], ["A third treatment option", "TREATMENT", 238, 262], ["the impacted second molar", "PROBLEM", 277, 302], ["impacted", "OBSERVATION_MODIFIER", 180, 188], ["second", "OBSERVATION_MODIFIER", 189, 195], ["molars", "OBSERVATION", 196, 202], ["autotransplant", "OBSERVATION_MODIFIER", 207, 221], ["third", "OBSERVATION_MODIFIER", 226, 231], ["molars", "OBSERVATION", 232, 238], ["impacted", "OBSERVATION_MODIFIER", 281, 289], ["second", "OBSERVATION_MODIFIER", 290, 296], ["molar", "OBSERVATION", 297, 302], ["autotransplant", "OBSERVATION", 307, 321], ["maxillary", "ANATOMY", 331, 340], ["mandibular", "ANATOMY", 344, 354], ["third", "ANATOMY_MODIFIER", 355, 360], ["molar", "OBSERVATION", 361, 366], ["second molar", "ANATOMY_MODIFIER", 376, 388], ["position", "OBSERVATION_MODIFIER", 389, 397]]], ["Indications for this choice of treatment are the family declines orthodontic treatment, advanced caries or ankylosis of the impacted second molar, and the root apices of the third molar are still open.", [["second molar", "ANATOMY", 133, 145], ["root apices", "ANATOMY", 155, 166], ["third molar", "ANATOMY", 174, 185], ["caries", "DISEASE", 97, 103], ["ankylosis", "DISEASE", 107, 116], ["root apices", "MULTI-TISSUE_STRUCTURE", 155, 166], ["molar", "ORGAN", 180, 185], ["treatment", "TREATMENT", 31, 40], ["orthodontic treatment", "TREATMENT", 65, 86], ["advanced caries", "PROBLEM", 88, 103], ["ankylosis of the impacted second molar", "PROBLEM", 107, 145], ["ankylosis", "OBSERVATION", 107, 116], ["impacted", "OBSERVATION_MODIFIER", 124, 132], ["second", "OBSERVATION_MODIFIER", 133, 139], ["molar", "OBSERVATION", 140, 145], ["root", "ANATOMY_MODIFIER", 155, 159], ["apices", "ANATOMY_MODIFIER", 160, 166], ["third molar", "ANATOMY", 174, 185], ["open", "OBSERVATION", 196, 200]]], ["The main benefit to this treatment approach is that no orthodontic treatment is necessary.", [["this treatment approach", "TREATMENT", 20, 43], ["orthodontic treatment", "TREATMENT", 55, 76], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The shortcoming is the success rate of this procedure.", [["this procedure", "TREATMENT", 39, 53]]], ["What do we know about the success of autotransplantation?", [["autotransplantation", "TREATMENT", 37, 56], ["autotransplantation", "OBSERVATION", 37, 56]]], ["Aside from being done by an experienced surgeon and performed at the correct stage of root development (ideally two-thirds to three-fourths root formation) success depends on what type of tooth is being harvested and into what position it is being repositioned to.", [["root", "ANATOMY", 86, 90], ["root", "ANATOMY", 140, 144], ["tooth", "ANATOMY", 188, 193], ["root", "ORGAN", 86, 90], ["root", "TISSUE", 140, 144], ["tooth", "ORGAN", 188, 193], ["root", "ANATOMY", 86, 90], ["tooth", "ANATOMY", 188, 193], ["harvested", "OBSERVATION", 203, 212]]], ["Kvint et al. [43] studied 215 consecutive patients treated by one surgeon over a period of 15 years.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50]]], ["The overall success of autotransplantation was 81% (175 of 215) with premolars showing the most success at 89% (68 of 76).", [["premolars", "ANATOMY", 69, 78], ["premolars", "ORGAN", 69, 78], ["autotransplantation", "TREATMENT", 23, 42], ["premolars", "TEST", 69, 78], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["success", "OBSERVATION_MODIFIER", 12, 19]]], ["Interestingly premolars transplanted to the maxillary incisor region showed 100% success (24 of 24) .", [["premolars", "ANATOMY", 14, 23], ["maxillary incisor", "ANATOMY", 44, 61], ["premolars", "ORGAN", 14, 23], ["maxillary incisor", "MULTI-TISSUE_STRUCTURE", 44, 61], ["Interestingly premolars", "PROBLEM", 0, 23], ["premolars", "OBSERVATION", 14, 23], ["maxillary", "ANATOMY", 44, 53], ["incisor", "ANATOMY_MODIFIER", 54, 61], ["100%", "OBSERVATION_MODIFIER", 76, 80], ["success", "OBSERVATION_MODIFIER", 81, 88]]], ["But the teeth we are concerned with in this article showed poorer results.", [["teeth", "ANATOMY", 8, 13], ["teeth", "ORGAN", 8, 13], ["teeth", "ANATOMY", 8, 13]]], ["The autotransplantation of maxillary or mandibular third molars to replace mandibular second molars had the worst prognosis (68%, 23 of 34) of all the teeth transplanted.", [["maxillary", "ANATOMY", 27, 36], ["mandibular third molars", "ANATOMY", 40, 63], ["mandibular second molars", "ANATOMY", 75, 99], ["teeth", "ANATOMY", 151, 156], ["maxillary", "ORGAN", 27, 36], ["molars", "ORGAN", 57, 63], ["mandibular", "ORGAN", 75, 85], ["molars", "ORGAN", 93, 99], ["teeth", "ORGAN", 151, 156], ["The autotransplantation of maxillary or mandibular third molars", "TREATMENT", 0, 63], ["mandibular second molars", "PROBLEM", 75, 99], ["autotransplantation", "OBSERVATION", 4, 23], ["maxillary", "ANATOMY", 27, 36], ["mandibular", "ANATOMY", 40, 50], ["mandibular", "ANATOMY", 75, 85], ["teeth", "ANATOMY", 151, 156]]], ["If the family declines orthodontic treatment, it might be more prudent to extract the impacted second molar and allow the third molar to develop rather than attempt autotransplantation.", [["molar", "ORGAN", 102, 107], ["orthodontic treatment", "TREATMENT", 23, 44], ["the impacted second molar", "PROBLEM", 82, 107], ["the third molar", "PROBLEM", 118, 133], ["autotransplantation", "TREATMENT", 165, 184]]], ["In the case where the second molar needs to be extracted because of caries or ankylosis, with no third molar in that quadrant, autotransplanting a third molar from another quadrant might be desirable.Extract the third molars, surgically expose the second molars and orthodontically uprightThe most common and predictable approach reported to treating the impacted second molar is to orthodontically upright the tooth with possible extraction of the third molar and surgical exposure of the second molar.", [["third molar", "ANATOMY", 147, 158], ["third molars", "ANATOMY", 212, 224], ["molars", "ANATOMY", 255, 261], ["tooth", "ANATOMY", 411, 416], ["third molar", "ANATOMY", 449, 460], ["caries", "DISEASE", 68, 74], ["ankylosis", "DISEASE", 78, 87], ["molars", "ORGAN", 218, 224], ["molars", "ORGAN", 255, 261], ["tooth", "ORGAN", 411, 416], ["the second molar", "PROBLEM", 18, 34], ["caries", "PROBLEM", 68, 74], ["ankylosis", "PROBLEM", 78, 87], ["third molar in that quadrant", "PROBLEM", 97, 125], ["Extract the third molars", "PROBLEM", 200, 224], ["the impacted second molar", "PROBLEM", 351, 376], ["the tooth", "PROBLEM", 407, 416], ["extraction", "TREATMENT", 431, 441], ["the third molar", "PROBLEM", 445, 460], ["surgical exposure of the second molar", "TREATMENT", 465, 502], ["caries", "OBSERVATION", 68, 74], ["ankylosis", "OBSERVATION", 78, 87], ["quadrant", "ANATOMY", 117, 125], ["third molars", "ANATOMY", 212, 224], ["surgically", "OBSERVATION", 226, 236], ["most common", "OBSERVATION_MODIFIER", 293, 304], ["impacted", "OBSERVATION_MODIFIER", 355, 363], ["second", "OBSERVATION_MODIFIER", 364, 370], ["molar", "OBSERVATION", 371, 376], ["tooth", "ANATOMY", 411, 416], ["third", "OBSERVATION_MODIFIER", 449, 454], ["molar", "OBSERVATION", 455, 460], ["surgical exposure", "OBSERVATION", 465, 482], ["second molar", "ANATOMY_MODIFIER", 490, 502]]], ["The reported success of surgical exposure and orthodontic uprighting varies from 68% to 75% [2, 6, 7] .", [["surgical exposure", "TREATMENT", 24, 41], ["orthodontic uprighting varies", "TEST", 46, 75], ["surgical", "OBSERVATION", 24, 32]]], ["Monaca et al. [7] found negative factors being total bone coverage, or impaction of the root apex with the inferior canal roof.", [["bone", "ANATOMY", 53, 57], ["root apex", "ANATOMY", 88, 97], ["inferior canal", "ANATOMY", 107, 121], ["bone", "TISSUE", 53, 57], ["root apex", "MULTI-TISSUE_STRUCTURE", 88, 97], ["inferior canal", "MULTI-TISSUE_STRUCTURE", 107, 121], ["total bone coverage", "TREATMENT", 47, 66], ["impaction of the root apex", "PROBLEM", 71, 97], ["impaction", "OBSERVATION", 71, 80], ["root", "ANATOMY_MODIFIER", 88, 92], ["apex", "ANATOMY_MODIFIER", 93, 97], ["inferior", "ANATOMY_MODIFIER", 107, 115], ["canal", "ANATOMY_MODIFIER", 116, 121], ["roof", "ANATOMY_MODIFIER", 122, 126]]], ["Others have reported higher success rates with mesially inclined impacted second molars (Johnson E, 2020, personal communication) [33] .", [["molars", "ANATOMY", 81, 87], ["molars", "ORGAN", 81, 87], ["higher", "OBSERVATION_MODIFIER", 21, 27]]], ["Monaca et al. [7] stated \"orthodontic uprighting was applied to partially erupted molars impacted against the distal surface of the adjacent tooth, given the presence of sufficient space for the anchor device placement and dental distal movement to reposition the molar.\"", [["molars", "ANATOMY", 82, 88], ["distal surface", "ANATOMY", 110, 124], ["tooth", "ANATOMY", 141, 146], ["molars", "ORGAN", 82, 88], ["tooth", "ORGAN", 141, 146], ["orthodontic uprighting", "TREATMENT", 26, 48], ["partially erupted molars", "PROBLEM", 64, 88], ["the adjacent tooth", "PROBLEM", 128, 146], ["the anchor device placement", "TREATMENT", 191, 218], ["dental distal movement", "TREATMENT", 223, 245], ["distal", "ANATOMY_MODIFIER", 110, 116], ["tooth", "ANATOMY", 141, 146]]], ["How much space is needed for anchor device placement?", [["anchor device placement", "TREATMENT", 29, 52]]], ["And how is sufficient space for molar distal movement determined?Extract the third molars, surgically expose the second molars and orthodontically uprightTo begin the uprighting and distalizing process one not even need to initially bond an attachment to the second molar [33, 77] .", [["third molars", "ANATOMY", 77, 89], ["molars", "ANATOMY", 120, 126], ["molars", "ORGAN", 83, 89], ["molars", "ORGAN", 120, 126], ["molar distal movement", "PROBLEM", 32, 53], ["Extract the third molars", "PROBLEM", 65, 89], ["distal", "OBSERVATION_MODIFIER", 38, 44], ["movement", "OBSERVATION", 45, 53], ["third molars", "ANATOMY", 77, 89], ["surgically", "OBSERVATION", 91, 101]]], ["Bach [77] described a method of using a straight section of a 0.014 \u00c2 0.025 copper NiTi wire placed vertically down the distal surface of the first molar to just clear the mesial marginal ridge of the impacted molar.", [["distal surface", "ANATOMY", 120, 134], ["molar", "ANATOMY", 210, 215], ["copper", "CHEMICAL", 76, 82], ["copper", "CHEMICAL", 76, 82], ["NiTi", "CHEMICAL", 83, 87], ["molar", "ORGAN", 210, 215], ["a straight section", "TREATMENT", 38, 56], ["a 0.014 \u00c2 0.025 copper NiTi wire", "TREATMENT", 60, 92], ["distal", "ANATOMY_MODIFIER", 120, 126], ["surface", "ANATOMY_MODIFIER", 127, 134], ["first molar", "ANATOMY", 142, 153], ["clear", "OBSERVATION", 162, 167], ["mesial", "OBSERVATION_MODIFIER", 172, 178], ["marginal", "OBSERVATION_MODIFIER", 179, 187], ["ridge", "OBSERVATION_MODIFIER", 188, 193], ["impacted", "OBSERVATION_MODIFIER", 201, 209], ["molar", "OBSERVATION", 210, 215]]], ["The NiTi wire is then bent 90 anteriorly across the occlusal surface of the first molar and is stabilized with light cured composite (Figs.", [["occlusal surface", "ANATOMY", 52, 68], ["molar", "ANATOMY", 82, 87], ["NiTi", "CHEMICAL", 4, 8], ["The NiTi wire", "TREATMENT", 0, 13], ["NiTi wire", "OBSERVATION", 4, 13], ["bent", "OBSERVATION_MODIFIER", 22, 26], ["anteriorly", "ANATOMY_MODIFIER", 30, 40], ["occlusal", "ANATOMY_MODIFIER", 52, 60], ["surface", "ANATOMY_MODIFIER", 61, 68], ["first molar", "ANATOMY", 76, 87], ["stabilized", "OBSERVATION_MODIFIER", 95, 105]]], ["Significant uprighting can occur with this approach following which attachments can be bonded to the tooth for further uprighting using one of many orthodontic methods.Extract the third molars, surgically expose the second molars and orthodontically uprightHow is sufficient space for dental distal movement determined?", [["tooth", "ANATOMY", 101, 106], ["third molars", "ANATOMY", 180, 192], ["molars", "ANATOMY", 223, 229], ["tooth", "ORGAN", 101, 106], ["molars", "ORGAN", 186, 192], ["molars", "ORGAN", 223, 229], ["many orthodontic methods", "TREATMENT", 143, 167], ["Extract the third molars", "PROBLEM", 168, 192], ["dental distal movement", "PROBLEM", 285, 307], ["third molars", "ANATOMY", 180, 192], ["surgically", "OBSERVATION", 194, 204]]], ["One way is to measure the distance from the distal of the first molar to the mesial of the third molar in relation to the mesiodistal width of the second molar.", [["third molar", "ANATOMY", 91, 102], ["distance", "OBSERVATION_MODIFIER", 26, 34], ["distal", "ANATOMY_MODIFIER", 44, 50], ["first molar", "ANATOMY_MODIFIER", 58, 69], ["mesial", "ANATOMY_MODIFIER", 77, 83], ["third", "OBSERVATION_MODIFIER", 91, 96], ["molar", "OBSERVATION", 97, 102], ["mesiodistal", "ANATOMY_MODIFIER", 122, 133], ["width", "OBSERVATION_MODIFIER", 134, 139], ["second molar", "ANATOMY_MODIFIER", 147, 159]]], ["But this assumes the third molar is in the distalization path and that the third molar will not be distalized as the second molar distalizes.", [["the third molar", "PROBLEM", 17, 32], ["the third molar", "PROBLEM", 71, 86], ["third", "OBSERVATION_MODIFIER", 21, 26], ["molar", "OBSERVATION", 27, 32]]], ["Neither of these may be the case.Extract the third molars, surgically expose the second molars and orthodontically upright6.5.", [["third molars", "ANATOMY", 45, 57], ["molars", "ANATOMY", 88, 94], ["molars", "ORGAN", 51, 57], ["molars", "ORGAN", 88, 94], ["Extract the third molars", "PROBLEM", 33, 57], ["third molars", "ANATOMY", 45, 57], ["surgically", "OBSERVATION", 59, 69]]], ["Does the impacted second molar need to be surgically exposed?Extract the third molars, surgically expose the second molars and orthodontically uprightAs previously described, initial uprighting can be accomplished with little clinical crown exposed by using a vertically placed rectangular NiTi sectional wire.", [["third molars", "ANATOMY", 73, 85], ["molars", "ANATOMY", 116, 122], ["NiTi", "CHEMICAL", 290, 294], ["molars", "ORGAN", 79, 85], ["molars", "ORGAN", 116, 122], ["the impacted second molar", "PROBLEM", 5, 30], ["Extract the third molars", "PROBLEM", 61, 85], ["a vertically placed rectangular NiTi sectional wire", "TREATMENT", 258, 309], ["third molars", "ANATOMY", 73, 85], ["surgically", "OBSERVATION", 87, 97]]], ["Or if there is at least a 4x4mm portion of the crown exposed, an orthodontic attachment can be bonded to the tooth for activation with various designed orthodontic systems.", [["tooth", "ANATOMY", 109, 114], ["tooth", "ORGAN", 109, 114], ["an orthodontic attachment", "PROBLEM", 62, 87], ["various designed orthodontic systems", "PROBLEM", 135, 171], ["4x4mm", "OBSERVATION_MODIFIER", 26, 31], ["crown", "OBSERVATION_MODIFIER", 47, 52]]], ["Surgical exposure is often not needed.", [["Surgical exposure", "TREATMENT", 0, 17]]], ["Johnson (2020, personal communication) comments \"orthodontists are incredibly buccal attachment oriented.", [["buccal", "ANATOMY", 78, 84], ["buccal", "TISSUE", 78, 84]]], ["Bonding to the buccal requires much more tissue removal.", [["buccal", "ANATOMY", 15, 21], ["tissue", "ANATOMY", 41, 47], ["buccal", "ORGAN", 15, 21], ["tissue", "TISSUE", 41, 47], ["much more tissue removal", "TREATMENT", 31, 55], ["buccal", "ANATOMY", 15, 21], ["more tissue", "OBSERVATION_MODIFIER", 36, 47], ["removal", "OBSERVATION", 48, 55]]], ["Minimal exposure and occlusal bonding are much easier on everybody.\" 6.6.", [["Minimal exposure", "PROBLEM", 0, 16], ["occlusal bonding", "PROBLEM", 21, 37], ["exposure", "OBSERVATION", 8, 16], ["occlusal bonding", "OBSERVATION", 21, 37]]], ["Does the third molar need to be extracted?Extract the third molars, surgically expose the second molars and orthodontically uprightSurgical exposure of the impacted second molar is most often performed in conjunction with extraction of the third molars.", [["third molars", "ANATOMY", 54, 66], ["molars", "ANATOMY", 97, 103], ["third molars", "ANATOMY", 240, 252], ["molars", "ORGAN", 60, 66], ["molars", "ORGAN", 97, 103], ["molar", "ORGAN", 172, 177], ["molars", "ORGAN", 246, 252], ["the third molar", "PROBLEM", 5, 20], ["Extract the third molars", "PROBLEM", 42, 66], ["the impacted second molar", "PROBLEM", 152, 177], ["extraction", "TREATMENT", 222, 232], ["third molars", "ANATOMY", 54, 66], ["surgically", "OBSERVATION", 68, 78], ["impacted", "OBSERVATION_MODIFIER", 156, 164], ["second", "OBSERVATION_MODIFIER", 165, 171], ["molar", "OBSERVATION", 172, 177], ["third molars", "ANATOMY", 240, 252]]], ["Valmaseda-Castellon et al. [2] stated \"in cases of surgical exposure.lower third molar extraction in the same operation is recommended when there is posterior crowding in the dental arch, because the lower third molar could prevent lower second molar eruption.\" [3, 5, 36] .Extract the third molars, surgically expose the second molars and orthodontically uprightHowever, numerous articles suggest uprighting of the second molar is not hindered by the presence of the third molar [7, 34, 37, 45, 46, 48, 51, 58, 60, 61, 78, 79] .", [["dental arch", "ANATOMY", 175, 186], ["lower third molar", "ANATOMY", 200, 217], ["lower second molar", "ANATOMY", 232, 250], ["third molars", "ANATOMY", 286, 298], ["molars", "ANATOMY", 329, 335], ["posterior", "ORGANISM_SUBDIVISION", 149, 158], ["dental arch", "MULTI-TISSUE_STRUCTURE", 175, 186], ["molars", "ORGAN", 292, 298], ["molars", "ORGAN", 329, 335], ["Valmaseda", "TREATMENT", 0, 9], ["surgical exposure", "PROBLEM", 51, 68], ["lower third molar extraction", "TREATMENT", 69, 97], ["the same operation", "TREATMENT", 101, 119], ["posterior crowding in the dental arch", "PROBLEM", 149, 186], ["the lower third molar", "PROBLEM", 196, 217], ["lower second molar eruption", "PROBLEM", 232, 259], ["Extract the third molars", "PROBLEM", 274, 298], ["surgical exposure", "OBSERVATION", 51, 68], ["molar", "OBSERVATION", 81, 86], ["posterior", "ANATOMY_MODIFIER", 149, 158], ["crowding", "OBSERVATION", 159, 167], ["dental arch", "ANATOMY", 175, 186], ["lower", "ANATOMY_MODIFIER", 200, 205], ["lower", "OBSERVATION_MODIFIER", 232, 237], ["second", "OBSERVATION_MODIFIER", 238, 244], ["molar", "OBSERVATION_MODIFIER", 245, 250], ["eruption", "OBSERVATION", 251, 259], ["third molars", "ANATOMY", 286, 298], ["surgically", "OBSERVATION", 300, 310], ["numerous", "OBSERVATION_MODIFIER", 372, 380], ["articles", "OBSERVATION", 381, 389], ["third", "ANATOMY_MODIFIER", 468, 473], ["molar", "ANATOMY_MODIFIER", 474, 479]]], ["The confusion over this is illustrated by Mah et al. [60] who state \"in patient 3, the third molar extraction was not helpful in uprighting the second molar and not needed; in patient 1, the value of extraction was doubtful.\"", [["confusion", "DISEASE", 4, 13], ["patient", "ORGANISM", 72, 79], ["patient", "ORGANISM", 176, 183], ["patient", "SPECIES", 72, 79], ["patient", "SPECIES", 176, 183], ["The confusion", "PROBLEM", 0, 13], ["the third molar extraction", "TREATMENT", 83, 109]]], ["But later in the article they state, \"to avoid uncertainty, we routinely order third molar extraction when second molar uprighting is needed.\"", [["third molar extraction", "TREATMENT", 79, 101]]], ["Melsen et al. [46] suggest maintaining the third molars may even be beneficial by preventing distal displacement of the second molar crown and preventing space from opening anterior to the second molar.", [["third molars", "ANATOMY", 43, 55], ["molar", "ANATOMY", 127, 132], ["molars", "ORGAN", 49, 55], ["anterior", "ORGAN", 173, 181], ["the third molars", "PROBLEM", 39, 55], ["distal displacement of the second molar crown", "PROBLEM", 93, 138], ["space", "PROBLEM", 154, 159], ["distal", "OBSERVATION_MODIFIER", 93, 99], ["displacement", "OBSERVATION", 100, 112], ["second", "OBSERVATION_MODIFIER", 120, 126], ["molar crown", "OBSERVATION", 127, 138], ["anterior", "ANATOMY_MODIFIER", 173, 181], ["second molar", "ANATOMY_MODIFIER", 189, 201]]], ["Treating without extracting the third molars and surgically exposing the second molars saves the family considerable expense as well as the morbidity associated with these surgical procedures (Figs.", [["molars", "ANATOMY", 38, 44], ["molars", "ANATOMY", 80, 86], ["molars", "ORGAN", 38, 44], ["molars", "ORGAN", 80, 86], ["the third molars", "PROBLEM", 28, 44], ["the morbidity", "PROBLEM", 136, 149], ["these surgical procedures", "TREATMENT", 166, 191]]], ["1, 10, 11) .Extract the third molars, surgically expose the second molars and orthodontically uprightAnd what happens if following the extraction of the third molar, the second molar cannot be repositioned and needs extraction?", [["third molars", "ANATOMY", 24, 36], ["molars", "ANATOMY", 67, 73], ["molars", "ORGAN", 30, 36], ["molars", "ORGAN", 67, 73], ["Extract the third molars", "PROBLEM", 12, 36], ["the extraction of the third molar", "TREATMENT", 131, 164], ["extraction", "TREATMENT", 216, 226], ["third molars", "ANATOMY", 24, 36], ["surgically", "OBSERVATION", 38, 48]]], ["The third molar could have been a replacement tooth.", [["third molar", "ANATOMY", 4, 15], ["tooth", "ANATOMY", 46, 51], ["tooth", "ORGAN", 46, 51], ["a replacement tooth", "TREATMENT", 32, 51], ["third", "OBSERVATION_MODIFIER", 4, 9], ["molar", "OBSERVATION", 10, 15], ["replacement tooth", "OBSERVATION", 34, 51]]], ["This approach is most indicated in an adolescent patient in whom the third molar is still developing distal to the impacted second molar.", [["third molar", "ANATOMY", 69, 80], ["patient", "ORGANISM", 49, 56], ["molar", "ORGAN", 75, 80], ["patient", "SPECIES", 49, 56], ["This approach", "TREATMENT", 0, 13], ["most indicated", "UNCERTAINTY", 17, 31], ["impacted", "OBSERVATION_MODIFIER", 115, 123], ["second", "OBSERVATION_MODIFIER", 124, 130], ["molar", "OBSERVATION", 131, 136]]], ["In an adult patient where the third molar may have erupted mesially and may be lying on top of the second molar, the extraction of the third molar or orthodontically uprighting it to provide access to the second molar, would be necessary [9, 38, 39, 41, 56] .SummaryMesially impacted mandibular second molars are a common occurrence in orthodontic practices, especially those using the lingual arch or lip bumper for alleviating anterior crowding.", [["third molar", "ANATOMY", 30, 41], ["mesially", "ANATOMY", 59, 67], ["mandibular second molars", "ANATOMY", 284, 308], ["lingual arch", "ANATOMY", 386, 398], ["lip", "ANATOMY", 402, 405], ["patient", "ORGANISM", 12, 19], ["mesially", "CANCER", 59, 67], ["molar", "ORGAN", 106, 111], ["mandibular", "ORGAN", 284, 294], ["molars", "ORGAN", 302, 308], ["lingual arch", "MULTI-TISSUE_STRUCTURE", 386, 398], ["lip", "ORGAN", 402, 405], ["anterior", "MULTI-TISSUE_STRUCTURE", 429, 437], ["patient", "SPECIES", 12, 19], ["the extraction of the third molar", "TREATMENT", 113, 146], ["SummaryMesially impacted mandibular second molars", "PROBLEM", 259, 308], ["orthodontic practices", "TREATMENT", 336, 357], ["anterior crowding", "PROBLEM", 429, 446], ["may be", "UNCERTAINTY", 72, 78], ["second", "OBSERVATION_MODIFIER", 99, 105], ["molar", "OBSERVATION", 106, 111], ["mandibular", "ANATOMY", 284, 294], ["second molars", "OBSERVATION", 295, 308], ["lingual arch", "ANATOMY", 386, 398], ["lip", "ANATOMY", 402, 405], ["bumper", "OBSERVATION", 406, 412], ["anterior", "ANATOMY_MODIFIER", 429, 437], ["crowding", "OBSERVATION", 438, 446]]], ["Horizontally impacted second molars, on the other hand, occur so infrequently that most practitioners have limited experience in treating such a patient.", [["molars", "ANATOMY", 29, 35], ["molars", "ORGAN", 29, 35], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["Horizontally impacted second molars", "PROBLEM", 0, 35], ["impacted", "OBSERVATION_MODIFIER", 13, 21], ["second", "OBSERVATION_MODIFIER", 22, 28], ["molars", "OBSERVATION", 29, 35]]], ["Because of this there is little consensus on the management of these cases.", [["little", "OBSERVATION_MODIFIER", 25, 31]]], ["Extraction of these teeth with or without auto transplantation of third molars is often suggested, but commonly presents poor results.", [["teeth", "ANATOMY", 20, 25], ["third molars", "ANATOMY", 66, 78], ["teeth", "ORGAN", 20, 25], ["molars", "ORGAN", 72, 78], ["Extraction", "TREATMENT", 0, 10], ["auto transplantation of third molars", "TREATMENT", 42, 78], ["teeth", "ANATOMY", 20, 25], ["third molars", "ANATOMY", 66, 78]]], ["Surgical uprighting is more successful in moderately tipped teeth and is mostly indicated in patients who decline orthodontic treatment.SummaryAs opposed to vertically impacted molars, which may be associated with ankylosis or other factors preventing eruption, the mesially angulated, horizontally impacted mandibular second molar usually has eruption potential, because its impaction is more commonly due to lack of space and/or abnormal eruption path.", [["teeth", "ANATOMY", 60, 65], ["molars", "ANATOMY", 177, 183], ["mandibular second molar", "ANATOMY", 308, 331], ["ankylosis", "DISEASE", 214, 223], ["eruption", "DISEASE", 252, 260], ["eruption", "DISEASE", 440, 448], ["teeth", "ORGAN", 60, 65], ["patients", "ORGANISM", 93, 101], ["molars", "ORGAN", 177, 183], ["mandibular", "ORGAN", 308, 318], ["patients", "SPECIES", 93, 101], ["moderately tipped teeth", "PROBLEM", 42, 65], ["orthodontic treatment", "TREATMENT", 114, 135], ["vertically impacted molars", "PROBLEM", 157, 183], ["ankylosis", "PROBLEM", 214, 223], ["other factors", "PROBLEM", 227, 240], ["eruption", "PROBLEM", 252, 260], ["the mesially angulated", "PROBLEM", 262, 284], ["horizontally impacted mandibular second molar", "PROBLEM", 286, 331], ["its impaction", "PROBLEM", 372, 385], ["lack of space", "PROBLEM", 410, 423], ["abnormal eruption path", "PROBLEM", 431, 453], ["more successful", "OBSERVATION_MODIFIER", 23, 38], ["moderately", "OBSERVATION_MODIFIER", 42, 52], ["tipped teeth", "OBSERVATION_MODIFIER", 53, 65], ["vertically", "OBSERVATION_MODIFIER", 157, 167], ["impacted", "OBSERVATION_MODIFIER", 168, 176], ["molars", "OBSERVATION", 177, 183], ["may be associated with", "UNCERTAINTY", 191, 213], ["ankylosis", "OBSERVATION", 214, 223], ["mesially", "OBSERVATION_MODIFIER", 266, 274], ["angulated", "OBSERVATION_MODIFIER", 275, 284], ["horizontally", "OBSERVATION_MODIFIER", 286, 298], ["impacted", "OBSERVATION_MODIFIER", 299, 307], ["mandibular", "ANATOMY", 308, 318], ["second", "OBSERVATION_MODIFIER", 319, 325], ["molar", "OBSERVATION", 326, 331], ["impaction", "OBSERVATION", 376, 385], ["abnormal", "OBSERVATION_MODIFIER", 431, 439], ["eruption", "OBSERVATION", 440, 448]]], ["Hence orthodontic uprighting shows the most promise and can commonly be done without extracting the third molar or surgically exposing the impacted second molar.", [["molar", "ORGAN", 106, 111], ["orthodontic uprighting", "TEST", 6, 28], ["the third molar", "PROBLEM", 96, 111], ["surgically", "OBSERVATION", 115, 125], ["impacted", "OBSERVATION_MODIFIER", 139, 147], ["second", "OBSERVATION_MODIFIER", 148, 154], ["molar", "OBSERVATION", 155, 160]]], ["Second molars can be uprighted initially with minimal clinical crown exposure, with the third molars providing little resistance to proper uprighting.", [["molars", "ANATOMY", 7, 13], ["molars", "ANATOMY", 94, 100], ["molars", "ORGAN", 7, 13], ["molars", "ORGAN", 94, 100], ["Second molars", "PROBLEM", 0, 13], ["minimal clinical crown exposure", "PROBLEM", 46, 77], ["the third molars", "PROBLEM", 84, 100], ["molars", "OBSERVATION", 7, 13], ["crown exposure", "OBSERVATION", 63, 77], ["little resistance", "OBSERVATION", 111, 128]]], ["The modern clinician has at their disposal a myriad of biomechanical choices that can be used to successfully reposition these teeth and enable finishing with an optimal occlusion.", [["teeth", "ANATOMY", 127, 132], ["teeth", "ORGAN", 127, 132], ["an optimal occlusion", "TREATMENT", 159, 179], ["occlusion", "OBSERVATION", 170, 179]]]], "755ec25f61808530b7363b2d595968012551632a": [["The coronavirus disease 2019 (COVID- 19) pandemic has rightfully captured our attention-with 11 688 913 confirmed infections and 539 993 deaths in over 185 countries and regions (19 May 2020) [1] .", [["coronavirus disease", "DISEASE", 4, 23], ["COVID- 19", "CHEMICAL", 30, 39], ["infections", "DISEASE", 114, 124], ["deaths", "DISEASE", 137, 143], ["coronavirus", "ORGANISM", 4, 15], ["coronavirus disease 2019 (COVID- 19", "SPECIES", 4, 39], ["The coronavirus disease", "PROBLEM", 0, 23], ["COVID", "TEST", 30, 35], ["pandemic", "PROBLEM", 41, 49], ["infections", "PROBLEM", 114, 124], ["coronavirus disease", "OBSERVATION", 4, 23]]], ["The impact on our public and individual health and economies is staggering [2] [3] [4] [5] -there are many questions including how did we find ourselves in deep economic and public health crisis in so many settings and what can we do to successfully survive the COVID-19 pandemic?", [["[2] [3] [4", "SIMPLE_CHEMICAL", 75, 85], ["the COVID", "TEST", 258, 267], ["pandemic", "PROBLEM", 271, 279]]], ["The COVID-19 testing debacle and response in many countries also raises pointed questions regarding global and national preparedness for a major pandemic that has been predicted for at least 2 decades [6, 7] .", [["The COVID", "TEST", 0, 9]]], ["Before COVID-19, Europe struggled to contain an ongoing human immunodeficiency virus (HIV) pandemic, and the article by Vourli et al in this issue of Clinical Infectious Diseases presents progress toward the global HIV 90-90-90 target [8] .", [["human immunodeficiency virus (HIV) pandemic", "DISEASE", 56, 99], ["Infectious Diseases", "DISEASE", 159, 178], ["human immunodeficiency virus", "ORGANISM", 56, 84], ["human", "SPECIES", 56, 61], ["immunodeficiency virus", "SPECIES", 62, 84], ["human immunodeficiency virus", "SPECIES", 56, 84], ["HIV", "SPECIES", 86, 89], ["COVID", "TEST", 7, 12], ["an ongoing human immunodeficiency virus", "PROBLEM", 45, 84], ["pandemic", "PROBLEM", 91, 99], ["Clinical Infectious Diseases", "PROBLEM", 150, 178], ["the global HIV", "TEST", 204, 218], ["Infectious", "OBSERVATION", 159, 169]]]]}